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Cancer, a global health issue
Cancer remains one of the leading causes of morbidity and mortality worldwide with a total 
of 14 million new cases and 8.2 million cancer-related deaths in 2012 [1]. It is predicted that 
within the next two decades, the number of new cancer cases in the world will increase to 
more than 22 million, with deaths increasing to more than 13 million each year [1]. With 
considerable annual budgets reserved for cancer research [2,3], much research effort is 
directed towards improving the understanding of cancer biology and development of more 
effective treatments [4]. 
 Over the last decades, development of new chemotherapy agents and especially 
molecularly targeted agents, together with improved radiotherapy techniques, have 
extended the therapeutic possibilities for patients with locally advanced and metastatic 
cancer [5]. Although remarkable treatment responses have been reported in individual 
patient cases, particularly when cancers harboured specific sensitizing mutations [6,7], the 
impact of these new therapies on patient outcome in the general population is relatively 
modest [8]. The specific mode of action of these targeted therapies emphasizes the 
requirement to carefully select and tailor anti-cancer treatment to the individual.
 However, the selection of an optimal management plan for a specific patient from 
a large number of possible treatment options, also known as ‘personalized medicine’, 
is a genuine challenge for clinicians [9]. In today’s clinical practice, physicians choose a 
treatment plan for every patient based on available information regarding the genetic 
signature of tumours, histological and/or cytological diagnosis, pre-treatment imaging, 
patient performance status and preferences. However, whether a specific therapy works 
is very difficult to predict on the individual level. Nevertheless, personalizing anti-cancer 
treatment is of great importance to optimize treatment efficacy and avoid unnecessary side 
effects and costs of ineffective treatment. The role of medical imaging, in particular imaging 
with positron emission tomography (PET), X-ray computed tomography (CT), and magnetic 
resonance (MR) imaging, is increasingly being recognized for this purpose. 
Personalizing medicine in oncology: From RECIST to PERCIST
Medical imaging has an established role in the clinical management of most cancers, 
ranging from initial staging and therapy planning towards response monitoring and 
follow-up. Traditionally, the use of imaging was limited to morphological measurements 
for the purpose of diagnosis and response measurements. One of the first important steps 
towards personalization of anti-cancer therapy using medical imaging was emergence of 
the response evaluation criteria in solid tumours (RECIST) for the purpose of standardizing 
response measurements [10]. RECIST uses the concept of morphological unidimensional 
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measurements (i.e. size of the target lesion) based on conventional radiological imaging 
modalities for response classification [10]. Although it is reported that RECIST can be used 
to evaluate the effect of therapy, morphological measurements and response to treatment 
are not always correlated. Furthermore, morphological changes typically occur later on in 
treatment when the patient already received several treatment cycles, thereby limiting 
patient benefit from early adaptation in case treatment is ineffective.
 PET imaging has been suggested to overcome the challenges associated with 
morphological measurements. In this regard, standardized criteria incorporating the use 
of quantitative PET-derived indices in response evaluation, known as the PET response 
criteria in solid tumours ‘PERCIST’, have been proposed [11]. Currently, the most widely 
used radiotracer for clinical PET is the radioactive glucose analogue 18F-fluorodeoxyglucose 
(FDG). The strength of FDG-PET is the ability to differentiate between tissues with varying 
metabolic states, because FDG predominately accumulates in cells with an increased 
glycolytic rate and, therefore, increased glucose uptake and turn-over. Transport of FDG over 
the cell membrane is mediated by glucose transporters (GLUT) [12]. Once in the intra-cellular 
space, FDG is phosphorylated by enhanced activity of hexokinases to FDG-6-phosphate 
[12]. Since the FDG-6-phosphate can not be catabolized further due to the missing hydroxyl 
(OH) group at its second (2’) position, and the dephosphorylation rate of FDG-6-phosphate 
to FDG is negligible in most tissues, the FDG-6-phosphate is trapped intracellularly [12].
Hence, FDG uptake is related to the expression of GLUT (particularly GLUT1 and GLUT3) 
and the enzymatic activity of hexokinases in tissue [12]. As an altered metabolism is an 
important hallmark of cancer, in which cancer cells have increased glucose consumption 
rates (i.e. the Warburg effect) [13], FDG is an excellent radiotracer for discriminating normal 
from cancerous tissues. Indeed, FDG uptake is strongly correlated with the expression levels 
of molecules associated with glucose metabolism (such as hexokinase I and GLUT1), and 
accumulates with high sensitivity in most cancer cells [14]. The high sensitivity for detecting 
lesions and the ability to detect early metabolic changes make FDG-PET imaging an 
excellent tool for the purpose of diagnosis and personalizing treatment to the individual 
patient. 
Thesis outline: PET imaging in oncological management of lung 
cancer
Lung cancer is one of the most common types of cancer, accounting for 13% of all diagnosed 
cancers (around 1.6 million new cases per year worldwide), and for 18% of all cancer-
related deaths (1.4 million annually) [15]. With an increasing incidence and a generally poor 
patient prognosis, there is much to gain in terms of patient outcome. The role of PET in 
personalizing oncological management of patients with lung cancer is increasingly being 
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recognized, which is the central theme of this thesis. In Chapter 2 the current status and 
future prospects of PET imaging in the oncological management of patients with locally 
advanced and metastatic non-small cell lung cancer (NSCLC) is discussed. In particular, 
the concept of PET as a multirole imaging modality for the purpose of diagnosis, therapy 
selection, and response monitoring in this patient group is addressed. 
 Although PET has a great potential for personalizing anti-cancer treatment to the 
individual patient, several methodological considerations have to be taken into account. 
One consideration is the effect of respiratory motion artefacts during PET imaging, which 
deteriorates image quality by distorting the appearance of thoracic anatomy and introducing 
quantitative inaccuracies. The clinical impact of correcting for these artefacts, commonly 
referred to as respiratory gating, in FDG-PET–CT imaging is discussed in Chapter 3. The 
central theme of Chapter 4 is the effect and management of respiratory motion artefacts 
in FDG-PET–CT imaging. Several approaches are discussed to correct for respiratory motion 
artefacts and to improve the spatial alignment between PET and CT images. Chapter 5 
addresses the impact of respiratory gating on target volume delineation in radiotherapy 
planning, evaluating whether reduction in gross tumour volume (GTV) delineated on PET 
images will yield significant reduction of radiation dose to organs at risk. 
 The use of FDG-PET for monitoring the response to therapy and the development and 
validation of image-derived response indices is studied in Chapters 6 and 7. In Chapter 
6, the performance of several automatic image segmentation algorithms for calculating 
total lesion glycolysis (TLG) in patients with locally advanced NSCLC is investigated. 
Specifically, the relation between primary tumour and lymph node TLG and its association 
with progressive free survival (PFS) and overall survival (OS) is determined in this patient 
population. Although the usefulness of these traditional volumetric image-derived indices 
for monitoring therapy response and prediction of patient outcome has been reported, these 
indices omit information regarding spatial heterogeneity of radiotracer uptake. Although, 
quantification of spatial heterogeneity has been reported to be of value for these purposes, 
there remains the issue of measurement stability and accuracy of these parameters under 
different imaging conditions and the presence of respiratory motion artefacts. In Chapter 
7, the effect of respiratory gating and different levels of image noise on quantification of 
intratumour heterogeneity of glucose metabolism is investigated. In this regard, several 
radiomics features which have been reported correlate with patient prognosis and therapy 
response, are compared on standard and respiratory gated PET images. 
 Finally in the general discussion and future prospects section, the future directions of 
PET–CT applications in lung cancer management are addressed.
503606-L-bw-Grootjans
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Abstract
Despite considerable improvements in the treatment options for advanced-stage non-small-
cell lung cancer (NSCLC), disease-specific survival remains poor. With the aim of improving 
patient outcome, the treatment paradigm of locally advanced NSCLC has shifted from solely 
radiotherapy towards combined and intensified treatment approaches. Also, treatment for 
patients with stage IV (oligo)metastatic NSCLC has evolved rapidly, with therapeutic options 
that include a number of targeted agents, surgery, and stereotactic ablative radiotherapy. 
However, personalizing treatment to the individual patient remains difficult and requires 
monitoring of biological parameters responsible for treatment resistance to facilitate 
treatment selection, guidance, and adaptation. PET is a well-established molecular imaging 
platform that enables non-invasive quantification of many biological parameters that are 
relevant to both local and systemic therapy. With increasing clinical evidence, PET has 
gradually evolved from a purely diagnostic tool to a multifunctional imaging modality that 
can be utilized for treatment selection, adaptation, early response monitoring, and follow 
up in patients with NSCLC. Herein, we provide a comprehensive overview of the available 
clinical data on the use of this modality in this setting, and discuss future perspectives of 
PET imaging for the clinical management of patients with locally advanced and metastatic 
NSCLC.
503606-L-bw-Grootjans
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Introduction
Worldwide, lung cancer accounts for 13% of all diagnosed cancers (around 1.6 million cases 
per year), and for 18% of all cancer-related deaths (1.4 million annually) [1]. Histologically, 
80–85% of lung tumours can be classified as non-small-cell lung cancer (NSCLC). Owing to 
the lack of disease-associated symptoms, many patients diagnosed with lung cancer already 
have advanced-stage disease at the time of presentation [2,3]. Over the past decades, 
advances in radiotherapy techniques for precise dose delivery and the development of 
molecularly targeted therapies have expanded the treatment options available for NSCLC. 
Nevertheless, these new therapeutic options have failed to substantially improve the 
overall long-term outcome of these patients, with only 10–15% surviving beyond 5 years 
after diagnosis [4]. However, specific patient groups can benefit from certain treatment 
approaches. This concept is well-illustrated in patients with cancers harbouring specific 
molecular alterations, such as mutations in the EGFR; in these patients, treatment with 
agents targeting EGFR, such as gefitinib, have yielded improved response rates when 
compared with conventional chemotherapies [5], whereas the use of these agents as 
standard therapy in the general NSCLC patient population was not associated with survival 
benefits [6,7]. Such findings can be explained by heterogeneity in the disease between 
patients with respect to histological and molecular features [8]. Thus, rational selection of 
the available treatment options based on tumour biology and early adaptation of therapy 
according to initial treatment responses might markedly improve patient outcome. This 
approach requires biological characterization of the mechanisms responsible for sensitivity 
and/or resistance to various cytotoxic therapies, which are intimately linked to tumour cell 
proliferation, metabolism, and hypoxia. In this regard, PET is a well-established molecular 
imaging platform that enables non-invasive quantification of the relevant biological 
tumour characteristics. Technological improvements combined with the development 
of new radiotracers over the past decade have extended the possibilities for disease 
characterization using PET. This Review discusses the role of modern PET imaging in 
diagnosis, treatment selection and adaptation, and follow-up assessments in patients with 
advanced-stage NSCLC.
PET in NSCLC diagnosis and staging
The introduction of PET imaging into clinical practice has been successful, thanks 
largely to the versatility of the most widely used radiotracer, the glucose analogue 
18F-fluorodeoxyglucose (FDG), in the diagnosis and characterization of a myriad of disorders. 
The strength of FDG-PET is the ability to differentiate tissues with varying metabolic 
states, because FDG predominately accumulates in cells with an elevated glycolytic rate 
503606-L-bw-Grootjans
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and, therefore, increased glucose consumption. As an altered metabolism is an important 
hallmark of cancer, FDG is an excellent radiotracer for discriminating normal from cancerous 
tissues. Indeed, FDG uptake is strongly correlated with the expression levels of molecules 
associated with glucose metabolism (such as hexokinase I and the glucose transporter 
GLUT1), and accumulates with high sensitivity in most cancer cells, including those 
comprising NSCLCs [9].
 The combined use of FDG-PET with Xray CT (PET–CT) imaging has a major impact on 
diagnosis and staging of NSCLC. The advantage of FDGPET–CT imaging over diagnostic CT 
imaging alone is a high sensitivity for detection of pulmonary lesions (90%), metastases 
in normal-sized hilar and/or mediastinal lymph nodes (74–85%), and distant metastases 
(93%) [10]. This added sensitivity of detection considerably improves patient management 
by increasing the accuracy of disease staging, reducing the number of futile thoracotomies 
and mediastinoscopies in patients with inoperable advanced-stage tumours [11], and 
permits selection of patients eligible for either definitive radiotherapy with curative intent 
or palliative treatment [12]. Of note, a variety of nonmalignant inflammatory disorders can 
also demonstrate considerable FDG uptake, and cytological and/or histological evaluation 
of FDG-PET positive lesions is mandatory.
 The limited specificity of FDG-PET for characterizing pulmonary lesions sparked the 
development of radiotracers that visualize other cancer hallmarks. As uncontrolled cell 
proliferation is a well-established characteristic of malignant cells, visualization of this 
parameter in vivo is of great interest. A direct indicator of cellular proliferation is DNA 
synthesis, which can be measured using radiolabelled thymidine, or its analogues, as 
PET tracers [13]. The most extensively studied thymidine analogue is 3’–deoxy3’–18F-
fluorothymidine (FLT). Intracellular accumulation of FLT is primarily related to the enzymatic 
activity of the Sphase-specific enzyme thymidine kinase 1 (TK1), the key enzyme of the 
salvage pathway of DNA synthesis [14]. Indeed, FLT-uptake is strongly correlated with 
cellular proliferation, as defined by Ki67 immunohistochemistry [15]. Evaluation of FLT–PET 
for NSCLC diagnosis and staging in prospective clinical trials revealed a very high specificity 
for the detection of primary malignant lesions and lymph-node metastasis, although the 
sensitivity of detection of primary and metastatic (locoregional and distant) lesions was 
generally poor (<70%) [16-18]. In addition, FLT–PET assessments did not result in statistically 
significant improvements in lymph-node staging when compared to FDG-PET [16,17] – in 
one of these studies, the reported accuracy of TNM staging was 67% for FLT–PET and 85% for 
FDG-PET [16]. Owing to the limited sensitivity of FLT–PET for the detection of locoregional 
and distant metastases, its use in the diagnosis and staging of NSCLC is not recommended, 
and FDG remains the radiotracer of choice.
503606-L-bw-Grootjans
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Role of PET in treatment selection
In current clinical practice, physicians choose a treatment plan for every patient based on 
the available information from the pretreatment PET–CT images, the histological and/or 
cytological diagnoses, and patient performance status. For most patients, the standard 
of care for unresectable locally advanced NSCLC (stage IIB–IIIB) is radiotherapy combined 
with (concurrent or sequential) chemotherapy [19], although concurrent chemotherapy 
improves patient survival when compared with sequential chemotherapy, this benefit 
comes at the cost of increased toxicity and, therefore, potentially reduced quality of life 
[4,20,21]. First-line chemotherapy usually comprises a platinum-based doublet – regimens 
in which a platinum-based agent, such as cisplatin or carboplatin, is combined with a new 
third-generation chemotherapeutic agent (paclitaxel, docetaxel, gemcitabine, vinorelbine, 
or irinotecan) [22]. The radiotherapy schedule consists of fractionated radiotherapy up to 
an equivalent dose of 60–66 Gy in daily fractions of 2.0–2.5 Gy [19]. For patients with (oligo)
metastatic disease (stage IV), the standard of care is systemic treatment with chemotherapy, 
or in selected cases, molecularly targeted agents.
Application in locally advanced NSCLC
The ultimate objective in cancer treatment is to improve locoregional control rates 
and prevent occurrence of the disease at distant sites. Currently, different treatment 
combinations and intensification regimens are being investigated in an attempt to improve 
patient outcome. For locally advanced disease, these include strategies such as the use of 
different platinum-based doublet regimens or alternative molecularly targeted agents, and 
the use of altered radiotherapy fractionation with a reduction in overall treatment times, or 
radiation-dose escalation. Although surgery after chemoradiotherapy is an option for some 
patients with locally advanced disease, the benefit of this approach on patient outcome 
might be limited owing to frequent occurrence of distant relapse in these patients [23]. 
Thus, identifying locally advanced NSCLC cases in which the added morbidity of surgery is 
justified remains an issue. Similarly, treatment intensification has the potential to improve 
locoregional control and survival [24]; however, distant relapse remains an important cause 
of treatment failure in this patient population. Furthermore, intensification of treatment is 
at the cost of severe toxicity, and a substantial number of patients show only a modest 
benefit in terms of overall survival and outcome, owing to therapy resistance.
 The exact mechanisms that mediate therapy resistance often remain enigmatic; 
nevertheless, a number of molecular, cellular, and microenvironmental features are linked 
to treatment resistance [25]. At the cellular level, factors related to drug uptake, efflux, 
binding to cytoplasmic proteins, and detoxification; metabolism; DNA repair; and apoptotic 
responses determine the degree of cytotoxicity achieved with specific agents. Furthermore, 
microenvironmental factors, such as interstitial fluid pressure, acidity, hypoxia, and tissue 
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perfusion, are often involved in acquired treatment resistance [26]. These issues emphasize 
the requirement for non-invasive characterization of the biological landscape of the 
primary tumour in patients with NSCLC to enable selection and tailoring of treatment to the 
individual.
Application in metastatic NSCLC
PET can also be used for global disease assessment in patients with metastatic disease. 
Most deaths from cancer are due to the development and growth of distant metastases, 
highlighting the importance of systemic disease control [27]. However, optimal selection of 
treatment for this patient group remains challenging. This issue was emphasized in a large 
trial that investigated the potential benefit of four platinum-based doublet chemotherapy 
regimens (cisplatin plus either paclitaxel, gemcitabine or docetaxel, and carboplatin plus 
paclitaxel) in 1,155 patients with metastatic NSCLC [28]. On the basis of the results of this 
study, it was concluded that none of the investigated chemotherapy regimens was superior 
to the others [28]. The knowledge that metastatic lesions can have a different biology, 
and thus may respond differently to therapy when compared with the primary tumour, 
emphasizes the importance for characterization of the biology of metastatic lesions [27]. 
Pretreatment characterization of tumours using PET might determine eligibility of patients 
for certain treatment approaches, such as certain chemotherapy agents or molecularly 
targeted therapies. Furthermore, PET during treatment could be used for response 
assessment, facilitating an early switch from ineffective but potentially toxic therapies to 
possibly beneficial treatments.
Assessing cell proliferation
Cellular repopulation during radiotherapy is an important factor mediating therapy 
resistance [29,30]. Altered radiotherapy fractionation has been proposed to counteract 
cellular repopulation; in particular, by hyperfractionation, whereby the dose per fraction is 
decreased but with two or three fractions delivered per day, or by accelerated fractionation, 
in which the radiation dose per fraction remains the same but is delivered at shorter 
time intervals [31]. In a meta-analysis, Mauguen et al. [31] reported a significant benefit 
in overall survival from accelerated or hyperfractionated radiotherapy in patients with 
nonmetastatic NSCLC, compared with conventional schedules (HR 0.88, 95% CI 0.80–0.97; 
p=0.009). However, careful patient selection is required because the use of these shortened 
and intensified radiotherapy schemes increased treatment-related toxicity [31], and might 
also be logistically difficult to implement. To this end, FLT–PET imaging might prove useful 
in selecting patients who would benefit from altered radiotherapy fractionation, as FLT 
uptake reflects the proliferative potential of NSCLC tumours. This concept was supported 
by a phase II study conducted by Everitt and co-workers [32], who reported the ability to 
use interim FLT–PET imaging to monitor the effects of radiotherapy, with greater sensitivity 
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than FDG-PET. Additionally, Yue and colleagues [33] reported the use of FLT–PET to non-
invasively assess cellular repopulation during radiotherapy in a preclinical model. However, 
prospective clinical trials are required to evaluate whether FLT-PET could be used to identify 
patients eligible for these modified radiotherapy treatment schemes.
Imaging hypoxia
Hypoxia is an important microenvironmental factor that can mediate therapy resistance. 
Hypoxia arises due to an imbalance between oxygen consumption and delivery, and results 
in the upregulation of several transcription factors and genes involved in cell proliferation, 
angiogenesis, metastasis, cell de-differentiation, and metabolism [34]. Most NSCLC tumours 
demonstrate some degree of hypoxia, which can be heterogeneously distributed throughout 
the lesion [35]. In general, glucose metabolism, as depicted by FDG-PET, correlates poorly 
with the presence of hypoxia, emphasizing the need for specific PET radiotracers to quantify 
hypoxia [35]. In this regard, several radiotracers, including 2–nitroimidazoles and nucleoside 
conjugates have been developed and used to quantify hypoxia [36]. 
 The radiotracer studied most extensively to date is 18Ffluoromisonidazole (FMISO); 
this compound has been used to image hypoxia in NSCLC [37]. However, the unfavourable 
pharmacokinetics of this radiotracer result in low contrast between hypoxic and normoxic 
tissue [37]. PET with second-generation agents with improved pharmacokinetic properties, 
such as 18F-fluoroerythronitroinmidazole (FETNIM) [38], 3–18F-fluoro-2-(4-((2-nitro-1H-
imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)-propan-1-ol (F-HX4) [39], and 1-α-D-(5-deoxy-5-
18F-fluoroarabinofuranosyl)-2-nitroimidazole (FAZA) [40], has been successfully utilized for 
imaging of hypoxia in NSCLC. Furthermore, imaging with the nucleoside conjugate 64Cu(II)-
diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) has shown potential in depicting 
hypoxia in NSCLC [41]. Although the performance of these hypoxia-imaging agents seems 
promising, larger clinical trials are required to assess the ability of the radiotracers to 
visualize different degrees of hypoxia within the lesions [42].
 Hypoxia imaging might serve to improve selection of patients eligible for treatment 
modifications, such as radiation-dose escalation to hypoxic tumour subvolumes, addition 
of hypoxic-cell radiosensitizers, and hyperbaric oxygen treatment, which could potentially 
improve locoregional control by counteracting hypoxia [43]. Furthermore, hypoxia imaging 
might enable identification of patients eligible for new treatment strategies, including the 
use of agents such as tirapazamine that can directly kill hypoxic cells [43]. In the South West 
Oncology Group (SWOG) S0003 trial [44], among the total study population of 367 patients, 
addition of tirapazamine to standard treatment with paclitaxel and carboplatin did not 
result in improved response rates, time to progression (TTP), or survival, but considerably 
increased toxicity; however, variable results were obtained at the individual patient level, 
and therefore, imaging of hypoxia could potentially facilitate selection of patients who 
are most likely to benefit from treatment with such agents [44]. The rationale for patient 
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stratification based on hypoxia imaging was supported by preliminary data demonstrating 
that serum levels of hypoxia-related proteins, including plasminogen activator inhibitor, 
vascular endothelial growth factor (VEGF), insulin-like growth factor-binding protein, 
and osteopontin, were predictive of response to tirapazamine in this trial [44]. Although 
prospective clinical trials are eagerly awaited to confirm the clinical impact of PET-based 
assessment of hypoxia, these results emphasize that PET might be a valuable tool for 
estimation of the hypoxic-cell fraction of the tumour, information which could be used to 
identify patients eligible for such treatment strategies.
Predicting and monitoring treatment toxicity
Accumulation of adverse events is particularly relevant to combined and/or intensified 
treatment approaches. According to the Common Terminology Criteria for Adverse Events 
version 4.03 (CTCAE v4.03) [45], more than 500 distinct adverse effects have been associated 
with modern cancer therapies. The substantial variability in treatment-related toxicity 
between individuals emphasizes the requirement for personalization of therapy. The use of 
PET imaging is increasingly being investigated for this purpose.
 For chemotherapy, monitoring the impact of treatment on the haematopoietic 
system is important, given the clinical significance of adverse effects induced by 
immunosuppression and thrombocytopenia. Leimgruber et al. [46] have demonstrated that 
FLT is a suitable radiotracer to predict the effect of chemotherapy on myeloproliferative 
organs, with changes in FLT uptake typically preceding reductions in neutrophil counts.
 Similarly, FDG-PET imaging has been utilized to predict and monitor toxicity in 
patients undergoing radiation treatment. Radiation-induced pneumonitis is a common 
adverse event associated with radiotherapy, and requires adequate management. Although 
different parameters, such as mean lung dose (MLD), radiation dose to perfused lung, and 
pre-radiotherapy lung function, are predictive of radiation pneumonitis development, 
accurate segregation of patients into high-risk and low-risk groups remains difficult [47]. In 
addition, pre-existing interstitial pneumonitis and other inflammatory lung disorders are 
associated with a higher incidence of radiotherapy-induced pneumonitis. Evaluation of pre-
existing lung pathology can be performed with FDG-PET–CT, as inflammatory disorders are 
associated with increased FDG uptake. Indeed, two retrospective studies have reported that 
elevated pre-radiotherapy FDG uptake in the lung predicted the development of radiation 
pneumonitis [48,49]. Furthermore, FDG-PET after radiotherapy can be used to confirm the 
presence and estimate the severity of radiation pneumonitis, and can, therefore, be used 
to guide and monitor treatment decisions for patients with radiation pneumonitis [50]. 
Although the number of studies leveraging PET to predict treatment-related toxicity during 
therapy are limited, these findings support the use of PET for novel treatment planning and 
monitoring approaches in NSCLC.
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PET-guided treatment adaptations
In the past two decades, advances in radiotherapy techniques have provided precise 
control over localization and delivery of the radiation dose for the treatment of NSCLC, 
with the intent to effectively irradiate tumour tissues and affected hilar and/or mediastinal 
lymph nodes, while sparing nearby normal tissue. Furthermore, the emergence of 
electronic portal imaging devices (EPIDs) and online cone-beam CT imaging enabled highly 
conformal image-guided radiotherapy (IGRT) to yield improved dose coverage of defined 
target volumes by accounting for interfractional geometric deviations – allowing for dose 
escalation to target volumes, but maintaining acceptable levels of toxicity. Incorporation 
of PET imaging before and during treatment can facilitate tailoring of radiotherapy to 
the individual patient, with respect to target-volume delineation, dose prescription, and 
treatment-response monitoring.
Definition of gross tumour volume
In light of improvements in the accuracy of dose delivery with current radiotherapy 
techniques, accurate definition of gross tumour volumes (GTV) on medical images is 
increasingly important. Incorrect GTV delineation can result in inadequate dose delivery 
to the tumour owing to geographical misses, which can result in higher probabilities of 
local control failure and/or increased toxicity due to irradiation of normal tissue. However, 
delineation of GTVs based exclusively on planning CT scans can be difficult, and is subject 
to considerable intraobserver and interobserver variability [51]. These difficulties are related 
to the limited contrast between the tumour and surrounding tissues with similar density on 
CT images, particularly in the presence of post-tumoural atelectasis (collapse or closure of 
the lung) or mediastinal invasion, and the decision on whether mediastinal lymph nodes 
should be included in the GTV.
 Incorporation of FDG-PET images in radiation-treatment planning has been 
demonstrated to reduce intraobserver and interobserver variability, and to improve the 
definition of GTVs [51]. Furthermore, a good correlation exists between macroscopic tumour 
dimensions determined using resected pathological specimens and size of the tumour on 
preoperative PET images [52]. Moreover, selective nodal irradiation based on FDG-PET data 
is associated with very low isolated nodal failure rates, suggesting that FDG-PET facilitates 
the concept of selective irradiation of mediastinal lymph nodes [53].
Molecular imaging-based dose painting
Incorporation of PET imaging in radiotherapy planning also permits the application of 
molecular imaging-based dose painting, which relies on sculpting the prescribed dose 
within the target volume according to a superimposed spatial molecular map that visualizes 
specific biological characteristics related to radiotherapy resistance [54]. Among the clinically 
503606-L-bw-Grootjans
30 | Chapter 2
available radiotracers, FDG is currently the best characterized for adaptive radiotherapy dose 
planning. Studies have demonstrated that sites of locoregional failure after radiotherapy 
in patients with NSCLC typically have higher levels of FDG uptake on pre-radiotherapy 
PET images [55]. Thus, the results of these studies indicate that FDG-PET imaging can be 
used to identify sites with a high probability of local recurrence to facilitate adaptation of 
radiotherapy planning to target these areas for treatment intensification. Currently, the 
possibility using FDG-PET to guide radiation-dose escalation is being examined in the 
randomized, phase II PET Boost trial (NCT01024829) [56]. This study is randomly assigning 
patients with NSCLC to receive dose escalation to either the entire primary tumour volume 
or only the regions of the tumour with high FDG uptake. In an analysis of the radiotherapy 
plans for the first 20 patients enrolled in this study, van Elmpt et al. [57] demonstrated the 
feasibility of FDG-PET-guided dose escalation using an integrated boost technique, without 
violation of the organs at risk (OAR) dose constraints. Similar strategies can be used with 
hypoxia imaging (for example, by F-HX4-PET; Figure 1), whereby the prescribed dose is 
increased to hypoxic tumour volumes to account for increased radioresistance in such 
areas. The NCT02354274 trial [58] will use a similar approach, whereby patients with stage 
III NSCLC will undergo individualized FDG-PET-guided radiotherapy, with dose escalation 
to FDG avid tumour areas, or standard radiotherapy; both arms will receive concomitant 
vinorelbine. However, whether these approaches will result in improved patient outcome 
remains unclear.
Adaptive radiotherapy
Geometric uncertainties during radiotherapy in patients with NSCLC, such as respiratory 
motion, anatomical changes due to treatment effects (including tumour regression, 
emergence of pleural effusion, and dissolving atelectasis), and differential baseline shift of 
the primary tumour and involved lymph nodes, require generous safety margins and, to a 
certain extent, limit the ability to perform radiation-dose escalation to improve treatment 
outcome [59]. Application of breathing-adapted radiotherapy in combination with the use 
of patient-specific margins, taking into account physiological variation in respiratory motion, 
permits the reduction of overall planning target volumes (PTVs), without compromising 
treatment outcome [59].
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Figure 1 | The application of PET imaging for dose-painting radiotherapy in a patient with NSCLC. 
a | A CT image taken for radiotherapy planning purposes shows the tumour in the lower lobe of 
the left lung. b | The metabolically active subvolume of the tumour can be defined in the combined 
FDG-PET and CT image. c | A combined F-HX4-PET and CT image additionally enables the hypoxic 
tumour subvolume to be mapped. d | This image shows a radiotherapy dose plan overlaid on the CT 
image of the tumour with dose escalation to the entire primary tumour up to 82.1 Gy (red shading). 
e | Incorporation of the FDG-PET data enables modification of the radiotherapy dose plan with a boost 
to the metabolically most-active tumour subvolumes, to a total dose of 93.1 Gy (purple shading). 
f | Radiotherapy dose planning with an increased dose of 129.6 Gy (blue shading) to hypoxic tumour 
subvolumes depicted on F-HX4-PET. In panels d–e, the yellow contour indicates that >90% of the 
volume receives a minimal dose of 66.0 Gy, and the thin red contour line indicates the planning target 
volume; the white contour lines indicate that >90% of the volume receives a dose of at least 82.1 Gy 
in panel d, 93.1 Gy in panel e, and 129.6 Gy in panel f. In each scenario, the radiation dose to the hilar 
and/or mediastinal lymph nodes remained unchanged and all normal tissue dose constraints were 
met for each technique. Abbreviations: FDG-PET, 18F-fluorodeoxyglucose PET; F-HX4-PET, 3-18F-fluoro2-
(4-((2-nitro-1H-imidazol1yl)methyl)-1H-1,2,3-triazol-1-yl)-propan-1-ol PET; NSCLC, non-small-cell lung 
cancer. Image courtesy of A. Even, MAASTRO clinic, Maastricht, Netherlands.
In addition, sequential imaging during radiotherapy can facilitate adaptive planning 
to correct for systemic errors due to treatment effects, a concept known as adaptive 
radiotherapy (ART). The relevance of considering these treatment effects during the course 
of radiotherapy was emphasized by Guckenberger and colleagues [60], who reported 
continuous tumour regression of approximately 1.2% per day, as measured by CT, with total 
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mean GTV reduction of 50% after 6 weeks of treatment. The decrease in tumour volume 
observed in this study emphasizes the opportunity to modify target volumes to spare normal 
tissues from radiation dose and indicates the possibility to perform dose escalation to the 
tumour. The knowledge that molecular changes typically precede morphological changes 
observed during treatment supports the idea of incorporating sequential PET imaging to 
facilitate more-accurate application of ART. In addition to depicting changes in tumour size, 
PET imaging early in the course of treatment can highlight specific regions of the tumour 
that are more resistant to therapy (such as hypoxic regions) and that are good targets for 
dose escalation. Sculpting the prescribed radiation dose during treatment according to 
available imaging data is known as image-guided adaptive radiotherapy (IGART). Figure 2 
illustrates the clinical implementation of IGART using sequential FDG-PET–CT imaging in a 
patient with stage IIIB NSCLC.
 Currently, a prospective, multi-institutional, randomized phase II trial of individualized 
PET–CT IGART in patients with inoperable or unresectable stage III NSCLC (RTOG 1106/
ACRIN 6697; NCT01507428) is ongoing [61]. Participants assigned to the experimental arm 
of this trial will receive an additional FDG-PET–CT scan 4 weeks into radiation treatment. For 
these patients, the radiation treatment plan will be adapted based on this scan acquired 
during treatment, with the aim of escalating the dose to residual metabolically active 
tumour, whereas patients in the control arm will receive standard radiotherapy [61]. Patients 
in both arms will also receive concomitant paclitaxel and carboplatin. Furthermore, baseline 
FMISOPET will be conducted in a subset of patients to identify and enable targeted dose 
escalation to hypoxic tumour regions.
 In two other clinical trials (NCT01207063 and NCT01190527) [62,63], IGART planning 
is being performed based on FDGPET assessments during the course of treatment, with 
redistribution of the radiation delivered for dose escalation in the high-risk areas based 
on PET imaging, and dose reduction in low-risk PTV areas based on OAR dose constraints. 
However, these trials are currently ongoing and whether IGART results in improved patient 
outcomes remains to be established.
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Figure 2 | Adaptive radiotherapy planning using serial FDG-PET–CT imaging in a patient with stage IIIB 
NSCLC. The initial radiotherapy plan was adapted twice because of changes in dose coverage observed 
during the course of treatment. The first column of images (plan 1) depicts the initial plan, with the 
CTV (magenta contour) of the primary tumour in the left lung and mediastinal metastatic lymph node 
(white arrow) overlaid on the pretreatment FDG-PET–CT image (top row). During the treatment an 
atelectasis developed (white asterisks) displacing the mediastinum to the left, visualized by CBCT 
imaging at fraction 11 (Fx 11; middle row). In addition to the CTV (magenta contour), the oesophagus 
(white contour) is delineated in the CBCT images. The resulting dose difference between planned and 
delivered dose is illustrated in the γ-evaluation (dose difference/distance-to-agreement: 3%/3 mm; γ 
Fx 11; bottom row) showing overdosage in the left lower lobe (red) and underdosage in the CTV of the 
lymph-node metastasis (blue), necessitating an FDG-PET–CT-based treatment adaptation. The second 
column (plan 2) shows the respective images with target volumes adapted to avoid overdosage of 
normal tissue (mediastinum and lung) and underdosage of metastatic lymph node as detected by the 
aforementioned γevaluation. Note that the additional ‘hotspot’ on the FDG-PET–CT (white arrowhead) 
corresponds to the myocardium. Upon resolution of the atelectasis after 29 fractions of treatment, 
which resulted in underdosing of the primary tumour at this time point (blue region in γ Fx 29 image; 
bottom row), a third treatment plan was generated (magenta contour; third column, top row); note the 
focal FDG uptake in the oesophagus (black arrow) due to treatment-induced inflammation. Respective 
CBCT and γevaluation images of this treatment plan (plan 3) at treatment fraction 32 are presented in the 
third column. Beyond this time point, no further treatment adaptation was necessary. Abbreviations: 
CBCT, cone beam CT; CTV, clinical target volume; FDG, 18F-fluorodeoxyglucose; NSCLC, non-small-cell 
lung cancer. Image courtesy of L.C.G.G. Persoon, MAASTRO clinic, Maastricht, Netherlands.
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Use of PET for response monitoring
Early assessment of response to therapy is important to identify patients who will not 
benefit from treatment, and to facilitate treatment adaptation in these patients to avoid 
unnecessary toxicity and costs associated with the ineffective therapy. This includes 
the choice to continue maintenance therapy, switch maintenance therapy, or initiate 
additional lines of therapy. Currently, response monitoring in NSCLC is mainly performed 
using morphological CT metrics [64]. However, difficulties associated with CT imaging are 
related to the inability to distinguish atelectasis or fibrotic tissue from vital residual tumour, 
and the fact that the absence or occurrence of morphological changes might not always 
be predictive of response to therapy [65]. Development of new PET-based metrics could 
potentially improve early response monitoring in NSCLC [65].
Assessment of locoregional control
Currently, PET evaluations of treatment response in NSCLC predominantly utilize the tracers 
FDG and FLT. In patients with NSCLC, FDG-PET using traditional standardized uptake value 
(SUV)-derived indices has been used for early response assessment to chemotherapy and 
radiotherapy. Several studies have demonstrated the potential to monitor treatment effects 
based on decreased SUVs on serial FDG-PET imaging of the primary tumour (Figure 3) 
[66,67]. Furthermore, evidence indicates that treatment effects on the primary tumour can 
be detected at an earlier stage using FDG-PET as compared with CT measurements, and a 
complete FDG-PET response was better correlated with long-term survival than a partial 
response on CT (no CTdefined complete responses were observed, precluding comparison 
of complete FDG-PET versus CT responses) [68]. Similarly, multiple studies have reported the 
possibility of performing response monitoring by quantifying tumour FLT uptake in patients 
with NSCLC treated with chemotherapy and radiotherapy [32,69]. In addition, increasing 
evidence indicates that FDG-PET and FLT–PET can be used for early evaluation of tumour 
response to molecularly targeted biological agents, such as erlotinib [70] and gefitinib 
[71]. In a study conducted by Zander and co-workers [72], an early FDG-PET response of 
the primary tumour to erlotinib (after 1 week of therapy) was predictive of absence of 
disease progression at 6 weeks, as well as progression-free survival (PFS) and overall 
survival, in unselected, previously untreated patients with stage IV NSCLC, independent of 
EGFR mutational status. Although these findings are promising, the routine use of PET for 
response assessment – with the primary objective of informing treatment continuation or 
switching – is currently not recommended, and validation of the utility of this approach in 
large clinical trials is required. In addition, prospective clinical trials applying the concept of 
PET-guided treatment decisions are required to determine the benefit on patient outcome.
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Figure 3 | Sequential FDGPET and low-dose CT imaging for treatment response monitoring in two 
patients with stage III NSCLC treated with concomitant chemoradiotherapy. For each of these patients, 
a pretreatment (D0), in-treatment (D15) and end-of-treatment (D66) FDG-PET scan was acquired. a | In 
the first patient (top row), a 14% decrease in in-treatment SUV and a 16% decrease in intreatment 
TLG was observed within a tumour in the left lung, and was associated with a PFS duration of 12 
months, and an overall survival duration of 16 months. The total decrease in mean SUV and TLG of the 
primary tumour during treatment was 64% and 95%, respectively. b | In the second patient (bottom 
row), a 7% decrease in in-treatment SUV but a 54% decrease in in-treatment TLG were observed for 
a tumour in the right lung; this patient was censored for both PFS and overall survival at 19 months. 
The overall decrease in mean SUV and TLG of the primary tumour during treatment was 83% and 91%, 
respectively. These examples emphasize the ability of FDG-PET to monitor response to therapy during 
and after treatment, although imaging results at 2 weeks into treatment are deemed most important 
for assessing response to treatment, and thus in facilitating treatment decision-making. Abbreviations: 
FDG-PET, 18F-fluorodeoxyglucose PET; NSCLC, non-small-cell lung cancer; PFS, progression-free 
survival; SUV, standardized uptake value; TLG, total lesion glycolysis.
PET-guided allocation of maintenance therapy
As well as enabling the early detection of treatment resistance and facilitating the choice 
to switch therapy, PET could also be a potentially useful tool for selecting patients eligible 
for maintenance therapy. The results of a FDG-PET study by Yoon et al. [73] indicate that 
a fractional decrease in the maximum SUV in the tumour (SUVmax) after four cycles of 
chemotherapy might predict TTP in patients with NSCLC; those patients predicted to 
have a short TTP based on a small fractional decrease in SUVmax might be candidates for 
maintenance treatment. The value of FDG-PET in this regard is supported by a retrospective 
analysis by Moon and colleagues [74], which demonstrated that the percentage decrease 
in total lesion glycolysis (TLG) was a parameter with the potential to identify a subgroup of 
patients with early disease progression who might be eligible for immediate maintenance 
treatment after first-line chemotherapy. Although the relationship between reduced FDG 
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and FLT uptake and increased treatment benefit is well established, large clinical trials are 
required to distinguish true biological effects from test-retest variability, in order to permit 
appropriate stratification of patients with NSCLC.
Use of PET for predicting distant relapse
The role of FDGPET in predicting treatment success and the probability of distant relapse in 
patients with locally advanced NSCLC is ambiguous. The rationale for using FDG-PET in this 
setting is based on the assumption that tumour glucose metabolism is related to metastatic 
potential of the primary tumour or lymph-node lesion. This concept is supported by a 
study conducted by Lopez Guerra et al. [75], which found that post-treatment SUVmax in the 
primary tumour and locoregional lymph nodes predicted distant-metastasis-free survival 
rates in patients with locally advanced NSCLC. The results of this study indicated that larger 
reductions in SUVmax, and lower post-treatment SUVmax values were associated with longer 
distant-metastasis-free survival rates and overall survival. In a multicentre prospective trial, 
Machtay et al. [76] reported that pretreatment and post-treatment SUVs were not strongly 
predictive for survival (at defined cutoff values), although considerably higher post-
treatment SUVpeak and SUVmax were associated with worse survival in patients with stage III 
NSCLC. Although the relationship between distant relapse and SUV measurements was not 
specifically addressed in this study, the absence of a correlation between SUV measurements 
and survival undermines support for a correlation between SUV with distant-metastasis-
free survival.
PET for global disease assessment
For patients with metastatic NSCLC, treatment is directed towards optimal systemic control 
of the disease. In this setting, the use of PET for global disease assessment at baseline and 
after intervention for prediction of patient outcome has received great interest. Indeed, 
calculation of metrics such as whole-body and lymph-node TLG on baseline FDG-PET has 
been demonstrated to have predictive value for PFS and overall survival [77,78]. Furthermore, 
in a meta-analysis that included data from 1,581 patients, Im et al. [79] reported that 
metabolic tumour volume (MTV) and TLG were significant prognostic factors for outcome 
in patients with NSCLC. However, the use of PET for image-guided treatment decisions in 
this setting remains limited.
 In the NCT00564733 trial [80], FDG-PET will be used for planning chemotherapy 
in patients with stage IIIB or IV NSCLC. In this phase II trial, patients will be treated with 
a carboplatin-paclitaxel doublet and early response assessment will be performed, with 
interim FDG-PET imaging performed 18–21 days after start of the treatment [80]. Patients 
classified as responders will continue with the carboplatin-paclitaxel doublet chemotherapy, 
whereas initial nonresponders will switch therapy and receive gemcitabine and docetaxel 
[80].
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The limited specificity of FDG-PET to distinguish therapy-induced inflammation from vital 
tumour tissue sparked the interest for investigating the value of other tracers, such as 
FMISO and FLT, for global disease assessment. Although the role of PET in global disease 
assessment has great potential, these approaches await validation in large prospective 
clinical trials. Ultimately, the use of PET in this setting could help guide treatment towards 
optimal systemic disease control in patients with advanced-stage NSCLC.
PET issues pertinent to response assessment
Harmonization of PET imaging
A wide variety of PET-image-derived response metrics rely on quantification of radiotracer 
uptake, highlighting the importance of reproducibility and quantitative accuracy of PET 
images. In order to compare data between different institutes, image harmonization is crucial, 
given the strong dependence of SUV quantification of PET-imaging data on acquisition and 
reconstruction parameters – particularly with current hardware and software evolutions. 
Adherence to strict acquisition protocols is necessary, including the use of similar patient-
preparation procedures, time points for assessment of radiotracer uptake, and scanning 
parameters [81-83]. In this regard, the European Association of Nuclear Medicine (EANM) 
provides guidelines on quantitative, multicentre FDG-PET–CT [83].
Quantitative accuracy of PET
Because the typical recording time for a single bed position in PET is several minutes, 
patients are instructed to breathe freely during image acquisition, and the images obtained 
will inevitably be averaged over several breathing cycles. Thus, the occurrence of respiratory 
motion artefacts during PET imaging can result in substantial underestimation of lesion 
radiotracer uptake and overestimation of volume. These issues are particularly relevant 
to response monitoring, the accuracy of which is highly dependent on the comparability 
of scans performed at different time points. Various methodologies enable correction for 
artefacts, resulting in data that more-accurately reflect the tumour biology and enable 
better comparisons during follow up.
 Specifically, respiratory gating approaches have been developed to correct PET images 
for respiratory motion artefacts. Correction of respiratory motion is usually accomplished 
by simultaneously recording a surrogate signal correlated with the patient’s respiratory 
cycle, together with the PET data [84-86]. Developments in respiratory gating strategies 
include the development of novel amplitude-based respiratory gating approaches that 
safeguard image quality while permitting efficient rejection of respiratory motion in PET 
images [86]. Alternatively, data-driven approaches (also known as list-mode gating), which 
do not incorporate measurement of respiratory surrogate signals, have been developed 
[87-89]. These methods rely on the concept that PET data inherently contain information on 
patient motion that can be used to correct for motion artefacts [89]. However, development, 
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validation, and refinement of these methods is ongoing. Another source of quantitative 
inaccuracies during PET evaluations is the occurrence of partial volume effects, particularly 
when imaging lesions that are less than two-to-three times smaller than the spatial 
resolution of the PET scanner, which can result in underestimation of the true radiotracer 
activity concentrations [90]. Software algorithms have been developed to correct for partial 
volume effects, resulting in improved quantitative accuracy [91].
 Although quantitative accuracy is improved using respiratory gating approaches, as 
determined by standardized phantom experiments, continuous development is ongoing 
to improve robustness in the presence of irregular patient breathing and to promote 
efficient use of PET data, in order to maintain image quality and reduce image acquisition 
time. Furthermore, different partial volume correction approaches are being developed to 
further improve quantitative accuracy and robustness under various imaging conditions.
 However, reproducibility of SUV-derived indices remains a challenge and studies 
are being performed to assess the usefulness of analysing radiotracer uptake patterns 
through calculation of PET-based textural features [92,93]. The rationale for quantification 
of tumour heterogeneity is its association with underlying tumour biology and physiology 
(that is, features such as perfusion, inflammation, and necrosis), which in turn could predict 
aggressiveness and response to therapy. Objective quantification of tumour heterogeneity 
in addition to SUV measurements might, therefore, contribute to patient stratification on 
baseline PET and response assessment during interim PET imaging. Although promising, 
development of these methods is ongoing and requires validation in prospective trials.
Therapy induced-inflammation
The limited specificity of FDG-PET has sparked interest in the development of approaches, 
such as dual-phase or delayed PET imaging, for improved discrimination between viable 
cancerous tissue and therapy-induced inflammation using FDG-PET [94]. Dual-phase PET 
imaging is performed by scanning the patient at two time points after FDG administration, 
and comparing FDG uptake in both images. The rationale for dual-phase PET imaging is that 
tumours continue to accumulate FDG at a higher rate than inflammatory tissue, reaching a 
plateau in FDG levels at a later time point [94]. The increment in SUVmax and retention index, 
that is, the percentage SUVmax increase between the delayed and initial PET image, have 
been shown to be predictive of PFS and overall survival in patients with NSCLC [94,95]. Using 
this strategy, improved discrimination between cancerous tissue and therapy-induced 
inflammation might be possible with FDG-PET, although more clinical data is required 
to determine the feasibility of such an approach for the purpose of improving response 
monitoring.
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Detecting disease recurrence using PET 
In addition to monitoring of treatment response and disease control in incurable disease, 
imaging-based surveillance and follow up is also important for detection of recurrent 
disease, treatment-related complications, and occurrence of second primary lung cancer 
in patients with NSCLC who are treated with curative intent [19,96]. Current guidelines for 
surveillance or follow-up imaging of the National Comprehensive Cancer Network (NCCN) 
and European Society for Medical Oncology (ESMO) advocate the use of contrast-enhanced 
diagnostic CT imaging [19,97]. However, diagnostic CT has a limited ability to distinguish 
vital tumour tissue from treatment-induced fibrosis or atelectasis [98]. Several studies have 
demonstrated improved sensitivity and specificity of FDG-PET–CT over diagnostic CT alone 
for detecting disease recurrence [98,99]. For example, in a prospective evaluation of 63 
patients with NSCLC with suspected relapse at least 6 months after definitive treatment, 
Hicks et al. [100] reported a sensitivity of 98% and specificity of 82% for the detection of 
recurrent disease with FDG-PET–CT; the PET findings prompted a change in management 
in 63% of patients during the study period of 2 years. Furthermore, on the basis of a 
retrospective study in 261 patients with lung cancer, Antoniou et al. [101] concluded that 
FDG-PET–CT performed beyond 6 months after treatment completion adds value to clinical 
judgement and is a prognostic marker of overall survival, regardless of the timing of the 
follow-up scan. However, the role of PET in follow-up surveillance after definitive treatment 
of NSCLC remains ambiguous and this modality is not currently recommended for use in 
routine clinical practice [19].
PET imaging of other cancer hallmarks
In addition to glucose metabolism, hypoxia, and cell proliferation, the versatility of PET 
permits the visualization of many other fundamental processes associated with tumour 
biology. The limited specificity of FDG, due to uptake associated with therapy-induced 
inflammation in addition to tumour tissues, stimulated the development of radiotracers 
that could be used to specifically monitor the viability of cancer cells or predict tumour 
response to therapy.
Maximizing the benefit of specific therapies
Radiolabelled chemotherapeutics 
Quantification of drug distribution and delivery through administration of a low dose of 
radiolabelled chemotherapeutic agent, a concept known as microdosing, can provide 
valuable information pertinent to prediction of therapeutic response and drug scheduling 
in individual patients [102]. Using the microdosing concept, van der Veldt et al. [103] 
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demonstrated that prediction of tumour docetaxel uptake at dosages that are therapeutic 
but are not associated with adverse events is possible with 11C-docetaxel-PET. In a separate 
study in patients with NSCLC [104], the effect of antiangiogenic therapy with the anti-VEGF 
antibody bevacizumab on docetaxel delivery was investigated using 11C-docetaxel; tumour 
perfusion and net influx rate of 11C-docetaxel was reduced within 5 h of bevacizumab 
administration and persisted beyond 4 days, highlighting the importance of drug scheduling 
[104]. Although the number of clinical studies exploiting such PET-based approaches 
remain limited, radiolabelling of new agents is expected to create increased possibilities to 
predict patient response to specific systemic therapies, and could facilitate individualized 
approaches to treatment selection that maximize the benefits and minimize toxicity.
Quantification of molecular targets
Molecularly targeted agents can provide clinical benefit in patients with NSCLC tumours 
that harbour specific mutations or particular molecular features. Currently, the molecular 
target most relevant to NSCLC therapy is the EGFR. First-line treatment with tyrosine kinase 
inhibitors (TKIs), such as gefitinib [5] and erlotinib [105],  has had an important impact on 
the treatment and survival of patients with NSCLC associated with sensitizing mutations 
in EGFR. However, these therapies fail to provide a clinically significant improvement in 
outcome for the general NSCLC population [6,7]. Furthermore, the role of these agents 
in the second-line and third-line treatment of NSCLC is unclear. In vivo visualization and 
quantification of EGFR expression might facilitate patient selection and guide dosing by 
measuring target-drug engagement. Thus, by monitoring receptor occupancy, duration of 
inhibition, and detecting the existence of primary or secondary mutations that confer either 
drug sensitivity or resistance, PET imaging could provide the possibility to individually tailor 
treatment approaches.
 Strategies for visualizing tumour EGFR expression using PET are based on 
radiolabelling of monoclonal antibodies or antibody fragments (immunoPET), or small-
molecule inhibitors (TKI–PET) that target this protein. Several immunoPET approaches to 
imaging EGFR expression, including 89Zr radiolabelling of cetuximab and panitumumab, 
have been investigated in a variety of malignancies [106]. However, experience in assessing 
EGFR expression using these approaches in NSCLC clinical trials remains limited. Difficulties 
associated with immunoPET approaches include unfavourable pharmacokinetics, due to 
the relatively slow clearance of these radiotracers from the blood and high physiological 
uptake in organs such as the liver and kidneys [106]. By contrast, a number of studies have 
reported results of TKI–PET in patients with NSCLC. Clinical results reported by Memon et 
al. [107] indicate that baseline TKI–PET with 11C-erlotinib can differentiate responders from 
nonresponders among patients with NSCLC who were treated with erlotinib, although 
validation of this approach in larger clinical trials is required. In a pilot study, Meng and 
colleagues [108] performed sequential PET imaging with the EGFR TKI analogue 11C-
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PD153035 in 21 patients with advanced-stage chemotherapy-refractory NSCLC who were 
treated with erlotinib. The results of this study indicate that it is possible to identify patients 
who are likely to respond to erlotinib treatment based on uptake of 11C-PD153035 at the 
baseline scan.
 In 2–7% of the NSCLC population, chromosomal inversion results in fusion of the 
echinoderm microtubule-associated protein-like 4 (ELM4) gene with the anaplastic 
lymphoma kinase (ALK) gene [109]. Additionally, approximately 1–2% of patients with 
NSCLC harbour tumours with genetic rearrangements involving the proto-oncogene 
receptor tyrosine kinase ROS1, which represent another specific disease subtype [110,111]. 
For these patient groups, treatment with the TKI crizotinib has yielded promising signs of 
efficacy [109,112]. In a phase III clinical trial involving 347 patients with advanced-stage 
ALK-positive NSCLC, crizotinib resulted in response rates up to 65% and was superior to 
standard treatment with pemetrexed or docetaxel [113]. Similarly, in a clinical phase I trial 
involving 50 patients with ROS1-positive NSCLC, the objective response rate with crizotinib 
treatment was 72% [112]. In the future, radiolabelling of inhibitors of NSCLC-associated 
fusion proteins, such as crizotinib, could enable PET-based quantification of the therapeutic 
targets and identification of resistance against these agents – information that would 
improve treatment stratification and dosing, and might further improve response rates and 
outcomes. However, to date, no published studies have visualized molecular ELM4-ALK or 
ROS1 targets using PET.
 With a variety of novel drugs targeting angiogenesis, visualization and quantification 
of this process will be of great importance for patient selection and monitoring of response 
to antiangiogenic therapies in a clinical setting. Several promising molecular targets for 
in vivo imaging of angiogenesis, such as metalloproteinases, αvβ3 integrins, and VEGF 
and its receptor (VEGFR), have been identified [114]. At present, promising angiogenesis 
radiotracers consisting of peptides containing arginine-glycine-aspartic acid (RGD) 
sequences, which bind to αvβ3 integrins, are being evaluated in early clinical trials [115]. 
Most clinical experience has been obtained with 18F-galacto-RGD, which can be used to 
quantify αvβ3 integrin expression using PET. In a study involving 10 patients with NSCLC, 
it was shown that 18F-galacto-RGD uptake was not strongly correlated with FDG uptake, 
suggesting that imaging with this tracer provides complementary information to that of 
FDG imaging [116]. Interestingly, bone lesions showed a tendency for higher uptake of 
18F-galacto-RGD [116], which is in line with the observation that αvβ3 integrin is an indicator 
for metastatic potential. Whether this tracer could be used for the purpose of stratification 
based on the risk of metastasis, monitoring therapy response, or adaptation of treatment 
remains to be established. Furthermore, although 18F-galacto-RGD uptake correlates well 
with αvβ3 expression and microvessel density, the specificity of 
18F-galacto-RGD–PET is 
limited owing to αvβ3 expression on cancer cells and in benign pathologies [115].
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Novel PET-markers of tumour-cell viability
Quantification of amino acid transport 
The limited specificity of FDG uptake for viable tumour tissues has generated interest 
in the development of radiotracers that more-specifically reflect tumour-cell viability. 
Amino acids are important metabolic substrates in many cancers; therefore, imaging the 
activity of amino acid transporters, assuming a relationship between the rate of amino 
acid uptake and tumour metabolism, has been the subject of great interest. Indeed, amino 
acid transporters are upregulated in many cancer types, including NSCLC [117]. Imaging 
of amino acid transport in NSCLC has been performed with tracers including 11C-tyrosine 
[118], O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) [119], 11C-methionine (11C-MET) [120], 18F-α-
methyltyrosine (FMT) [121,122], and (4S)-4-(3-18F-fluoropropyl)-L-glutamate [123]. Of note, 
in a study in 98 patients with NSCLC, response assessment with FMT provided independent 
prognostic information in addition to FDG, particularly in adenocarcinomas [121]. Although 
the sensitivity of most of these tracers for viable tumour tissue seems to be inferior to that of 
FDG, it might be possible to use them to predict response to therapy more accurately than 
is possible by FDG-PET [121,124], although this remains a subject for future studies.
Imaging of apoptosis
In addition to visualizing tumour cell viability, reciprocal monitoring of apoptosis might be 
important for determining response of cancer cells to cytotoxic therapy. Molecular targets for 
imaging apoptosis include phosphatidylserine expression on the cell surface, caspase-3/7 
activation, mitochondrial and plasma membrane depolarization, DNA fragmentation, and 
loss of plasma membrane integrity [125]. In a small study of six patients with NSCLC and 
brain metastases, Allen et al. [126] demonstrated a strong correlation between PET-detected 
tumour uptake of the radiotracer 2-(5-18F-fluoro-pentyl)-2-methyl-malonic acid (18F-ML-10), 
depicting specific plasma membrane changes associated with apoptosis, and anatomical 
measurements based on MRI data. The main limitation of apoptosis imaging is related to 
the small temporal window in which transient apoptotic markers are expressed and the 
relatively small number of apoptotic cells present at any given time point [127]. Although 
apoptosis imaging might provide an early indication of treatment success and failure, the 
difficulties associated with apoptosis imaging could potentially limit its widespread use 
in clinical practice. However, these markers could be leveraged in mechanistic studies 
to provide information valuable to drug development – for example, by facilitating 
determination of the optimal timing of combination therapy.
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Conclusions
Recent developments in radiopharmaceuticals and technological advancements in PET 
hardware and software have resulted in exciting possibilities to repetitively visualize and 
reproducibly quantify important molecular and microenvironmental features related 
to treatment response and resistance mechanisms in NSCLC. Clinical studies have 
demonstrated the potential value of PET imaging before, during, and after treatment to 
individually tailor treatment schedules and facilitate clinical decision-making. Currently, 
FDG remains the most widely used and best characterized PET radiotracer. The availability, 
low cost, ease of fabrication, and high sensitivity render FDG-PET a powerful modality 
for diagnosis, treatment planning, and response monitoring; furthermore, FDG-PET can 
provide, to some extent, specific PET probes, such as cell viability (proliferation) and tissue 
hypoxia. Although the specificity of FDG in discriminating inflammatory responses from 
malignancy is limited, multiple studies have demonstrated the possibilities for prediction 
of patient response to treatment and early detection of disease recurrence offered by 
FDG-PET. Similarly, imaging with FLT has shown potential in early assessment of treatment 
response in patients with NSCLC. Furthermore, exciting developments in imaging hypoxia 
with 18F-labelled 2-nitromidazoles have yielded interesting results with respect to prediction 
of prognosis and therapy adaptation. There remains a strong requirement for large clinical 
trials and correlative studies with these tracers to further assess the clinical impact of this 
imaging modality. In particular, additional studies of PET use for image-guided treatment 
decision-making and its association with clinical outcome are essential before full integration 
of PET in the clinical management of this patient group will be possible. Although clinical 
experience with other PET radiotracers is limited, several interesting approaches for imaging 
angiogenesis, apoptosis, and EGFR expression have been described, and have potential 
implications for treatment selection and assessment of response to therapy. Although it 
is unlikely that these tracers will become widely applicable to clinical practice in the near 
future, they are powerful tools for use in uncovering molecular mechanisms associated 
with therapy resistance and drug interactions. Given these developments, the role of PET in 
improving the management of NSCLC is likely to expand, and might ultimately contribute 
to improved outcomes and reductions in the frequency of acute and late treatment-related 
adverse events.
Review Criteria
References for this Review were identified through searches of PubMed, Google Scholar, and 
the Cochrane Library, with the search terms “advanced-stage non-small-cell lung cancer”, 
“PET imaging”, “response monitoring”, “treatment adaptation”, “molecular targeted therapy”, 
503606-L-bw-Grootjans
44 | Chapter 2
“treatment resistance”, and “radiotherapy”. Articles were also identified through searches of 
the authors’ own bibliographic files and the reference lists of the articles identified. Only 
papers published between 1995 and January 2015 in English were reviewed. The final 
reference list was generated on the basis of originality and relevance to the broad scope of 
this Review.
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Abstract
Objectives 
Respiratory motion artefacts during positron emission tomography (PET) deteriorate image 
quality, potentially introducing diagnostic uncertainties. The objective of this study was to 
determine the impact of optimal respiratory gating on clinical staging and management of 
patients with primary lung cancer. 
Materials and Methods 
From our fast-track outpatient diagnostic program, 55 patients with primary lung cancer, 
who underwent whole body 18F-fluorodeoxyglucose (FDG) PET, were included. Respiratory 
gating was performed on bed positions covering the thorax and abdomen. Independent 
reading was conducted by two nuclear medicine physicians. The observers scored the 
number and anatomical location of the lesions, lymph node basins and the presence 
of distant metastasis in non-gated and gated images. A tumor (T), lymph node (N), and 
metastasis (M) stage was assigned to each patient according to the 7th revision of the TNM 
classification. Staging accuracy was determined using histopathological data and follow-up 
CT imaging. In addition, a management plan was created for each patient based on non-
gated and gated images by an experienced pulmonologist.  
Results 
For nuclear medicine physician 1 and 2, respiratory gating resulted in detection of more 
lesions in five and eight patients (9% and 15%) respectively. However, this did not result 
in any migration in T or M-stage. Migration in N-stage was observed in four and seven 
patients (7% and 13%) for nuclear medicine physician 1 and 2 respectively. Staging accuracy 
was slightly improved when respiratory gating was performed. Furthermore, there was 
substantial agreement in patient management between non-gated and gated images. 
Conclusions 
Respiratory gating improved staging accuracy, mainly in assessment of lymph node 
involvement. However, the effect on patient management was limited due to the presence 
of already advanced disease stage in many patients. These findings suggest that the 
expected impact of respiratory gating will be solely on management of patients with early 
disease stages.
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Introduction
Positron emission tomography (PET) with the glucose analogue 18F-fluorodeoxyglucose 
(FDG) is an imaging modality which is of pivotal importance for accurate staging and 
management of patients with primary lung cancer [1]. The advantage of FDG-PET imaging 
in combination with X-ray computed tomography (CT) is a high sensitivity for the detection 
of pulmonary lesions, metastatic hilar/mediastinal lymph nodes, and distant metastases, 
when compared to contrast-enhanced CT imaging alone [2,3]. It has been established that 
patient management is considerably improved when FDG-PET–CT imaging is incorporated 
in the management algorithm of patients with suspected lung cancer due to the reduction 
of the number of futile thoracotomies and mediastinoscopies [3-7]. In addition to disease 
assessment, FDG-PET–CT guides management decisions regarding the choice of additional 
diagnostic procedures such as mediastinoscopy, endoscopic ultrasound-guided fine needle 
aspiration (EUS-FNA), or endobronchial ultrasound-guided transbronchial needle biopsy 
(TBNA), which are required for a definitive histopathological diagnosis [8-10]. 
 However, due to the relatively long image acquisition times, typically 3–4 minutes per 
bed position, patients are instructed to breathe freely during PET imaging. As a consequence, 
motion artefacts due the patient respiration can result in significant blurring of anatomical 
structures within the thorax and upper abdomen, reducing image contrast and distorting 
the appearance of anatomical structures [11]. In order to correct PET images for respiratory 
motion artefacts, different respiratory gating methods have been developed, relying on the 
selection of PET data at time intervals corresponding to a specific respiratory phase. This is 
usually accomplished by simultaneously recording of PET data and a surrogate signal that is 
correlated with the patients’ respiratory cycle [12-14]. Image reconstruction of the selected 
PET data then results in an image in which the main respiratory motion component is 
removed.
 Whether respiratory gating actually affects diagnosis and management of patient 
with primary lung cancer remains to be established. In this regard, the impact of respiratory 
gating with the optimal respiratory gating (ORG) algorithm in combination with high 
resolution time-of-flight (TOF) PET imaging on the clinical management of patients with 
primary lung cancer was evaluated. In particular, the effect on clinical staging accuracy and 
selected diagnostic procedures and treatment was investigated. 
Materials and Methods
Patients
A total of 55 patients from our fast-track outpatient diagnostic program with histologically 
confirmed primary lung cancer were included in this study. At our institute, all patients 
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with an abnormal chest X-ray that is suspicious for lung cancer are enrolled in the fast-track 
outpatient diagnostic program, which includes both first-line diagnostic CT and FDG-
PET imaging. Patient characteristics are summarized in Table 1. This study was approved 
by the institutional review board (IRB) of the Radboud university medical center and the 
requirement for written informed consent was waived.
Table 1| Patient characteristics
Characteristics of patient population
Male(Female) 32(23)
Median age (range) [y] 66(33–86)
Body massa [kg] 77±15
Administered FDG activitya [MBq] 247±47
Incubation time FDGa [min] 71±11
Histological type
Small cell lung cancer 6
Non-small cell lung cancer
Squamous cell carcinoma 24
Adenocarcinoma 21
Large cell carcinoma 1
Bronchioloalveolar carcinoma 2
Adenosquamous carcinoma 1
Disease stageb
IA 6
IB 5
IIA 2
IIB 1
IIIA 9
IIIB 11
IV 21
aData are reported as mean±standard deviation, bDisease stage according to the 7th revision of the International Association 
for the Study of Lung Cancer (IASLC), FDG = 18F-fluorodeoxyglucose.
Image Acquisition 
Whole body FDG-PET imaging was performed using a Biograph 40 mCT (Siemens Medical 
Solutions, Knoxville Tennessee, USA) PET–CT scanner. The PET scanner is configured with 
four lutetium oxy-orthosilicate (LSO) detector rings (TrueV), providing an extended axial 
field of view (FOV) that covers a total of 216 mm. The amount of administered FDG was 
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adjusted to the patient’s weight (3.2±0.2 MBq/kg). Respiratory gating was performed on 
bed positions covering the thorax and upper abdomen. The gated bed positions were 
acquired for 6 minutes while the non-gated bed positions were acquired for 2 minutes. The 
respiratory signal was obtained using an Anzai AZ-733V respiratory gating system (Anzai 
Medical Co. Ltd., Tokyo, Japan), consisting of a pressure sensor integrated in an elastic belt 
which is placed around the patient’s thorax. A whole body low dose (LD) CT was acquired 
during free-breathing for the purpose of attenuation correction and anatomical reference. 
The X-ray tube peak voltage (kVp) was set to 100 and 120 kV for patients with body mass 
<70 kg and >70 kg, respectively. Conversion of CT images acquired using different X-ray 
tube voltages to 511 keV annihilation photon attenuation maps was performed using 
a kVp-dependent transformation, as implemented in the Siemens mCT software [15]. 
Furthermore, the X-ray tube current was modulated using CARE Dose4D, with a reference 
tube current of 50 mAs.
Respiratory gating
Respiratory gating was performed using an amplitude-based optimal respiratory gating 
(ORG) algorithm, as integrated in the Syngo 2011A MI.PET/CT software (HD∙Chest). The 
primary input for this algorithm is the percentage duty cycle, which is the fraction of the 
total acquired PET data used for image reconstruction. For each duty cycle specified, the 
algorithm calculates an optimal amplitude range, taking the characteristics of the entire 
respiratory signal into account [11,16].  The ORG images were reconstructed using a duty 
cycle of 35%, providing a good balance between motion rejection and image quality 
[11]. Non-gated equivalent images were reconstructed using the first 126 seconds of the 
acquired PET data, resulting in images with comparable noise characteristics as the ORG 
images reconstructed with a duty cycle of 35%.
Image Reconstruction
The CT images used for attenuation correction were reconstructed with a B19f convolution 
kernel and a slice thickness of 5.0 mm, whereas CT images used for the purpose of anatomical 
reference were reconstructed with a B31f convolution kernel and a slice thickness of 3.0 mm. 
The PET images were reconstructed using the TrueX algorithm (with a spatially varying 
point spread function (PSF)) and the incorporation of TOF measurements (Ultra-HD PET), 
with 3 iterations, 21 subsets, and a matrix size of 400×400 (pixel spacing of 2.04 mm). The 
slice thickness of the PET images was matched to the slice thickness of the attenuation CT. 
Post reconstruction filtering was performed with a 3D Gaussian filter kernel with a full width 
at half maximum (FWHM) of 3.0 mm. 
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Reading
Independent readings were performed by two experienced nuclear medicine physicians, 
blinded to all other information. The observers scored the number and anatomical location 
of the lesions, lymph node stations and the presence of distant metastases in non-gated and 
gated PET images provided in random order. A tumor (T), lymph node (N), and metastasis 
(M) stage was assigned to each patient according to the 7th revision of the TNM classification 
[17]. The lymph node stations (I–XIV), as described in the TNM classification, were grouped 
into three anatomical groups 1) superior mediastinal nodes (station I–IV), 2) aortic lymph 
nodes (station V and VI), 3) inferior mediastinal nodes (station VII–IX), and 4) peripheral hilar 
lymph nodes (station X–XIV), as depicted in Figure 1.
Superior mediastinal lymph nodes (I–IV)
Hilar lymph nodes (X–XIV)
Aortic lymph nodes (V and VI)
Inferior mediastinal lymph nodes (VII–IX)
Figure 1| Defined anatomical lymph node regions 1) superior mediastinal nodes (stations I–IV) (red), 
2) aortic lymph nodes (stations V and VI) (orange), 3) inferior mediastinal lymph nodes (stations VII–IX) 
(blue), 4) peripheral hilar lymph nodes (stations X–XIV) (green).
The performance of both observers regarding mediastinal staging using gated and non-
gated PET images was evaluated with available histopathology data and radiological follow-
up. Radiological follow-up was performed according to the guidelines, where chest X-ray 
was mostly conducted for the early stage patients six weeks after surgery. For patients with 
locally advanced disease stages, contrast-enhanced CT was performed during treatment 
(to monitor therapy response), and within six weeks after treatment completion. Contrast-
enhanced CT imaging was also performed in patients with advanced disease stages during 
treatment for the purpose of treatment response monitoring. These CT scans were used to 
evaluate whether FDG positive lesions suspected for cancer were correctly identified on the 
PET images. Correct classification of FDG positive lesions on the PET images was defined 
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as disease progression at sites which were initially FDG avid (e.g. hilar/mediastinal lymph 
nodes).
Patient management plan
In addition to the nuclear medicine readings, an individual patient management plan was 
created by an experienced pulmonologist, blinded to all information except for the PET–CT 
findings. In the first section of this management plan, the pulmonologist was required 
to select the diagnostic procedure that would prove the highest disease stage. Available 
options included; mediastinoscopy, endobronchial ultrasound (EBUS), endoscopic 
ultrasound (EUS), a combined EBUS and EUS procedure, bronchoscopy, CT-guided biopsy, 
ultrasound-guided biopsy, and pleural fluid cytology. Subsequently, the pulmonologist 
was asked to select a second procedure if the first procedure would theoretically yield 
inconclusive results. In the second section of the management plan, the pulmonologist was 
required to select the primary treatment based on the gated and non-gated PET findings of 
the nuclear medicine physicians. Available treatment options included; surgery (lobectomy, 
bilobectomy, pneumonectomy) for early stage lung cancer, chemoradiotherapy for locally 
advanced lung cancer, chemotherapy for advanced stage lung cancer, and radiotherapy 
(with a palliative intent). If the patient was eligible for a lobectomy, the pulmonologist was 
asked if stereotactic ablative radiotherapy (SABR) would also be considered a treatment 
option (for cT1-2N0 disease). In addition to the primary treatment option, the pulmonologist 
was required to indicate whether the patient would be eligible for restaging and possibly 
a subsequent lobectomy after successful chemoradiotherapy for stage III disease or 
prescription of adjuvant chemotherapy after surgery for early N1 stage based on the 
FDG-PET–CT results.
Statistics
Statistical analysis was performed with SPSS Statistics 21 (IBM, Armonk, New York, USA). 
The level of agreement between the observers was determined using Cohen’s kappa (κ). 
The κ-value was provided together with a 95% confidence interval (CI). Interpretation of 
the κ-value was performed according to the criteria as described by Landis and Koch [18].
Results
For nuclear medicine physician 1 and 2, respiratory gating resulted in detection of more 
lesions in five and eight patients (9% and 15%) respectively. However, detection of more 
lesions did not result in migration of T or M stages, and was primarily due to the recovery 
of satellite lesions and loco-regional metastatic lesions that would have otherwise been 
obscured by tumour motion. The additionally detected lesions on the PET images became 
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apparent on follow-up CT imaging. Figure 2 depicts such recovery of a satellite lesion in 
the right lower lobe. In addition to detection of satellite lesions, small ipsilateral pulmonary 
metastases were detected in the respiratory gated images in patients with more advanced 
disease stages.
Figure 2 | Non-gated and optimally respiratory gated (ORG) PET images of a patient with a primary 
non-small cell lung cancer (NSCLC) lesion in the right lung hilum. a | Non-gated PET image fused with 
a low dose (LD) CT image. b | ORG PET image reconstructed with a 35% duty cycle fused with a LDCT 
image. Respiratory gating in this patient resulted in improved contrast recovery of satellite lesions 
adjacent to the primary lesion. The presence of the lesion was confirmed on follow-up CT imaging. For 
this patient, detection of additional lesions did not result in migration of lymph node (N) or metastasis 
(M) stage.
N-Stage migration
There was a substantial inter-observer agreement with regard to N-staging and the level 
of agreement on gated images (κ=0.77, 95% CI (0.63–0.90), p<0.0001) was increased with 
respect to that of the non-gated images (κ=0.66, 95% CI (0.50–0.82), p<0.0001). For nuclear 
medicine physician 1 and 2, respiratory gating affected the N-stage in four and six patients 
(7% and 11%) respectively. There was a perfect overlap between observer 1 and 2 with 
respect to patients in which stage migration occurred. For nuclear medicine physician 1 and 
2, migration in N-stage was supported by histopathological data and radiological follow-up 
in 2 and 4 cases respectively. Both of the observers up-staged two patients with an M0-stage 
from N0 to any positive N-stage (N+). Figure 3 depicts the FDG-PET–CT images of a hilar 
lymph node in station X of a patient with a solitary NSCLC nodule in the left lower lobe in 
which up-staging from N0 to N+ occurred. 
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Figure 3 | Non-gated and optimally gated (ORG) FDG-PET–CT images depicting a hilar lymph node in 
station X in a patient with a solitary non-small cell lung cancer (NSCLC) lesion in the left lower lobe. a 
| Non-gated PET image fused with a low dose (LD) CT image. b | ORG PET image reconstructed with 
a 35% duty cycle fused with a LDCT image. Both nuclear medicine physicians upstaged this patient 
from cT1N0M0 to cT1N1M0. Upstaging would have resulted in the requirement for evaluation of the hilar 
lymph node. This changed the first selected diagnostic procedure from bronchoscopy to EBUS. Based 
on both the non-gated and gated PET images, a lobectomy would have been performed.
Similarly, observers 1 and 2 down-staged one and three patients from N+ to N0 respectively. 
Table 2 provides an overview of N-stage migration in these patients.
 Respiratory gating resulted in a significant increase of the number of lymph nodes 
that were considered positive on the FDG-PET–CT images. Particularly, hilar lymph nodes 
were more frequently considered positive in the respiratory gated FDG-PET–CT images. 
Furthermore, respiratory gating also affected recovery of aortic, inferior and superior 
mediastinal lymph nodes, although to a lesser extent. Although histopathological or 
radiological follow-up data was not always available for specific lymph nodes, in a number 
of patients, the detection of lymph nodes was supported by the available follow-up data. 
Table 3 summarizes the scoring of different lymph node regions in the non-gated and gated 
FDG-PET–CT images together with histopathological data and radiological follow-up.
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Table 3 | Effect of respiratory gating on lymph node detection in the following defined anatomical 
regions 1) superior mediastinal nodes (stations I–IV), 2) aortic lymph nodes (stations V and VI), 
3) inferior mediastinal lymph nodes (stations VII–IX), 4) peripheral hilar lymph nodes (stations X–XIV). 
Values in this table represent the number of patients in which lymph node detection was affected 
by respiratory gating. Respiratory gating resulted in detection of more peripheral hilar lymph nodes. 
Although respiratory gating resulted in detection of intermediate mediastinal lymph nodes in a 
number of patients, there were also patients in which the lymph nodes were considered positive on 
the non-gated images and negative on respiratory gated images
Superior mediastinal lymph nodes (stations I–IV)
Observer ↑ ↓ Supported Not supported No data
1 3 5 2 1 5
2 3 6 4 0 5
Aortic lymph nodes (stations V and VI)
↑ ↓ Supported Not supported No data
1 4 3 3 0 4
2 3 6 2 1 6
Inferior mediastinal lymph nodes (stations VII–IX)
↑ ↓ Supported Not supported No data
1 2 4 0 1 4
2 1 6 2 1 4
Hilar lymph nodes (stations X–XIV)
↑ ↓ Supported Not supported No data
1  11 2 3 1 9
2 6 2 2 2 4
↑ = Anatomical regions negative on non-gated images whilst positive on respiratory gated images 
↓ = Anatomical regions positive on non-gated images whilst negative on respiratory gated images.
M-Stage Migration
Respiratory gating did not result in changes in assigned M-stage and there was a perfect 
agreement between both observers for all patients. Although the M-stage was not affected, 
both observers agreed that respiratory gating did improve the visualization of pulmonary 
and abdominal lesions.
Staging accuracy
In 46 of the 55 patients, follow-up CT imaging and additional histopathological data 
regarding disease sites other than the primary tumour and specific lymph nodes were 
available. Of these 46 patients, 5 patients had a distant metastatic lesion located outside 
the gated bed positions and could therefore not be included in the analysis for staging 
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accuracy. Respiratory gating resulted in a slight improvement in staging accuracy when 
compared to pathological staging. For observer 1, the agreement between pathological 
and clinical stage, based on non-gated and gated PET, was κ=0.73 (95% CI (0.58–0.88), 
p<0.0001) and κ=0.76 (95% CI (0.62–0.90), p<0.0001) respectively. For observer 2, there 
was an increase in agreement between pathological and clinical stage from κ=0.64 (95% CI 
(0.47–0.80), p<0.0001) to κ=0.70 (95% CI (0.55–0.85), p<0.0001) for non-gated and gated 
PET respectively.
Patient management plan
Evaluation of the management plans with the pulmonologists revealed that respiratory 
gating did not considerably affect the prescribed diagnostic procedures or assigned 
treatment when concerning the entire patient cohort. The level of agreement of the first 
selected diagnostic procedure based on non-gated and gated PET images was substantial 
(κ=0.81, 95% CI (0.68–0.94), p<0.0001). Similar results were obtained for the second selected 
diagnostic procedure, yielding an agreement of (κ=0.65, 95% CI (0.50–0.80), p<0.0001). 
Treatment
There were no clinically relevant differences in assigned treatment based on the non-
gated and gated images. The largest variability occurred in choosing either neo-adjuvant 
or adjuvant treatment in addition to the primary treatment. This was primarily due to the 
detection of more lymph nodes that were considered positive in the gated PET images. 
The agreement for the first treatment step between non-gated and gated images was 
к=0.68 (95% CI (0.52–0.83), p<0.0001). Similarly, the agreement between non-gated and 
gated PET images for the second treatment step was к=0.69 (95% CI (0.49–0.88), p<0.0001). 
Simplification of the prescribed treatment into either curative or palliative approach 
resulted in almost perfect agreement of к=0.84 (95% CI (0.69–0.99), p<0.0001). 
Surgical group
Stage migration can have important consequences for patients with early disease stages. 
The current patient population contained a total of 14 stage I and II patients. Within this 
patient subgroup, stage migration occurred in 3 and 4 patients for observer 1 and 2 
respectively. Migration to the correct stage occurred in 2 and 3 patients for observer 1 and 
2 respectively. For the remaining patients, respiratory gating resulted in migration towards 
lower disease stages, which was supported by histopathological data and radiological 
follow-up. These stage migrations mainly affected the selected diagnostic procedure, whilst 
surgery remained the principal treatment approach. However, the changes diagnostic 
management would have benefited some patients, as can be deduced from Table 2. 
Respiratory gating influenced the decision to prescribe adjuvant chemotherapy due to the 
presence of positive lymph nodes in three patients.
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Discussion
In this study, the impact of respiratory gating on clinical management of patients with 
lung cancer was investigated. In general, respiratory gating improves image quality by 
increasing image contrast and reducing shape distortions due to respiratory motion. This is 
reflected by a higher number of detected lesions in a number of patients in the respiratory 
gated images, particularly due to the recovery of satellite lesions which would otherwise be 
obscured by respiratory motion. In a few patient cases, additional pulmonary metastases 
were detected, albeit that respiratory gating did not result in the detection of additional 
extrathoracic metastatic lesions. However, detection of additional lesions did not result 
in any T- or M-stage migration and differences in the management in this patient group. 
Nevertheless, both observers agreed that lesion visibility improved and became more easily 
detectable.
 Furthermore, FDG-PET–CT imaging has an important role in evaluation of hilar and 
mediastinal lymph nodes, and to guide invasive diagnostic procedures [9,10]. Analysing 
lymph node recovery revealed that depiction of particularly hilar lymph nodes was improved 
when respiratory gating was performed. Conversely, in a number of patients, lymph node 
regions that were considered positive in the non-gated images were scored negative in the 
respiratory gated images, particularly in the intermediate mediastinal regions. Re-evaluation 
of these images with the observers revealed that this is, at least partially, attributable to 
reduced distortion of thoracic anatomy. However, in some patients, the FDG uptake was 
lower in the respiratory gated images when compared to the non-gated images. These 
counter-intuitive results could be due to the occurrence of a spatial mismatch between PET 
and CT images. In this study, the CT images used for attenuation correction were acquired 
during patient free breathing, resulting in a possible spatial mismatch between PET and CT 
images. This is an important issue that needs to be addressed, since spatial mismatching 
between PET and CT images can result in inappropriate attenuation correction, which 
may in turn result in misdiagnosis. Optimizing the spatial matching of PET and attenuation 
CT images in combination with the ORG algorithm is the subject of ongoing study at 
our institute [19]. Unfortunately, due to the limited detailed follow-up data and number 
of patients in which N-stage migration occurred, no definitive conclusion can be drawn 
on whether respiratory gating has a clinically significant impact on the false-positive or 
negative rates for hilar and mediastinal lymph node staging, though this will be subject of 
ongoing study. However, accuracy of clinical staging was improved when respiratory gating 
was performed and stage migrations largely supported by follow-up data.
 The advantage of the ORG algorithm used in this study is that it safeguards image 
quality of the reconstructed PET images, preventing the generation of noisy images that 
are diagnostically unacceptable. However, this method is still dependent on a good quality 
of the surrogate signal acquired. In this regard, respiratory gating methods that are solely 
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data-driven, also known as list-mode gating, omitting the use of respiratory surrogate 
signals, have been developed [20-23]. These methods rely on the concept that PET data 
inherently contains information about patient motion which can be used to correct motion 
artifacts, although further development and refinement is ongoing. The flexibility of the 
current respiratory gating method used permitted that the entire respiratory gated PET 
scan fitted within the length of a standard clinical protocol. Therefore, this protocol can be 
used in a clinical setting without compromising workflow and patient throughput.
 In this study, the clinical work-flow as implemented in this hospital was simulated. At 
our institute, patients with suspected lung cancer are enrolled in the fast-track outpatient 
diagnostic program with integrated PET–CT and diagnostic CT as a first-line imaging tool, 
directly following an abnormal chest X-ray [24]. Based on the results of these imaging 
procedures, a patient management plan is determined in a multidisciplinary setting, 
integrating all clinical information. However, in order to solely evaluate the effect of 
respiratory gating, the nuclear medicine physicians and pulmonologist did not receive 
access to any clinical information of the patients in this study and no multidisciplinary 
joined reading integrating all available information was performed, which is a limitation 
of this study. During clinical practice, joined reading and additional clinical information 
regarding patient habits is relevant when evaluating hilar and mediastinal lymph nodes 
and can influence clinical decision making.
 Respiratory gating had only limited effect on patient management in this study due to 
the presence of already advanced disease stages in many patients. Unfortunately, it is known 
from clinical practice that as much as two third of the patients already present with locally 
advanced disease stages at the time of diagnosis [25]. In this study, 75% of the patients 
had a disease stage IIIA or higher, with often larger primary tumours and multiple lymph 
node involvement. However, the results of this study emphasize that respiratory gating 
could be important for management of patients with early disease stages. In particular, the 
detection of additional pulmonary lesions or lymph nodes can considerably affect clinical 
management in patients with early disease stages [8].
Conclusions
The impact of respiratory gating on patient management was limited due to the presence 
of already an advanced disease stage in many patients. Respiratory gating slightly improved 
the accuracy of clinical staging and inter-observer agreement between the two nuclear 
medicine physicians. These findings suggest that the expected impact of respiratory gating 
on patient management will be solely on staging of patients with early disease stages.
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Abstract
Objectives 
Respiratory motion during PET imaging introduces quantitative and diagnostic inaccuracies, 
which may result in non-optimal patient management. This study investigated the effects 
of respiratory gating on image quantification using an amplitude-based optimal respiratory 
gating (ORG) algorithm. 
Materials and Methods 
Whole body FDG-PET–CT was performed in 66 lung cancer patients. The respiratory signal 
was obtained using a pressure sensor integrated in an elastic belt placed around the patient’s 
thorax. ORG images were reconstructed with 50%, 35%, and 20% of acquired PET data 
(duty cycle). Lesions were grouped into anatomical locations. Differences in lesion volume 
between ORG and non-gated images, and mean FDG uptake (SUVmean) were calculated. 
Results 
Lesions in the middle and lower lobes demonstrated a significant SUVmean increase and 
volume decrease in the ORG images for all duty cycles. Significant increase in SUVmean and 
decrease in volume for lesions in the upper lobes were observed for a 20% duty cycle. The 
SUVmean increase for central lesions was significant for duty cycles of 35%, and 20%, whereas 
a significant volume decrease was observed for a duty cycle of 20%. 
Conclusions 
This study implies that ORG could influence clinical PET imaging with respect to response 
monitoring and radiotherapy planning.
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Introduction
Positron Emission Tomography (PET) in combination with X-ray computed tomography 
(CT) is an essential multimodality molecular imaging platform for accurate staging and 
diagnosis of a variety of diseases, particularly in oncology [1,2]. The advantage of PET–CT 
imaging is that it permits the acquisition of both anatomical and functional images of the 
patient, improving detection, localization and characterization of disease sites [2,3]. In 
addition, quantitative indices in PET, such as the standardized uptake value (SUV)[4] and 
total lesion glycolysis (TLG) [5,6], can be used to provide important prognostic information. 
Furthermore, it has been established that molecular imaging with PET is valuable in the 
early assessment and prediction of therapy response of several cancers [7-10].
 However, due to the relatively long image acquisition times, typically 3–4 minutes for 
a single bed position, patients are instructed to breathe freely during PET imaging. As a 
consequence, motion artefacts due the respiratory cycle can result in significant blurring 
of structures within the thorax and upper abdomen, resulting in underestimation of lesion 
radiotracer uptake and overestimation of lesion volume in PET images [11-13]. If uncorrected, 
these artefacts can introduce diagnostic uncertainties, inaccuracies in definition of target 
volumes for radiation treatment planning, and hinders adequate monitoring of therapy 
response 
 Several methods, have been developed in order to correct PET images for these 
respiratory motion artefacts, which are commonly referred to as respiratory gating. 
Retrospective respiratory gating techniques in PET typically rely on the selection of data 
at specific time intervals within the respiratory cycle, thereby creating an image in which 
the main respiratory motion components are removed. This is usually accomplished by 
simultaneously recording a surrogate signal, correlated with the patient’s respiratory cycle, 
with the PET data [14,15]. Using the surrogate signal acquired, PET data can be selected by 
means of dividing each respiratory cycle into a fixed number of gates (phase-based gating) 
or by defining a certain amplitude range (amplitude-based gating), as depicted in Figure 1 
[12,16,17].
 However, difficulties in retrospective gating approaches is the maintenance of 
acceptable image quality in the presence of irregular breathing frequencies. Particularly 
in phase-based respiratory gating approaches, discarded PET data due to rejection 
of inappropriate triggers results in reduction of image quality whilst acceptation of 
inappropriate triggers results in the definition of gates in different phases of the respiratory 
cycle, as depicted in Figure 1a. In this study, the effect of respiratory gating in modern 
high resolution PET imaging, on quantification of lesion volume and FDG uptake for lung 
cancer lesions, was investigated using an amplitude-based optimal respiratory gating 
(ORG) algorithm. In contrast to many other respiratory gating algorithms, ORG safeguards 
image quality through calculation of an optimal amplitude range for a specified percentage 
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of acquired PET data. The performance of ORG in a clinical whole body imaging protocol 
was evaluated in a large representative group of patients with primary lung cancer. In 
particular, the effect of lesion anatomical location and different inputs for the algorithm, 
were investigated. 
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Figure 1| Phase- and amplitude-based gating approaches for PET. a | Phase-based gating. b | Amplitude-
based gating. In phase-based gating, each respiratory cycle is divided in a fixed number of gates (in this 
case 4) and data acquired in a specific gate is used for image reconstruction. Amplitude-based gating 
relies on definition of an upper and lower amplitude limit. PET data acquired when the amplitude of 
the respiratory signal falls in the defined amplitude range will be used for image reconstruction. In 
case of the ORG algorithm, an optimal amplitude range is defined according to the specified amount 
of data that needs to be used for image reconstruction (total sum of the areas shaded in blue). 
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Materials and Methods
Patients
This study was approved by the institutional review board (IRB) of the Radboud university 
medical center. A total of 66 patients from our fast-track outpatient diagnostic program 
with histologically confirmed primary lung cancer were included in this study. Patient 
characteristics are summarized in Table 1.
Table 1 | Characteristics of patients included in this study
Male(Female) 44(22)
Median age (range) [y] 66 (33–85)
Body massa [kg)] 78±15
Administered FDG activitya [MBq] 253±49
Histological type
Small cell lung cancer 6
Non-small cell lung cancer 60b
Squamous cell carcinoma 29
Adenocarcinoma 26
Large cell carcinoma 1
Bronchioloalveolar carcinoma 2
Adenosquamous carcinoma 1
Disease stagec
Ia 5
Ib 7
IIa 8
IIb 0
IIIa 13
IIIb 14
IV 19
aData are reported as mean±standard deviation; bHistology confirmed the presence of a NSCLC lesion in one patient. 
However, further immunohistological differentiation was not possible due to the quality of the obtained histological 
specimen and additional invasive diagnostic procedures were waived due to severe morbidity of the patient; cDisease stage 
at the time of the gated PET acquisition. FDG,18F-fluorodeoxyglucose; NSCLC,Non-small cell lung cancer.
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Image acquisition
Whole body FDG-PET imaging was performed using a Siemens Biograph 40 mCT PET–CT 
scanner. The PET scanner has an extended axial field of view (FOV) of 216 mm with four 
lutetium oxy-orthosilicate (LSO) detector rings (TrueV). The amount of administered FDG 
was adjusted to the patient’s weight (3.2±0.2 MBq/kg). Respiratory gating was performed 
on bed positions covering the thorax and upper abdomen. Gated and non-gated bed 
positions were acquired during patient free breathing for 6 and 2 minutes, respectively. 
The respiratory signal was obtained using an Anzai AZ-733V respiratory gating system. This 
system consists of a pressure sensor integrated in an elastic belt which is placed around the 
patient’s thorax. A whole body low dose (LD) CT was acquired during free-breathing for the 
purpose of attenuation correction and anatomical reference. The X-ray tube peak voltage 
(kVp) was set to 100 and 120 kV for patients with body mass <70 kg and >70 kg, respectively. 
Appropriate conversion of CT images acquired using different kVps to 511 keV annihilation 
photon attenuation maps was performed using a kVp-dependent transformation, as 
implemented in the Siemens mCT software [18]. The X-ray tube current was modulated 
using CARE Dose4D, with a reference tube current of 50 mAs. 
Respiratory gating
Respiratory gating was performed on the list-mode data with an amplitude-based ORG 
algorithm, integrated in the Syngo 2011A MI.PET/CT software, designated HD·Chest by 
Siemens. The main user input for the ORG algorithm is the percentage duty cycle, which 
is the percentage of the acquired list-mode data used for image reconstruction. The ORG 
algorithm calculates an optimal amplitude range for a given duty cycle [13]. The algorithm 
starts by calculating the amplitude range for different values of the lower limit (L). With 
each value of L, the upper limit (U) is adjusted to include the specified percentage of the 
acquired PET data, and an amplitude range (W) is calculated through a simple subtraction 
(U-L). The optimal amplitude range is defined as the smallest amplitude range obtained and 
calculated by minimizing W, as depicted in Figure 1b.
 Selection of the percentage duty cycle permits the user to control the amount of 
noise versus the residual motion component in the reconstructed images. In this study, 
ORG images were reconstructed using duty cycles of 20%, 35%, and 50%, corresponding 
with 72, 126 and 180 seconds of PET data, respectively. For the non-gated images, the first 
126 seconds of the acquired data were used for image reconstruction, resulting in an equal 
amount of acquired true coincidences as the ORG images reconstructed with a duty cycle 
of 35%.
Image reconstruction
The CT images used for attenuation correction were reconstructed with a B19f convolution 
kernel and a slice thickness of 5.0 mm, whereas CT images used for the purpose of anatomical 
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reference were reconstructed with a B31f convolution kernel and a slice thickness of 3.0 mm. 
The PET images were reconstructed with the TrueX algorithm (with a spatially varying point 
spread function (PSF)) and the incorporation of time-of-flight (TOF) measurements (Ultra-
HD PET). Image reconstruction was performed with 3 iterations, 21 subsets, and a matrix size 
of 400×400 (pixel spacing of 2.04 mm). The slice thickness of the PET images was matched 
to the slice thickness of the attenuation CT and post reconstruction filtering was performed 
with a 3D Gaussian filter kernel with a full width at half maximum (FWHM) of 3.0 mm. 
Image analysis
Analysis of the FDG-PET images was performed using the Inveon Research Workplace 
4.1 Software (Preclinical Solutions, Siemens Medical Solutions USA, Knoxville Tennessee, 
USA). Lesions were delineated using a region growing segmentation algorithm with a 
segmentation threshold at 40% of SUVmax [19]. Differences in lesion volume between 
non-gated and ORG images, as determined by the 40% SUVmax isocontour, and in mean 
FDG uptake of the corresponding volumes (SUVmean) were calculated. In addition, noise 
characteristics were determined by placing a volume of interest (VOI) in the parenchyma 
of the contralateral lung and recording the mean and standard deviation of the SUV voxel 
values within these volumes. Image noise was expressed by the coefficient of variation, 
defined as the ratio of the standard deviation to the mean.
Lesion localization
It has been well-established that the nature and magnitude of the motion of structures 
within the thorax are dependent on anatomical location [14]. Therefore, it is expected that 
the effects of respiratory gating also demonstrate such an anatomical dependency. In order 
to determine the effect of anatomical location on the quantification of lesion volume and 
FDG uptake, lesions were grouped according to their anatomical location within the lungs. 
These locations are the 1) mediastinum/lung hilum (central group), 2) middle and lower 
lobes, 3) and upper lobes. Lesions which demonstrate invasive growth into or attachment to 
large structures (i.e. the main bronchi, arteries and veins) of the lung hilum or mediastinum, 
are assigned to the central group. The anatomical groups defined for this study are depicted 
in Figure 2. 
Statistics
Statistical analysis was performed using the Wilcoxon signed-rank test for paired variables 
using SPSS Statistics 20 (IBM, Armonk, New York, USA) and statistical significance was 
defined for p<0.05. Lesion volume and SUVmean in the ORG images reconstructed with 
different duty cycles were compared with the non-gated images of the same patient. A 
Bonferroni correction was performed to correct for multiple testing through multiplication 
503606-L-bw-Grootjans
82 | Chapter 4.1
of the p-value with the number of statistical tests (in this case 6). Reported p-values have 
been Bonferroni corrected unless otherwise stated.
Upper lung lobes
Middle and lower lung lobes
Mediastinum/ Lung hilum
Figure 2 | Schematic representation of the three anatomical groups defined.
Results
Lesions in the ORG images demonstrated a statistically significant increase in SUVmean values 
when compared to the non-gated images. The SUVmean increase was 6.2±12.2% (p<0.0001), 
7.4±13.3% (p<0.0001), and 9.2±14.0% (p<0.0001), for duty cycles of 50%, 35% and 20% 
respectively. Furthermore, a concomitant decrease in lesion volume of 6.9±19.6% (p=0.02), 
8.5±19.3% (p<0.0001), and 11.3±20.2% (p<0.0001) was observed. The mean volume of the 
lesions, as determined on the non-gated images, was 18.7±33.9 mL (range 0.37–230 mL). 
The absolute SUVmean value of the lesions on non-gated images was 10.7±6.3 g∙mL
-1. In 
ORG images reconstructed with a duty cycle of 50%, 35%, and 20%, the absolute SUVmean 
increased to 11.2±6.5, 11.4±6.6, and 11.5±6.6, respectively. In addition to the observed 
differences in SUVmean and volume, some lesions also demonstrated marked changes in 
morphology when respiratory gating was performed. These effects of respiratory gating 
are readily shown in Figure 3, depicting non-gated and ORG PET images of a patient with a 
non-small cell lung cancer (NSCLC) lesion in the left lower lobe. 
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Figure 3 | Coronal non-gated and optimally respiratory gated (ORG) PET images of a patient with a 
NSCLC lesion in the left lower lobe fused with LDCT images. a | Non-gated PET image fused with a 
LDCT image, b | ORG PET image reconstructed with a 35% duty cycle fused with a LDCT image. The PET 
and CT images are displayed with equal window-level settings. In addition to a different morphological 
appearance of the lesion between the non-gated and ORG PET images, there is a considerable increase 
in SUVmean of 69.5% and a decrease in volume of 80.2%. SUV, standardized uptake value.
A considerable difference in magnitude of the effect of ORG on lesion volume and on 
SUVmean for the different anatomical locations was observed. The mean increase in lesion 
SUVmean and volume as a function of the percentage duty cycle and anatomical location are 
summarized in Table 2 and Table 3 respectively. 
 The changes in SUVmean and volume were the largest for lesions in the middle and lower 
lobes. For lesions located in the middle and lower lobes, statistically significant increases in 
SUVmean were observed for duty cycles of 50%, 35% and 20%, whereas statistically significant 
volume reductions were observed for duty cycles of 35% and 20%. However, for lesions 
located in the upper lobes and centrally located lesions, the effect of ORG was smaller. For 
centrally located lesions, a statistically significant SUVmean increase was observed for duty 
cycles of 50%, 35% and 20%, whereas a statistically significant volume reduction was only 
observed for a duty cycle of 20%. For lesions located in the upper lobes, a statistically 
significant increase in lesion SUVmean and reduction in volume was observed only for duty 
cycles of 20%. Figure 4 readily depicts such an anatomical dependency of the effects of ORG 
in a single patient with two NSCLC lesions, one located in the left lower lobe and one in the 
left lung hilum.
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Table 2 | Relative SUVmean increase of lesions in the optimal respiratory gated (ORG) PET images 
compared to the non-gated images for different anatomical locations and percentages duty cycle
Anatomical location Duty Cycle [%]
50 35 20
Upper lobes (n=28) 3.6±11.6%  
p=0.8
5.0±12.2% 
p=0.2
6.9±13.5%  
p=0.02*
Middle and lower lobes (n=26) 12.3±15.7%  
p<0.0001*
13.7±16.8%  
p<0.0001*
15.5±17.7%  
p<0.0001*
Central (n=29) 3.2±5.8%  
p=0.04*
4.2±7.3%  
p=0.01*
5.8±7.7%  
p<0.0001*
All locations (n=83) 6.2±12.2%  
p<0.0001*
7.4±13.3%  
p<0.0001*
9.2±14.0%  
p<0.0001*
Data are reported as mean±standard deviation. Statistically significance is indicated by an asterisk ‘*’. 
Table 3 | Relative volume decrease of lesions in the optimal respiratory gated (ORG) PET images 
compared to the non-gated images for different anatomical locations and percentages duty cycle
Anatomical location Duty Cycle [%]
50 35 20
Upper lobes (n=28) 3.3±17.5%  
p=1
5.8±19.9% 
 p=1
8.2±23.3%  
p=0.03*
Middle and lower lobes (n=26) 13.3±24.9%  
p=0.07
14.8±23.3% 
p=0.006*
17.7±21.0%  
p<0.0001*
Central (n=29) 4.7±15.1% 
p=1
5.3±13.1%  
p=0.4
8.6±14.9%  
p=0.02*
All locations (n=83) 6.9±19.6%  
p=0.02*
8.5±19.3%  
p<0.0001*
11.3±20.2%  
p<0.0001*
Data are reported as mean±standard deviation. Statistically significance is indicated by an asterisk ‘*’.
In this patient, the large NSCLC lesion located in the left lung hilum (depicted in Figure 
3c and d) exhibits invasive growth into the left main bronchus, causing a post obstructive 
atelectasis of the left lower lobe in which a second NSCLC lesion is located. For the lesion 
in the left lung hilum, the SUVmean increase in the ORG image was 5.3% when compared 
to the non-gated image, and a concomitant decrease in volume of 1.9% was observed. 
The effects of ORG on the lesion in the left lower lobe were considerably larger, showing a 
SUVmean increase of 31.9% and a concomitant volume decrease of 23.0%. Analysis revealed 
no correlation between lesion size, as determined on the non-gated images, and relative 
increase in SUVmean. The Spearman correlation coefficient ‘ρ’, describing the relation between 
lesion size and SUVmean increase, was -0.129, -0.169, and -0.212 for duty cycles of 50%, 35%, 
and 20% respectively.
503606-L-bw-Grootjans
85Respiratory gated PET in patients with lung cancer |
4
The values for the coefficients of variation revealed that the amount of image noise is 
increased when lower percentages of the duty cycle are used for image reconstruction. The 
mean coefficients of variation of the VOIs located in the contralateral lung parenchyma of 
the 66 patients are summarized in Table 4. 
Figure 4 | Non-gated and optimally respiratory gated (ORG) PET images fused with LDCT images of a 
patient with NSCLC lesions in the left lower lobe and lung hilum. a | Non-gated PET image fused with 
a LDCT image depicting a lesion in the left lower lobe, b | ORG PET image, reconstructed with a duty 
cycle of 35%, fused with a LDCT image of a lesion in the left lower lobe, c | Non-gated PET image fused 
with a LDCT image depicting a lesion in the left lung hilum, d | ORG PET image, reconstructed with a 
duty cycle of 35%, fused with a LDCT image of a lesion in the left lung hilum. The PET and CT images 
are displayed using equal window-level settings. In this patient, the anatomical dependency of the 
effects of ORG is clearly demonstrated. For the lesion in the left lung hilum, the SUVmean increase in the 
ORG image was 5.3% while a concomitant decrease in volume of 1.9% was observed. A considerable 
larger increase in SUVmean of 31.9% and decrease in volume of 23.0% was observed for the lesion in the 
left lower lung lobe. SUV, standardized uptake value.
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Table 4 | Mean coefficient of variation for the VOIs in the contralateral lung parenchyma for duty cycles 
of 50%, 35%, and 20%. The non-gated images were reconstructed with 360 s (100%) and 126 (35%) of 
the acquired list-mode data per bed position
Percentage duty cycle (%) Non-gated 50 Non-gated 35 20
List-mode data (s) 360 180 126 126 72
Coefficient of variation (%) 26.1±6.4 30.1±8.0 31.8±5.6 32.8±6.4 39.4±7.5
Data are reported as mean±standard deviation.
Although selection of a higher percentage duty cycle for image reconstruction reduces 
the amount of image noise, this will inevitably result in calculation of a wider amplitude 
range and a larger residual motion component residing in the reconstructed images. The 
mean width of the amplitude range for duty cycles of 50%, 35%, and 20%, is summarized 
in Table 5.
Table 5 | Mean width of the amplitude range used for optimal respiratory gated (ORG) PET for duty 
cycles of 50%, 35%, and 20%. The amplitude range is calculated by subtracting the value for the lower 
amplitude limit from that of the upper amplitude limit
Percentage duty cycle [%] 50 35 20
Width of amplitude range [%] 20.9±5.9 12.9±5.1 7.3±2.4
Data are reported as mean±standard deviation.
Discussion
The clinical role of FDG-PET for management of patients with primary lung cancer is 
increasingly being recognized [3,20,21]. Several authors report a correlation between changes 
in lesion glucose metabolism in subsequent PET imaging and treatment response [7,22,23].
However, respiratory motion can introduce random errors during image quantification in 
PET and, if uncorrected, may hinder adequate patient management. Reducing inaccuracies 
regarding quantification of lesion volume and radiotracer uptake may improve monitoring 
treatment response in early stages of cancer therapy, facilitating clinical decision making 
by switching to a different treatment regimen, thereby avoiding administration of several 
cycles of ineffective anticancer treatment [10]. Furthermore, with the increasing tendency 
to incorporate functional information provided by PET imaging into radiation treatment 
planning schemes, correction of PET images for respiratory motion artefacts may enable 
the possibility to employ a more individually tailored radiation therapy [24-26]. Particularly, 
the reduction in target volume could be used to perform radiation dose escalation whilst 
limiting the dose to organs at risk. 
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Traditionally, techniques that rely on the use of a respiratory surrogate signal in order to 
perform respiratory gating, can be characterized as either phase-based or amplitude-based. 
Phased-based respiratory gating methods perform sorting of list-mode data by dividing 
each respiratory cycle into a fixed number of respiratory gates of equal duration. Respiratory 
gating of PET data is then performed by using PET data collected in a specific gate for image 
reconstruction. However, these methods are sensitive to the emergence irregular breathing 
patterns during image acquisition. These irregular patterns hinder appropriate detection 
of respiratory peaks in the signal resulting in rejection of respiratory cycles that can be 
used for gating. Discarding PET data can considerably reduce diagnostic quality of the PET 
images due to increased amounts of image noise. Several authors reported that amplitude-
based approaches are more robust in the presence of irregular breathing patterns when 
compared to phase-based gating approaches [12,16,17]. However, most of these algorithms 
do not take the characteristics of the respiratory signal into consideration. The advantage 
of the ORG algorithm is that it finds the optimal amplitude range for the specified duty 
cycle. Calculation of the optimal amplitude range is achieved by searching throughout the 
entire respiratory signal of the gated bed positions the smallest amplitude range which still 
contains the specified amount of PET data. The ORG algorithm therefore makes optimal 
use of specific characteristics of the respiratory signal, such as plateau phases, to define 
an optimal amplitude range while maintaining image quality. Selection of the duty cycle 
permits the user to control the amount of noise and residual motion in the image.
 The results of this study show that respiratory gating with HD·Chest considerably 
affects quantification of lesion volume and FDG uptake during PET imaging of the thorax. 
The effects are dependent on the anatomical location of the lesion and percentage duty 
cycle used for image reconstruction. In general, lesions in the middle and lower lung lobes 
demonstrate a considerable increase in SUVmean and reduction in volume when ORG is 
performed. However, the effect of ORG on lesions located centrally and in the upper lobes 
is more heterogeneous. The heterogeneity of the observed effects can be explained by 
the classification of the lesions into three main anatomical groups used during this study. 
The exact location of a lesion, as well as the extension of lesion growth (e.g. attachment 
to other anatomical structures), determines the displacement of the lesion during the 
patient’s respiratory cycle. For the upper lung lobes, lesions in the apical segments usually 
experienced limited displacement during the respiratory cycle, whilst lesions in the 
inferior segments demonstrated more substantial displacement. The same differences 
were observed for centrally located lesions, where lesions located in the periphery of the 
lung hilum demonstrated substantial displacement whereas almost no displacement was 
observed for mediastinal and subcarinal lesions. 
 In this study, we examined a representative patient population from our fast-track 
outpatient diagnostic program. However, a number of these patients presented with 
additional pulmonary diseases such as lung emphysema and fibrosis. Particularly in patients 
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with severe lung emphysema, thoracic wall excursions and displacement of anatomical 
structures can be reduced due to hyperinflation. In this patient population, approximately 
one third of the patients had radiological evidence of mild lung emphysema. However no 
considerable reduction in breathing excursions on the acquired respiratory signals were 
observed as compared to the patients without emphysema. Furthermore, there was no 
correlation other than anatomical location between the presence of lung emphysema and 
observed increases in SUVmean and decreases in volume.
 It should be mentioned that the ORG algorithm deals with PET data only. Since the CT 
scans have been performed without respiratory gating and without breathing instructions, 
there can exist a spatial mismatch between the PET and CT images, particularly for structures 
which exhibit a large displacement during the respiratory cycle. Spatial mismatch between 
the PET and CT datasets may result in inappropriate attenuation correction and subsequent 
inaccuracies in quantification of the PET images. Several authors report strategies to 
improve spatial match between PET and CT images [27,28]. These strategies include the 
use of breathing instructions, and respiratory triggered or gated CT acquisitions using the 
same respiratory signal as during PET gating. Optimizing the spatial matching of PET and 
attenuation CT images in combination with the ORG algorithm will be the subject of future 
study. 
 Respiratory gating with HD·Chest permits convenient integration of respiratory 
gating of multiple bed positions in a whole body PET imaging protocol, and can easily be 
integrated in a routine clinical PET workflow. Furthermore, the advantages of modern PET 
reconstruction algorithms, including the incorporation of TOF and a spatially varying PSF 
can be used in image reconstruction of respiratory gated PET data. The results of this study 
suggest that respiratory gating could influence clinical PET imaging with respect to therapy 
response monitoring and radiation treatment planning.
Conclusions
ORG with HD·Chest markedly affects quantification of lesion volume and FDG uptake in PET 
imaging of the thorax, particularly for lesions located in the middle and lower lung lobes. The 
results of this study show that the magnitude of the effects is dependent on the anatomical 
location of the lesion and the percentage duty cycle used for image reconstruction. These 
results imply that ORG could influence clinical PET imaging with respect to therapy response 
monitoring and radiation treatment planning.
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Abstract
Objectives 
Respiratory motion during positron emission tomography (PET) has a significant effect on 
the quantification of radiotracer uptake in PET images. Even when respiratory motion is taken 
into account by using PET gating techniques, inaccuracies in standardized uptake values 
(SUVs) can be caused by inappropriate attenuation correction due to a spatial mismatch 
between PET and CT. In this study, the effect of breath hold-CT imaging on the spatial match 
between CT and amplitude-based respiratory gated PET images was investigated. 
Materials and Methods 
Whole body 18F-fluorodeoxyglucose (FDG) PET–CT imaging was performed in 52 patients 
with 125 lung lesions. FDG-PET was performed using optimized, amplitude-based 
respiratory gating. For CT, 36 patients were randomly assigned to the free-breathing (FB) 
group and 16 to the rest-expiratory breath-hold (BH) group. Spatial mismatch between the 
PET and CT images was quantified by measuring the distance between the centroids of the 
PET and CT lesions and calculating the Jaccard similarity coefficient (JSC). 
Results 
In the upper lobes, the average distance between the centroids of the lesions on PET and 
CT was 4.7±3.1 mm and 6.0±3.0 mm for the FB and the BH group, respectively (p=0.11). 
For the middle/lower lobes, the distances were 5.8±4.3 mm and 5.1±2.9 mm (p=0.70), and 
for the central region 4.8±4.6 mm and 5.6±2.0 mm (p=0.24). The JSC for the upper lobes 
was 0.28±0.17 and 0.28±0.19, for the FB and the BH group, respectively (p=0.83). For the 
middle/lower lobes the JSC was 0.22±0.16 and 0.28±0.18 (p=0.20), and for the central region 
0.39±0.17 and 0.13±0.04 (p=0.04). 
Conclusions 
Providing breathing instructions to the patients during the CT acquisition did not improve 
the spatial alignment between the respiratory gated PET images and the CT images. 
The difficulty experienced in using this clinical protocol, such as patient compliance and 
operator dependence, emphasizes the need for other strategies.
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Introduction
Positron Emission Tomography (PET) combined with X-ray computed tomography (CT) is 
an essential multimodality molecular imaging method for accurate staging and diagnosis 
of a variety of diseases, particularly in oncology [1,2]. The advantage of combined PET–CT 
imaging is that it provides both anatomical and molecular information of the patient, 
improving detection, localization and characterization of disease [2]. Besides improving the 
anatomical localization of radiotracer uptake in PET, the CT images can be used for PET 
attenuation correction. This is important, given that quantitative indices in PET, such as the 
standardized uptake values (SUV) [3], metabolic tumour volume (MTV), and total lesion 
glycolysis (TLG) [4,5], can be used to diagnose disease, provide prognostic information, and 
to optimize radiotherapy planning. Furthermore, it has been established that molecular 
imaging with PET is valuable in the early assessment of therapy response of several tumour 
types [6-9]. 
 However, due to the relatively long acquisition times, patients are usually instructed 
to breathe freely during PET imaging. As a consequence, respiratory motion can result 
in significant blurring of structures within the thorax and upper abdomen, reducing 
quantitative accuracy of radiotracer uptake and accurate volume definition in PET images 
[10-13]. Different strategies have been developed in an attempt to correct PET images 
for respiratory motion. These methods, collectively known as respiratory gating, have 
demonstrated that breathing-induced image-blurring can have a significant effect on the 
quantification of radiotracer uptake and volume in PET images. 
 Additionally, underestimation and overestimation of the SUVs can also be caused by a 
spatial mismatch between PET and CT, resulting in inappropriate PET attenuation correction 
[14,15]. The spatial mismatch can increase by performing respiratory gated PET, since 
lesions in the PET images can be captured in a different respiratory phase than in the CT 
images. The effect of inappropriate attenuation correction on quantification of radiotracer 
uptake will be largest in moving lesions at the interface of anatomical regions with different 
densities (e.g. the lower lung and the liver dome) [16]. Improving the spatial match between 
the PET and CT images can therefore result in more accurate attenuation correction and 
quantification of lesion SUVs. This may ultimately contribute to an improved diagnostic 
accuracy of PET imaging, facilitate clinical decision making during early treatment response 
monitoring, and the incorporation of PET in radiotherapy treatment planning [13].
 In order to improve PET–CT co-registration, it has been suggested to provide breathing 
instructions during CT imaging [15,17,18]. In the present study, the effect of free-breathing 
(FB) and breath-hold (BH) CT imaging on the spatial match between CT and amplitude-
based respiratory gated PET images was investigated. 
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Materials and Methods
Patients
Whole body 18F-fluorodeoxyglucose (FDG) PET–CT imaging was performed in 52 patients 
with 125 lung lesions. Patient demographics are summarized in Table 1. 
Table 1 | Demographics of the patient population included in this study
Free-breathing group Breath-hold group
Agea (y) 66.7±9.5 70.9±9.8
Body massa (kg) 80.5±15.7 70.6±11.9
Male(female) (24)12 10(6)
Lesion type
Primary lung cancer
Pulmonary metastasis from other malignancy
Other & unconfirmed
25
3
8
10
3
3
Lesion volume on CTa (mL) 8.3±22.9 8.9±21.9
Administered FDG activitya (MBq) 248±40 225±42
Minimum SUVmax (g/mL) 0.67 1.03
aData are reported as mean±standard deviation; FDG,18F-fluorodeoxyglucose.
When respiratory gating became available for FDG-PET–CT in our institute, it was included 
in the routine diagnostic work-up of patients with suspected lung cancer. Patients were 
scanned with or without respiratory instruction during the CT scan. This study was approved 
by the institutional review board (IRB) and the requirement to obtain written informed 
consent was waived. The number of lesions for each different anatomical location used for 
image analysis are summarized in Table 2.
Table 2 | Number of lesions for the free breathing group and the breath hold group for different 
anatomical locations
Anatomical location Free-breathing group Breath-hold group
Upper lobes 45 17
Middle and lower lobes 30 19
Central 11 3
Total 86 39
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Image Acquisition
Images were acquired using a Siemens Biograph 40 mCT PET–CT scanner using optimized, 
amplitude-based respiratory gating (HD·Chest) [12]. The PET scanner has an extended axial 
field of view (FOV) of 216 mm with four lutetium oxy-orthosilicate (LSO) detector rings. A 
dose of 3.2 MBq FDG per kg body weight was administered to the patient. Respiratory gating 
was performed on bed positions covering the thorax. Gated and non-gated bed positions 
were acquired during free-breathing for 6 and 2 minutes, respectively. The respiratory signal 
was obtained using an Anzai AZ-733V respiratory gating system. This system consists of a 
pressure sensor integrated in an elastic belt placed around the patient’s thorax. A whole 
body low-dose CT (LDCT) was acquired for attenuation correction and anatomical reference. 
The X-ray tube peak voltage (kVp) was set to 100 and 120 kV for patients with body mass 
<70 kg and >70 kg, respectively. The tube current was modulated using CARE Dose4D, with 
a reference setting of 50 mAs. The CT scan was acquired with 5.0 mm slices (16x1.2), a pitch 
of 1.0 and a rotation time of 0.5 sec. Patients were sequentially assigned to two groups using 
different breathing protocols: 1) a FB group (n=63) and 2) a BH group (n=41). In the FB group, 
no breathing instructions were given to the patients during CT imaging. The patients in the 
BH group received an end rest-expiratory breath-hold instruction during CT imaging. The 
signal amplitude of the pressure sensor during the breath hold CT was matched as closely 
as possible to the gating setting used for PET reconstruction. Seven patients originally 
assigned to the BH group, could not comply with the respiratory instruction. These patients 
were assigned to the FB group.
Image Reconstruction
The PET images were reconstructed using a 3D ordered subset expectation (3DOSEM) 
algorithm with a spatially varying point spread function incorporating time-of-flight 
information (UltraHD PET). Image reconstruction was performed with 3 iterations, 
21 subsets, and a transaxial matrix size of 400x400 (pixel size 2.04x2.04 mm2). The slice 
thickness of the PET images was matched to the slice thickness of the attenuation CT, and 
post reconstruction filtering was performed with a 3D Gaussian filter kernel with a full 
width at half maximum of 3.0 mm. Respiratory gating was performed on the list-mode 
data with an amplitude-based optimal respiratory gating (ORG) algorithm, integrated in 
the Syngo 2011A MI.PET/CT software. The main user input for the ORG algorithm is the 
percentage duty cycle, which is the percentage of the acquired PET data that is used for 
image reconstruction. The ORG algorithm then calculates an optimal amplitude range for a 
given duty cycle [12]. Selection of the percentage duty cycle permits the user to control the 
amount of noise versus the residual motion components in the reconstructed images. In 
this study, images were reconstructed using a duty cycle of 35%, providing the best trade-
off between number of counts, scan time and reduction of motion artefacts [12,13]. 
503606-L-bw-Grootjans
96 | Chapter 4.2
The CT images for attenuation correction were reconstructed with a B19f convolution 
kernel and a slice thickness of 5.0 mm, whereas CT images for anatomical reference were 
reconstructed with a B31f convolution kernel and a slice thickness of 3.0 mm.
Image Analysis
Analysis of the FDG-PET and the CT images was performed using the Siemens Inveon 
Research Workplace 4.1 Software (Preclinical Solutions, Siemens Medical Solutions USA, 
Knoxville Tennessee, USA). To quantify the mismatch between lesions in the PET and CT 
images, two methods were used: (1) measurement of the distance between the centroids 
of the lesions on PET and CT images [16,17] and (2) calculation of the Jaccard similarity 
coefficient (JSC) of the volume of interest (VOI) of the lesions defined on the PET and CT 
images. The JSC quantifies the spatial overlap of the two volumes and can be calculated 
using equation (1.1) [19].
JSC(VOICT,VOIPET)=
VOICT  VOIPET
—————— (1.1)
VOICT  VOIPET
The volume of interest (VOI) on the PET images (VOIPET) was delineated using a fixed 
threshold region growing segmentation algorithm. The threshold was set to 40% of the 
SUVmax [13,16,20]. Lesions were manually delineated on the LDCT images (VOICT) using a lung 
window level setting (window centre, -450 HU; width, 1500 HU), by an imaging scientist. In a 
number of cases, additional contrast enhanced CT imaging was used for improved depiction 
of the lesion during the process of delineation. Supervision took place by an expert nuclear 
medicine physician. 
 It has been well-established that the motion of structures within the thorax are 
typically dependent on anatomical location [21]. Therefore, it is expected that the effects 
of respiratory gating, and the probability of misalignment of the lesions between PET and 
CT images, also demonstrate such an anatomical dependency. In order to determine the 
effect of anatomical location on mismatch between PET and CT scan, lesions were grouped 
according to their anatomical location within the lungs. These 3 locations are the upper 
lobes, middle and lower lobes and the lung hilum as described by Grootjans et al [13]. 
Lesions which demonstrated invasive growth into or attachment to large structures (i.e. the 
main bronchi, arteries and veins) of the lung hilum were assigned to the central group.
Statistics
Statistical analysis was performed using the Mann-Whitney U test. Statistical significance 
was defined for p<0.05.
503606-L-bw-Grootjans
97Breath-hold CT in respiratory gated PET |
4
Results
Visual assessment of spatial alignment
Visual assessment of the images revealed that there was a clear spatial mismatch between 
the PET and CT images in a number of cases in the FB group. Figure 1a depicts a patient 
of the FB group where such a spatial mismatch between the FDG-PET and CT images was 
observed. Figure 1b depicts the FDG-PET–CT images of a patient with a similar lesion 
assigned to the BH group, where only a limited spatial mismatch between the FDG-PET and 
CT images was observed.
Figure 1 | Coronal optimal respiratory gated (ORG) PET fused with low dose CT (LDCT) images, with 
lesion contours based on PET and LDCT depicted in green and red respectively. a | Patient with a 
non-small cell lung cancer (NSCLC) (squamous cell carcinoma) in the free-breathing (FB) group. The 
difference between the centroids of the lesions on PET and LDCT is 10.5 mm, while the Jaccard similarity 
coefficient (JSC) is 0.29. b | Patient in the breath-hold (BH) group with a NSCLC (adenocarcinoma). The 
difference between the centroids of the lesion on PET and CT is 4.0 mm, the JSC is 0.50.
Quantification of spatial alignment
However, there were no considerable differences between the FB and BH group regarding 
quantification of spatial matching between PET and CT images. The distance between the 
centroids of the lesions on PET and CT images in the upper lobes and the central region 
appeared smaller for the FB group, while for the BH group the distance was smaller in the 
middle and lower lobes. However, these differences were not statistically significant. The 
distance of the centroids of the lesions on PET and CT, and the JSC for the different groups 
are summarized in Table 3 and 4 respectively. 
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Table 3 | Distance between centroids of the lesions determined on PET and CT images
Location Free-breathing group 
(mm)
Breath-hold group (mm) Significance level
Upper lobes 4.7±3.1 6.0±3.0 p=0.11
Middle and lower lobes 5.8±4.3 5.1±2.9 p=0.70
Central 4.8±4.6 5.6±2.0 p=0.24
Total 5.1±3.8 5.5±2.9 p=0.16
Data are reported as mean±standard deviation.
Table 4 | Jaccard similarity coefficient (JSC) of the volumes of interest (VOIs) determined on PET and 
CT images
Location Free- breathing group Breath-hold group Significance level
Upper lobes 0.28±0.17 0.28±0.19 p=0.83
Middle and lower lobes 0.22±0.16 0.28±0.18 p=0.20
Central 0.39±0.17 0.13±0.04 p=0.04*
Total 0.27±0.17 0.27±0.18 p=0.95
Data are reported as mean±standard deviation. Statistically significance is indicated by an asterisk ‘*’.
The results show that there was no statistically significant difference in the calculated JSC 
between the upper/middle and lower lobes. However, there was a statistically significant 
difference between both groups in the lesions located near the lung hilum. 9.3% of the 
lesions in the FB group and 15% in the BH group showed no overlap of the lesions on 
the PET and the CT image. Assignment of the 7 patients, who could not comply with the 
respiratory instruction, to the FB group did not affect distribution of patient characteristics 
between the two groups. Exclusion of these 7 patients from the analysis did not affect the 
results (data not shown). There was a similar distribution of the values for the calculated 
distances between the centroids on PET and CT in both the FB and de BH group. Figure 2 
and 3 depict box and whisker plots of the distance between the centroids of the lesions on 
PET and CT images, and the JSC of the VOIPET and VOICT, respectively
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Figure 2 | Differences between the centroids of the lung lesions on PET and CT images. Lesions in the 
upper lung lobes (UL), middle and lower lung lobes (LL), mediastinal and hilar lesions (central). Outliers 
are depicted as ‘o’, which are values that do not fall in the inner fences of the whiskers. Extreme outliers, 
which are more than three times the height of the boxes, are depicted as ‘*’.
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Figure 3 | Jaccard similarity coefficient (JSC) of lesion volumes determined on PET and CT images. 
Lesions in the upper lung lobes (UL), middle and lower lung lobes (LL), mediastinal and hilar lesions 
(central). Outliers are depicted as ‘o’, which are values that do not fall in the inner fences of the whiskers.
No specific explanation could be found for the outliers shown in Figure 2 and 3. These 
lesions were therefore not excluded from the analysis.
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Discussion
This study showed that breathing instructions provided to the patient during the CT scan 
had no significant impact on the spatial alignment of respiratory gated PET with the CT 
images. There were differences in the spatial match of the lesions on PET and CT between 
different anatomical locations of the lesions, but these did not reach statistical significance. 
Providing breathing instructions during CT resulted in a significant difference in spatial 
match between PET and CT images of lesions in the lung hilum, as depicted in Figure 3. 
However, no definite conclusions can be drawn, due to the limited number of lesions in the 
lung hilum in the BH group.
 Theoretically, a perfect spatial match could be achieved when a BHCT is acquired at 
the same respiratory phase as the gated PET images. However, in practice, this is dependent 
on the patient’s capability to correctly execute the instructions, on the accuracy of the 
instructions provided by the technologist, and on the interpretation of these instructions by 
the patient [22]. The results of our study imply that the majority of BHCT scans were acquired 
during a forced deep-expiration and not during rest-expiration. This suggest that providing 
breathing instructions can result in actually inducing spatial mismatching between the PET 
and CT images, highlighting the difficulties associated with this method.
In this study, patients were assigned to two groups: one group received a breathing 
instruction during the CT scan, while the other group did not receive instructions. A more 
accurate way to compare the free breathing CT to the breath hold CT protocol would have 
been an intra-patient comparison by performing both techniques on the same patient. 
Such a study design permits to investigate the effect of spatial alignment on quantification 
of SUV values, which was not possible in the current setting. However, it was decided 
not to perform such study design after ethical consideration and for reasons of radiation 
protection.
 The optimal gate for the PET scans is usually defined during the end expiratory plateau 
of the respiratory curve. Therefore, to find the best match between the PET and CT scan, 
patients need to exhale during the CT scan. This is a more difficult manoeuvre than when a 
patient is instructed to inhale, which is usually performed during a diagnostic CT imaging. In 
this study, respiratory gating was performed in patients with suspected lung lesions, some 
of whom experienced respiratory difficulties, such as dyspnoea. Therefore, complying with 
the provided respiratory instructions is especially strenuous for these patients as illustrated 
by the 7 patients who could not comply with the respiratory instruction. In previous studies, 
a significantly better match between the PET and the CT images was found when using a 
BHCT protocol [16,17,19]. In these studies, the amplitude of the respiratory surrogate signal 
during the BHCT was used to define respiratory gates used to rebin the PET data. However, 
in order to safeguard the statistical quality of the PET images, our approach focused on the 
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optimal use of the PET data for the purpose of respiratory gating. Therefore, we attempted 
to match the BHCT to the optimal gate of the PET. 
 The rationale for using breathing instructions to improve the spatial alignment 
between PET and CT images is that, in contrast to many other methods, this method can be 
directly implemented into clinical practice without compromising patient throughput and 
without installing any additional hard- or software. However, there are other techniques 
to match the CT scan with the optimal gate of the PET scan. These methods, such as 
respiratory triggered or gated CT acquisitions, may improve spatial matching between 
PET and CT. However, full CT gating will inevitably increase radiation dose to the patient 
compared to standard low dose CT acquisitions [23]. Fortunately, dose reduction strategies 
in CT imaging is an area of active research [24]. These strategies include modulation of 
X-ray tube voltage [25] in addition to modulation of X-ray tube current, and employment 
of iterative CT reconstructions [26] to reduce radiation dose to the patient. We are currently 
investigating the feasibility of respiratory triggered CT acquisitions in combination with 
these dose reduction strategies in order to improve spatial matching of optimal respiratory 
gated PET with CT images.
Conclusions
Providing breathing instructions to the patients during the CT acquisition did not improve 
the spatial alignment between the PET and CT images. The difficulties experienced in 
employing this clinical protocol, such as patient compliance and operator dependence, 
emphasizes the need for other strategies in order to improve spatial matching between PET 
and CT. Without such other strategies, it is therefore preferred to use a free-breathing CT 
acquisition protocol.
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Abstract 
Objectives 
Respiratory motion during PET can cause inaccuracies in the quantification of radiotracer 
uptake, which negatively affects PET-guided radiotherapy planning and response 
monitoring. Quantitative accuracy can be improved by respiratory gating. However, 
additional miscalculation of standardized uptake values (SUVs) in PET images can be caused 
by inappropriate attenuation correction due to a spatial mismatch between gated PET and 
CT. In this study, the effect of respiratory triggered CT on the spatial match between CT and 
amplitude-based respiratory gated PET images is investigated. 
Materials and Methods 
FDG-PET–CT was performed in 38 patients. Images were acquired on two PET–CT scanners, 
one without and one with continuous bed motion during PET acquisition. The amplitude 
limits of the amplitude-based respiratory gated PET were used for the respiratory triggered 
sequential low-dose CT. Both standard (spiral) and triggered CT scans were used to 
reconstruct the PET data. Spatial mismatch was quantified using the position difference 
between the lung-liver boundary in PET and CT images, the distance between PET and 
CT lung lesions’ centroids, and the amount of overlap of lesions indicated by the Jaccard 
similarity coefficient (JSC). Furthermore, the effect of attenuation correction was quantified 
by measuring SUVs in lung lesions. 
Results 
For triggered CT, the average distance between the lung-liver boundary in PET and CT was 
significantly reduced (4.5±6.7 mm) when compared to standard CT (9.2±8.1 mm) (p<0.001). 
The mean distance between the lesions centroids in PET and CT images were 6.3±4.0 and 
5.6±4.2 mm (p=0.424), for the standard and triggered CT respectively. Similarly, the JSC was 
0.30±0.21 and 0.32±0.20 (p=0.609), for standard and triggered CT. For 6 lesions there was no 
overlap of PET and CT when the standard CT was used, compared to the triggered CT these 
lesions showed (partial) overlap. The SUVmax and SUVmean increase of the PET–CT compared 
to the PET/triggered CT was 5.7±11.2% (p<0.001) and 6.1±10.2% (p=0.001), respectively. 
Conclusions 
Amplitude-based respiratory gated PET in combination with respiratory triggered CT 
resulted in a significantly improved match in the area of the liver dome and a significantly 
higher SUV for lung lesions. However, lesions in the lungs did not show a consistent 
improvement in spatial match. 
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Introduction
The combination of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and 
X-ray computed tomography (CT) is widely used in oncology [1-3]. FDG-PET–CT imaging 
provides anatomical and metabolic information of tissues, which is important for detection, 
localization and characterization of disease [2,3]. Furthermore, quantitative indices in FDG-
PET, such as standardized uptake values (SUVs) [4,5], metabolic volume [6,7], and total lesion 
glycolysis [5-7], can be used to provide prognostic information, and predict and monitor 
therapy response [4-7]. 
 Due to the relatively long acquisition times, patients are usually instructed to breathe 
freely during the PET acquisition, resulting in respiratory motion artifacts [3,8,9]. Within the 
thorax and upper abdomen, significant blurring can occur, resulting in an overestimation 
of the size of structures and an underestimation of SUVs [3,8-10]. If the PET images are 
not corrected for respiratory motion, the artefacts can introduce diagnostic uncertainties, 
inaccuracies in quantitative indices and delineation of target volumes, which can result 
in an unnecessarily high radiation dose to normal tissue in radiotherapy planning, and 
inadequate monitoring of therapy response [3,10,11]. 
 Methods are available to reduce these respiratory motion artefacts in PET images, 
commonly referred to as respiratory gating. These methods typically rely on the use of PET 
data acquired at specific time intervals, resulting in a motion reduced image reconstruction 
[11]. Since the low-dose (LD) CT is usually performed without breathing instructions, a 
significant spatial mismatch between PET and CT can occur for structures that move during 
respiration [11,12]. The LDCT is used for attenuation correction of the PET image, which is 
one of the most important correction stages in PET [9]. A mismatch between PET and CT can 
therefore lead to quantitative inaccuracies in PET [11]. In sum, spatial matching of PET and 
CT is important, especially for lesions located near the transition of anatomic regions with 
different densities (e.g., the lower lung and liver dome) [13,14].
 Several methods have been proposed to improve the spatial matching of LDCT with 
PET, for example breathing instructions [12,15] or rigid/non-rigid transformations [16]. Van 
Elmpt et al. suggested that respiratory triggered CT could be used for this purpose [17]. 
In the present study, we pursued the triggered CT concept, comparing results based on 
free-breathing spiral and triggered CT for improving spatial matching of CT with amplitude-
based optimally respiratory gated (ORG) PET imaging. 
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Materials and Methods
Patients
Whole body FDG-PET–CT imaging was performed in 38 patients with suspected lung cancer. 
Thirty patients were recruited at the Radboud university medical center (Radboudumc), and 
8 patients at the University of Tennessee Medical Center (UT). The local Institutional Review 
Board (IRB) of the Radboudumc waived the need to assess the protocol, nevertheless, all the 
patients signed informed consent. Data from the UT Medical Center was collected under a 
UT IRB approved protocol. Patient characteristics are summarized in Table 1.
Table 1 | Characteristics of patients included in this study. Lesions showing invasive growth into or 
attachment to large anatomical structures (the arteries, veins and main bronchi) were assigned to the 
lung hilum group
Patient characteristic Patients scanned with step and 
shoot method  
(Biograph 40 mCT)
Patients scanned with the 
continuous bed motion method 
(Biograph 64 mCT Flow)
Male(Female) 19(11) 5(3)
Mean agea [y] 69±9 66±6
Body massa [kg] 82±17 69±19
Location of lesion
Upper lung lobes 19 4
Middle and lower lung lobes 13 9
Lung hilum 8 3
Duration of triggered CT [min]a 3.1±1.6 1.7±0.7
Length of triggered CT (cm]a 46.8±7.0 32.0±3.9
aData are reported as mean±standard deviation.
Patient preparation
At the Radboudumc, administration of FDG was dependent on patient weight 
(3.1±0.2 MBq·kg-1). The mean incubation time was 74 minutes. At the UT, the administered 
amount of FDG was independent of patient weight. The mean administered activity at this 
institute was 371±25 MBq, with a mean incubation time of 80 minutes. 
PET acquisition and respiratory gating
The Biograph 40 mCT PET–CT scanner with extended field of view (TrueV) was used (Siemens 
Healthcare, Knoxville, Tennessee, USA) at the Radboudumc. This scanner is EARL accredited 
[18]. The Biograph 64 mCT Flow PET–CT scanner (Siemens Healthcare, Knoxville, Tennessee, 
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USA) was used at UT. PET images from both scanners were acquired using an optimized, 
amplitude-based ORG algorithm (HD·Chest) integrated in the PET–CT software [11,17]. For 
the Biograph 40 mCT, the respiratory gating was performed on bed positions covering the 
thorax and upper abdomen. Gated and non-gated bed positions were acquired during free 
breathing for 6 and 2 minutes, respectively. The difference in acquisition time led to similar 
count densities after gating. For the Biograph 64 mCT Flow scanner [19], continuous bed 
motion acquisitions were performed using three ranges with two different table speeds. 
Through all areas other than the thorax and upper abdomen, a table speed of 1.5 mm/s 
was used. When gating was applied, the table speed was slowed to 0.4 mm/s to acquire 
similar count densities as those found in the standard 1.5 mm/s ranges. On both scanners, a 
respiratory amplitude signal was acquired with an AZ-733V respiratory gating system (Anzai 
Medical Co, Ltd., Tokyo, Japan) with a pressure sensor integrated in an elastic belt placed 
around the patient’s abdomen. Respiratory gating was performed with a duty cycle of 35%, 
providing a good balance between image quality and motion rejection [11]. This was done 
with standard components in the PET–CT scanner, with digitized respiratory amplitude 
signals from AZ-733V electronics. 
PET image reconstruction
The PET images for both scanners were reconstructed using a 3D ordered subset expectation 
(3DOSEM) algorithm with a spatially varying point spread function incorporating time-of-
flight information (UltraHD PET). Image reconstruction was performed with 3 iterations and 
21 subsets. The slice thickness of the PET reconstructions was matched with the attenuation 
correction CT. Post reconstruction filtering was performed using a 3D Gaussian filter kernel 
with a full width at half maximum of 3.0 mm. A transaxial matrix size of 400x400 was used 
for the PET reconstructions of the Biograph 40 mCT scanner, for the Biograph 64 mCT Flow 
scanner a matrix size of 200x200 was used.
Standard free breathing low-dose spiral CT imaging
A standard LD spiral CT (standard CT) was acquired for attenuation correction and anatomical 
reference. This standard CT was acquired with a free breathing protocol. For the Biograph 
40 mCT scanner the X-ray tube voltage was chosen using CARE kV, with a reference tube 
voltage of 100 kV. For the Biograph 64 mCT Flow, 120 kV was used for all patients. The tube 
current was for both scanners modulated using CARE Dose4D, with a reference tube current 
of 50 mAs. CT images were made with a 0.5 s tube rotation time and 16x1.2 mm collimation, 
a reconstruction with an increment of 3 mm and a reconstructed slice width of 5.0 mm was 
made. In the case of the Biograph 40 mCT, additional reconstructions of 3.0 mm slice width 
were used to quantify the lung-liver boundary mismatch.
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Respiratory triggered low-dose sequential CT imaging
Patients received an additional respiratory triggered LDCT scan (triggered CT) covering 
the thorax, in which we prospectively used the defined amplitude range from the gating 
algorithm of the PET reconstructions. The respiratory triggered CT approach was not entirely 
integrated into the PET–CT scanner. Instead, AZ-733V electronics digitized the respiratory 
amplitudes and issued a trigger to the CT gantry, with the amplitude matched to the 
amplitudes determined by the gating algorithm [20]. The CT scanner acquired a CT image 
in response to each trigger, then advanced to the next position (sequential mode). The time 
required to cover the thorax was between one minute and several minutes, depending on 
the scan range and the respiration of the patient. For the Biograph 40 mCT scanner the 
tube peak voltage (kVp) was chosen using CARE kV, with a reference tube voltage of 100 
kVp. For the Biograph 64 mCT Flow 120 kVp was used for all patients. The tube current was 
modulated for both scanners using CARE Dose4D, with a reference tube current of 35 mAs 
for the Biograph 40 mCT scanner and 50 mAs for the Biograph 64 mCT Flow. X-ray dose in 
the triggered CT scan was similar to a spiral CT with the same voltage and current settings.
At the Radboudumc, two acquisition settings were used for the triggered CT. For the first 
6 patients, triggered CT scans were made using 5.0 mm slices (1x5.0 mm), 5 mm table feed 
and a rotation time of 0.36 sec. Because the acquisition time was long for those patients and 
the slice thickness was large, we scanned the other patients with a larger table feed and a 
possibility to reconstruct the data with thinner slices. These patients were scanned with 4.8 
mm slices (16x1.2 mm), 19 mm table feed and a rotation time of 0.36 sec for the Biograph 
40 mCT scanner. The 4.8 mm reconstructions were used for the attenuation correction and 
lesion delineation. Additional reconstructions were made with a slice width of 2.4 mm 
for the determination of lung-liver boundaries. At the UT, a method similar to the second 
approach was used, but with a slice thickness of 2.0 mm.
Image Analysis
Analysis of the PET and the CT images was performed using the Siemens Inveon Research 
Workplace 4.1 Software (Preclinical solutions, Siemens Medical Solutions, Knoxville 
Tennessee, USA). Spatial alignment between PET and CT structures was quantified using 
four methods. First, quantification of the mismatch for the liver dome in the craniocaudal 
direction. The liver dome was determined visually in the axial plane. The most cranial plane 
where the liver was visible was measured for the PET and the CT scan and the difference in 
craniocaudal direction was reported. The CT images were analysed using the lung setting 
(window centre, -450 HU; width, 1500 HU) was used. The alignment of the lung lesions 
was determined by delineating lesions in the PET and CT images. The lesions on the PET 
images were delineated using a fixed threshold region growing segmentation algorithm. 
The threshold was set to 40% of the SUVmax, which is recognized as a suitable threshold 
level for delineation of lung lesions [11-13,21]. The lesions in the CT images were manually 
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delineated using the lung setting. To quantify the spatial alignment, the distance between 
PET and CT lesions’ centroids was calculated [13,15]. Spatial overlap was determined by 
calculating the Jaccard similarity coefficient (JSC) [9,12], as defined by equation 4.1. 
JSC(VOICT,VOIPET)=
VOICT  VOIPET
(4.1)——————
VOICT  VOIPET
In this equation, VOIPET and VOICT denotes the volume of interest defined on PET and CT 
imaging respectively. Furthermore, the SUVmax and SUVmean were compared between PET 
images reconstructed using the standard and triggered CT scan. Lesions were excluded if 
the segmentation was not possible on either PET or CT.
Statistical analysis
Since not all the paired groups were normally distributed, statistical analysis was performed 
using the Wilcoxon Signed Ranks test using SPSS Statistics 20 (IBM, Armonk, New York, USA) 
and statistical significance was defined for p<0.05. A Bonferroni correction was performed 
to correct for multiple testing, so all effects are reported at a 0.01 level of significance.
Results
Visual assessment of respiratory triggered CT
In total 38 patients were included in this study. For 36 patients the lung-liver boundary was 
determined and 56 lesions were delineated. The average size of the lesions was 26.4±56.5 cm3 
as determined on CT. The triggered CT scan can result in a considerable improvement of the 
spatial alignment of the PET and CT images, as shown in Figure 1.
Quantification of spatial alignment
There was a significantly better match for the lung-liver boundary when the triggered CT 
was used in combination with the respiratory gated PET compared to the standard CT and 
respiratory gated PET, respectively 4.5±6.7 mm and 9.2 ± 8.1 mm (p<0.001). Radiotracer 
uptake was significantly different when comparing the two PET reconstructions: the 
difference in SUVmax and SUVmean for the PET images reconstructed with the triggered CT 
compared to the standard CT was 10.9±6.7 and 10.5±6.7 (p<0.001) for the SUVmax and 
6.4±4.0 and 6.1±4.0 (p=0.001) for the SUVmean respectively. Although there was only a small 
increment in SUVmax and SUVmean in the PET scans reconstructed with the triggered CT versus 
the standard CT, for 42 and 41 lesions the SUVmax and SUVmean, respectively, was higher for 
the triggered CT compared to the standard CT. The results regarding spatial alignment and 
SUV measurements based on the standard and triggered CT are summarized in Table 2. 
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Figure 1 | Optimally respiratory gated (ORG) 18F-fluorodeoxyglucose (FDG) PET fused with low dose 
(LD) standard and triggered CT for two patients with non-small cell lung cancer (NSCLC). Both patients 
were scanned on the Biograph 40 mCT and the ORG PET images are reconstructed with a duty cycle 
of 35%. The first patient (a and b) is diagnosed with a squamous-cell carcinoma, whilst the second 
patient (c and d) is diagnosed with an adenocarcinoma. a | Coronal ORG FDG-PET image fused with a 
standard LDCT of the first patient. b | Coronal ORG FDG-PET image fused with a triggered LDCT of the 
first patient. c | Axial ORG FDG-PET image fused with a standard LDCT of the second patient. d | Axial 
ORG FDG-PET image fused with a triggered LDCT of the second patient. For both patients, using the 
triggered CT resulted in an improved spatial alignment between ORG PET and CT when compared to 
ORG PET and standard CT. The ORG PET and triggered CT (b and d) show a perfect match as indicated 
by the single arrows, while there is a mismatch for the ORG PET and standard CT group (a and c). 
For the coronal ORG PET and standard CT scan (a) two arrows were used to indicate the lung-liver 
boundary on ORG PET and CT.
Table 2 | Results of the analyses of spatial alignment and measurement of the mean and maximum 
standardized uptake value (SUV) on standard and triggered CT of both patient groups (that is, scanned 
on the Biograph 40 mCT and on the Biograph 64 mCT Flow scanner). Significant differences are flagged 
with an asterisk ‘*’
Standard CT Triggered CT Significance level
Mismatch of lung-liver boundary [mm] 9.2±8.1 4.5±6.7 <0.001*
Average distance lesion centroids [mm] 6.3±4.0 5.6±4.2 0.4
Jaccard similarity coefficient 0.30±0.21 0.32±0.20 0.6
SUVmax [g/cm
3] 10.5±6.7 10.9±6.7 <0.001*
SUVmean  [g/cm
3] 6.1±4.0 6.4±4.0 0.001*
Data are reported as mean±standard deviation.
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For 22 patients the difference of the lung-liver boundary for standard CT scans and the 
PET scan was more than 5 mm. For those patients where the mismatch due to motion was 
>5 mm, the measured prevalence of improved lung-liver boundary matching using the 
triggered CT was approximately 84%. The spatial alignment (JSC and distance between 
centroids) of the lesions did not show a significant improvement when PET was matched 
with triggered CT. Not seeing a difference in average values for this comparatively small 
population, we looked at individual cases. For 6 lesions there was no overlap of PET and 
CT (JSC=0) when the standard CT was used, whereas using the triggered CT, these lesions 
showed overlap. We investigated how often the mismatch between PET and CT was 5 mm 
or less, which is depicted in Figure 2. 
Figure 2 | Scatterplot showing the results of the distance between centroids for the lesions between 
triggered CT and standard CT. Lesions with a good alignment for both protocols – lesions with a 
distance between centroids less than 5 mm – are indicated in black. The lesions who showed decreased 
spatial alignment with the standard CT protocol (>5 mm) and improved with the triggered CT protocol 
(<5 mm) are shown in green. Lesions were spatial alignment decreased when the triggered CT was 
used (standard CT <5 mm, triggered CT >5 mm) are indicated in red. If there was no close match for 
both CT protocols (>5mm) lesions are shown in gray.
There was a good match for both standard and triggered CT in 17 lesions. For 22 lesions in 
the lower and middle lung lobes, a close match (by this definition) was seen for 12 lesions 
when triggered CT was used, compared to 7 lesions of the standard CT group. The axial 
range and duration of the triggered CT scan differed between the two PET–CT scanners. 
For the Biograph 40 mCT scanner the triggered CT had to cover the whole bed position to 
be able to reconstruct the PET image. This was not the case for the Biograph 64 mCT Flow. 
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As a consequence, the range and the duration of the triggered CT scans was longer for 
the Biograph 40 mCT compared to the Biograph 64 mCT Flow, respectively 46.8±7.0 and 
32.0±3.9 cm, and 3.1±1.6 and 1.7±0.7 minutes. 
Discussion
Our study showed a significantly better alignment of PET and triggered CT compared to the 
standard free-breathing CT, when the figure of merit was based on the lung-liver boundary. 
When we considered lung lesions, in 6 patients there was no overlap at all between the 
lesions on PET and standard CT, while there was overlap on PET and triggered CT in these 
patients. Unfortunately, we could not demonstrate statistical significance regarding 
improved spatial alignment of the lung lesions when a triggered CT was used, probably 
due to the limited number of patients included in this study. Although the SUV increased 
significantly for the lung lesions, the difference in absolute SUV was small, indicating limited 
relevance for diagnosis. However, the results indicate that SUV measurements are affected, 
which can be of importance when measuring therapy response or for the purpose of 
radiotherapy planning.
 The use of continuous bed motion acquisition techniques (Biograph 64 mCT Flow) 
led to shorter setup and acquisition times, which is patient friendly and will more easily be 
implemented in routine clinical care. These time savings were a direct result of the selection 
of axial range in which gating would be applied. For standard step and shoot imaging, 
extending the axial selection past a single bed position requires the addition of a full bed. 
This is not a prerequisite for continuous bed motion acquisition, resulting in shorter image 
acquisition times. The average acquisition time of the triggered CT for the Biograph 40 mCT 
scanner was 3 minutes and 7 seconds, and 1 minute and 39 seconds for the Biograph 64 
mCT Flow scanner, as described in Table 1. 
 Although the protocol for triggered CT was comparatively easy for a skilled technologist 
or physicist, it was not integrated in the workstation and required 1–2 minutes extra time 
during the examination. In our prototype, we used an additional computer to determine the 
trigger points and manually matched the respiratory signal settings to the HD amplitude 
range determined by the PET workstation. The additional computer was the same one that 
has long been used in respiratory gated PET and CT imaging using the AZ-733V respiratory 
gating system. The manual adjustment caused some uncertainty in the measurement of the 
trigger points. We do not know if this uncertainty would have clinical importance. 
 In some cases, when PET and standard CT was compared to PET and triggered CT, 
the matching was improved in the liver but degraded in the lung. This phenomenon was 
observed in 5 patients in the group scanned with the Biograph 40 mCT, and in 1 patient 
scanned with the Biograph 64 mCT Flow scanner, as depicted in Figure 3.
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Figure 3 | Optimally respiratory gated (ORG) 18F-fluorodeoxyglucose (FDG) PET fused with standard 
free-breathing and respiratory triggered low dose (LD) CT images of a patient with a non-small cell 
lung cancer (NSCLC) lesion in the right upper lobe. a |Coronal ORG FDG-PET fused with standard LDCT 
images. b | Coronal ORG FDG-PET fused with triggered LDCT images. c | Axial ORG FDG-PET fused with 
standard LDCT images. d | Axial ORG FDG-PET fused with triggered LDCT images. An improved match 
for the lung-liver boundary can be seen when the triggered CT is used (a and c), however, the spatial 
alignment for the lung lesion between PET and CT images is decreased in the triggered CT (b and d). 
This patient was scanned on the Biograph 40 mCT scanner.
This might be caused by the respiratory tracking method, using a pressure sensor in a 
belt located around the patient’s abdomen [22]. Movement of the different areas in the 
thorax, however, is more complex and cannot be accurately measured with the use of one 
abdominal belt sensor. This is depicted in Figure 4, where differences in abdominal and 
thoracic respiration results in considerable movement of structures in the thorax whilst 
there is limited movement registered at the abdominal wall where the pressure sensor is 
located. 
 Other tracking methods might be more appropriate for lesions in different regions 
in the lungs, such as methods that track the respiration of the patient by measuring the 
breathed airflow (spirometer) or changing temperature of breathed air (temperature 
sensor) [10,23]. However, these methods are not commonly used in clinical routine [23]. 
Another method to gate the PET data is to use reconstructed images with a high time 
resolution and to use a (elastic) transformation to match each image, known as list-mode 
gating [24,25]. However, this method is not yet implemented in the clinical routine and still 
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has some problems to overcome, for instance the noise level in the data [23]. This suggests 
that more research is needed to find the best respiratory tracking method for clinical use. 
Thoracic respiration
Abdominal respiration
Figure 4 | Illustration of the mismatch in two scans caused by a difference in breathing. One scan 
was made during thoracic respiration (dashed blue line) and one during abdominal respiration (solid 
green line). The pressure sensor is located at the same position, indicating that the two scans were 
acquired at a similar time during the respiratory cycle (left corner). The excursion of the abdominal wall 
at the location of the pressure sensor differs from that at the position at the thoracic wall, suggesting 
a less effective tracking of respiratory motion. Even though the scans were made during the same 
respiratory phase, it did not result in a better match for the lung lesion.
Should this technique, which has the potential to match PET and CT precisely in some cases, 
be used clinically? We believe it is reasonable and important to improve the match, if it can 
be done conveniently and without unwarranted additional time or radiation dose to the 
patient. Our protocol includes a standard CT, followed by PET, followed by a prospectively 
triggered CT scan. There is room for improvement in three areas. First, to keep the X-ray 
dose as low as reasonably achievable, the standard scan can be skipped in areas that are 
also scanned in triggered CT. Second, the scan duration for triggered CT is long. Triggered 
CT can be replaced with a spiral acquisition during a breath hold that has been amplitude-
matched to the PET scan. We are examining this possibility and hope to report our results in 
the near future. Third, this research protocol can be integrated into the scanner’s hardware 
and software.
 The possibility of performing CT after PET, instead of before PET, is a novel aspect 
of our protocol. Since optimal gating of PET depends on the patient’s breathing patterns 
during the PET scan, a CT scan that matches the ORG PET can be realized in just one of four 
ways: by using free-breathing CT (the usual approach) or CT under appropriate breathing 
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instructions; by acquiring CT data during all phases of breathing, followed by matching 
retrospectively; with slow or time-averaged CT; or with the described prospective approach. 
The first approach, however, does not guarantee to provide a proper match. The second and 
third method typically requires a high X-ray dose. Our novel prospective method has the 
potential to provide both: a good match at low-dose settings suitable for clinical routine 
use.
Conclusion
ORG PET in combination with a respiratory triggered CT scan resulted in a significantly 
better match in the region of the liver dome and a significantly higher SUV for lesions in the 
lungs. In every lung tumour considered, the new technique based on triggered CT provided 
partial overlap of PET and CT, whereas the standard approach based on spiral CT sometimes 
failed. However, we were unable to demonstrate a statistically significant improvement in 
the alignment of PET and CT for lung lesions. A different respiratory tracking method might 
be the key to making the method robust.
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Abstract
Objectives 
This radiotherapy planning study evaluated tumor delineation using both optimally 
respiratory gated (ORG) and non-gated 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET). 
Materials and Methods 
For 22 non-small cell lung cancer (NSCLC) patient, non-gated and ORG FDG-PET scans were 
used to create the non-gated (ng) and gated (g) gross tumor volumes (GTV), designated 
GTVng and GTVg respectively, together with the accompanying clinical target volumes (CTV) 
and planning target volumes (PTV). The size of the target volumes (TV) was evaluated and 
the accompanying radiotherapy plans were created to study the radiation doses to the 
organs at risk (OAR). 
Results 
The median volumes of GTVg, CTVg and PTVg were statistically significantly smaller 
compared to the corresponding non-gated volumes resulting in a median TV reduction of 
0.5 cm3 (inter quartile range (IQR) 0.1–1.2), 1.5 cm3 (-0.2–7.0) and 2.3 cm3 (-0.5–11.3) for the 
GTVg, CTVg and PTVg, respectively. For the OAR, only the percentage of lung (GTV included) 
receiving ≥35 Gy was significantly smaller after gating with a median difference in lung 
volume receiving ≥35 Gy of 5.7 cm3 (IQR -0.8–30.50). 
Conclusions  
Compared to non-gated FDG-PET, the TVs obtained with ORG FDG-PET were significantly 
smaller, however, without a clinically relevant difference in radiation dose to the OAR.
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Introduction
The overall survival (OS) rates for advanced stage non-small cell lung cancer (NSCLC) 
remain poor [1]. Treatment intensification such as concurrent chemoradiotherapy showed 
some benefit compared to sequential regimens increasing the two year OS from 30.3% 
to 35.6% at the cost of increased acute oesophageal toxicity [2]. For radiotherapy dose 
escalation strategies with three-dimensional conformal radiotherapy, treatment related 
toxicity is often the dose-limiting factor [3]. Compared to these older techniques, modern 
intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy 
(VMAT) techniques enable more conformal high-dose irradiation of the tumour [4,5]. Hence, 
radiation dose escalation is possible at the cost of a limited increase in toxicity [6-8].
 Besides improved radiotherapy delivery techniques a better depiction of the primary 
tumour decreases uncertainties regarding tumour delineation, which may contribute 
to smaller target volumes. Bradley et al. [9] showed that the gross tumour volume (GTV) 
as delineated on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) was 
significantly smaller than the GTV derived from computed tomography (CT) alone. This 
increased accuracy of FDG-PET tumour delineation was confirmed in studies comparing the 
delineated CT and FDG-PET volumes to the pathology specimens [10,11]. Thus, FDG-PET–CT 
incorporated in radiotherapy planning may contribute to more conformal treatment plans. 
Moreover, FDG-PET–CT can be used for functional response monitoring [12] and it provides 
the possibility to define certain tumour subvolumes harbouring unfavourable tumour 
characteristics (e.g. high metabolic activity) that can be a specific target for radiotherapy 
dose escalation [13,14]. 
 Because of the relative long image acquisition times, patients breathe freely during 
PET imaging. For lung tumours this results in motion artefacts, underestimating tracer 
uptake and overestimating the tumour volume in PET images [15]. To overcome this 
problem several respiratory gating methods have been developed [16]. These methods 
usually rely on the simultaneous acquisition of a respiratory signal with PET data that is used 
to select specific parts of the PET data corresponding to the same respiratory phase. This 
results in rejection of respiratory motion from the PET images with reduced blurring of the 
tumour. Amplitude-based optimal respiratory gating (ORG) in FDG-PET imaging resulted in 
a significant increase in mean tracer uptake [17,18] with a concordant significant decrease 
in lesion volume, whilst safeguarding good image quality [18]. This indicates that the use 
of gated FDG-PET improves tumour visualization and the quantification of tumour volume 
and tracer uptake, which is important in tumour staging, treatment response assessment, 
and probably also for radiotherapy planning. 
 We hypothesize that the smaller volumes obtained with gated FDG-PET lead to 
smaller target volumes for radiotherapy planning and thus improve healthy tissue sparing. 
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Therefore, we investigated the effect of amplitude-based ORG FDG-PET imaging, as 
compared to conventional non-gated FDG-PET imaging, on radiotherapy planning with 
regard to radiation dose delivered to healthy tissues.
Materials and Methods
This retrospective study evaluated the added value of high resolution ORG FDG-PET imaging 
on radiotherapy planning. We used the diagnostic FDG-PET scans of patients with NSCLC as 
acquired in the study by Grootjans et al. [18]. The study has been carried out in accordance 
with the national applicable rules concerning the review of research ethics committees 
and informed consent. In 21 patients, 22 equally distributed primary tumours (8 upper 
lobe, 8 lower lobe and 6 located at the lung hilum) were analysed displaying the largest 
differences in the gated versus non-gated tumour volumes. After co-registration with the 
low dose CT scans, the FDG-PET–CT images were transferred to the radiotherapy planning 
system Pinnacle3 (Version 9.6; Philips Radiation Oncology Systems, Best, The Netherlands). 
Information on image acquisition and image reconstruction will be described briefly as 
more detailed information has been described elsewhere [18]. After administration of FDG 
(adjusted to patients weight; 3.2±0.2 MBq/kg), whole body FDG-PET images were acquired 
using a Siemens Biograph 40 mCT PET–CT scanner (Siemens Medical Solutions USA, Inc., 
Knoxville, TN). The respiratory signal was obtained using an Anzai AZ-733V respiratory gating 
system (Anzai Medical Co., Tokyo, Japan). Respiratory gating of the PET data was performed 
with the ORG algorithm (HD·Chest) using 35% of the acquired PET data, providing a good 
balance between motion rejection and image quality [18]. For the purpose of attenuation 
correction, anatomical reference and radiotherapy planning, a free breathing total body low 
dose CT was performed. The FDG-PET images were reconstructed with the Siemens TrueX 
algorithm with time-of-flight (TOF) measurements incorporated. Image reconstruction was 
performed with 3 iterations, 21 subsets, and a matrix size of 400×400 (2.04 mm × 2.04 mm).
 All primary tumours were delineated twice. Once using the non-gated FDG-PET 
images and once using the ORG FDG-PET images. To minimize intra-observer variation due 
to manual contouring, automatic delineation of the tumour was performed with a fixed 
threshold region growing segmentation algorithm. The threshold chosen to represent 
the GTV was 40% of the maximum standardized uptake value (SUVmax) [19], which was 
visually checked for plausible segmentation results. According to local protocol a 10 mm 
circumferential margin for the Clinical Target Volume (CTV) was added to both GTVng 
and GTVg (ng and g refer to the non-gated and ORG PET images, respectively). Organs 
at risk (OAR), i.e. healthy lung tissue (delineated twice, once including the GTV and once 
excluding the GTV), heart, oesophagus and spinal cord, were delineated as well (for detailed 
information see the materials and methods section in reference [8]) and subtracted from 
the CTV in case tumour involvement was absent. When the tumour was located near other 
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healthy tissues such as the thoracic wall or spine, these non-involved structures were 
manually delineated creating a single contour, which could also be subtracted from CTVng 
and CTVg. The planning target volume (PTV) was generated by expanding the CTVng and 
CTVg with a 5 mm circumferential margin. Although this margin may seem inappropriate 
(especially in case of increased tumour motion), this approach was considered adequate 
for the evaluation of the added value of gated FDG-PET imaging in radiotherapy planning. 
Treatment plans were generated for both the PTVng and PTVg planning 66 Gy in 33 
fractions using a VMAT technique. To avoid differences in outcome due to different planning 
strategies, all factors involved in treatment planning (such as beam angles, number of 
segments, objectives and constraints) were kept equal for both treatment plans. A dose 
coverage of 99% for the 95% isodose for the PTV was aimed for. If a 99% coverage was not 
obtained because of unacceptable high doses to the OAR, a lower coverage was accepted 
to generate a clinical acceptable treatment plan. For both plans the dose coverage for the 
PTV was equalized manually by adjusting the number of monitor units (which quantifies the 
amount of radiation delivered by the linear accelerator). Treatment plans were evaluated 
for the following endpoints: PTV dose coverage, maximum dose to the organ at risk (Dmax), 
mean dose to the organ at risk (Dmean) and the percentage of an organ exceeding a certain 
dose (for example 20% of lung receiving 5 Gy or more, denoted as V5lung=20%). The latter 
was done for organ volumes receiving doses from 5 to 70 Gy with 5 Gy intervals. The isodose 
lines (range 5 to 70 Gy, again with 5 Gy intervals) were converted to contours so the actual 
volume (cm3) of an organ receiving a certain radiation dose was calculated. 
Statistics
All statistical analyses were performed using the Wilcoxon signed-rank test for paired 
variables (SPSS software, version 20.0; Chicago, IL). A p-value of <0.05 was considered 
statistically significant. The reported significance levels were adjusted for multiple testing 
using the Bonferroni correction.
Results
Definition of gross tumour volume
As reported by Grootjans et al. [18], ORG FDG-PET resulted in a significant increase in SUVmean 
(mean standardized uptake value) with a concomitant significant decrease in lesion volume. 
Figure 1 depicts a patient with a NSCLC lesion in the left lower lobe where a remarkable 
reduction in GTV was observed in the ORG compared to the non-gated PET images.
 The observed reduction in tumour volume observed previously was also true for our 
results as all but two of the gated GTVs were smaller compared to the non-gated GTVs. The 
target volumes, together with their absolute and relative reductions between non-gated 
and respiratory gated PET images are summarized in Table 1.
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Figure 1 | Optimally respiratory gated (ORG) 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) image fused with the accompanying low dose (LD) CT image, showing a remarkable 
reduction in gated (g) gross tumour volume (GTV, red; 0.45 cm3) compared to the non-gated (ng) GTV 
(yellow; 0.87 cm3). The bar-graph shows both the non-gated and gated GTV, clinical target volume 
(CTV), and planning target volume (PTV) for this patient.
The median volume of GTVg, CTVg and PTVg [4.6 cm3 (inter quartile range; IQR 2.2–13.9), 
50.8 cm3 (32.8–109.6) and 99.8 cm3 (70.7–189.8), respectively] were statistically significantly 
smaller compared to the corresponding non-gated volumes [5.8 cm3 (2.7–15.4), 52.8 cm3 
(32.4–112.1) and 103.7 cm3 (69.8–193.4); p=0.003, p=0.02 and p=0.04, respectively]. This 
resulted in a median target volume reduction of 0.5 cm3 (IQR 0.1–1.2), 1.5 cm3 (-0.2–7.0) and 
2.3 cm3 (-0.5–11.3) for the GTVg, CTVg and PTVg, respectively. The median GTV, CTV, and 
PTV volumes together with the difference in median volume between non-gated and ORG 
PET images, is depicted in Figure 2. 
 We repeated the analysis taking into account anatomical differences that may influence 
tumour motion. Three subgroups were defined (upper lobes, lung hilum and lower lobes) 
showing only the gated upper lobe GTVs to be significantly smaller. The differences were 
small with a median volume of the gated upper and lower lobe GTVs of 3.1 cm3 (IQR 1.7–7.5) 
and 3.0 cm3 (1.7–14.2), respectively, compared to the respective non-gated GTVs [3.3 cm3 
(1.9–8.3) and 3.5 cm3 (1.7–14.9); p=0.04 and p=0.05, respectively]. No statistical significant 
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reduction in the median volume of the upper lobe CTVs (non-gated 37.7 cm3 versus gated 
34.6 cm3; p=1), lower lobe CTVs (non-gated 43.1 cm3 versus gated 38.7 cm3; p=0.3), upper 
lobe PTVs (non-gated 79.5 cm3 versus gated 73.9 cm3; p=1) and lower lobe PTVs (non-gated 
88.3 cm3 versus gated 79.4 cm3; p=1) were found. Accordingly, no significant differences in 
dose volume distribution could be identified. 
Figure 2 | Bar graphs displaying the median target volume differences and reduction. a | Median 
volumes of the non-gated (ng) and gated (g) gross tumour volume (GTV), clinical target volume (CTV) 
and planning target volume (PTV). b | Median differences (ng volume minus g volume) for GTV, CTV 
and PTV. Statistically significant results are flagged with an asterisk ‘*’
Radiation dose to organs at risk
Subsequently, we analysed the effect of these smaller target volumes on the radiation doses 
to the OARs. Only the volume of lung (GTV included) receiving ≥35 Gy was significantly 
smaller for the treatment plans with the gated target volumes [median volume 265 cm3 
(gated) versus 284 cm3 (non-gated); p=0.05]. This corresponded to a median difference in 
lung volume of 5.7 cm3 (IQR -0.8–30.5) comprising 0.15% of the median total lung volume. 
Dose distributions for the lung minus GTV and the other organs at risk did not show any 
significant difference. Dose coverage for PTVng and PTVg were identical (median coverage 
by the 95% isodose was 99% for both PTVs; p=0.9). The effects of target volume reduction 
on the dose distribution for the organs at risk are depicted in Figure 3.
503606-L-bw-Grootjans
132 | Chapter 5
Figure 3 | The effect of target volume reduction on the dose distributions for the organs at risk. The 
bar-graphs display the paired (ng=non-gated and g=gated) median volume percentages of a certain 
dose level for the specific organ at risk (e.g. V5 denotes percentage receiving ≥5 Gy). GTV, gross tumour 
volume; CTV, clinical target volume; PTV, planning target volume; MLD, mean lung dose. Statistically 
significant results are indicated by an asterisk ‘*’.
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Discussion
The incorporation of ORG FDG-PET imaging in radiotherapy planning for NSCLC showed 
that the acquired gated GTVs, CTVs and PTVs were significantly smaller, however, without 
the desirable relevant reduction of radiation dose to the OAR. Although the lung volume 
receiving ≥35 Gy (V35lung) was significantly smaller for the gated FDG-PET planned treatment 
plans, the actual median V35lung reduction was minimal. The evaluation of tumour localization 
on target volume resulted in smaller GTVs for the upper lobes, but again, without any effect 
on the corresponding dose distributions. 
 Although smaller target volumes are generated using gated FDG-PET, the expected 
beneficial effect on treatment planning was small. This is demonstrated by the fact that only 
one iso-dose level appeared significantly different showing a relative decrease in volume of 
the lung receiving ≥35 Gy of only 0.15%. Albeit statistically significant, this small decrease 
of radiation exposure to healthy lung tissue is most likely clinically irrelevant. 
 The explanation for the discrepancy between reduced target volumes with almost no 
gain in radiotherapy planning lays in the fact that the absolute reduction in target volume 
is small. This might be a result of the method we used for gating as the software identifies 
the smallest amplitude range of the respiratory signal whilst still using 35% of the total 
acquired PET data (duty cycle). This ‘movement-weighted’ approach often selects the FDG-
PET data from the end-expiration phase to reconstruct the image [17]. Notwithstanding 
reduction of tumour motion is achieved, residual tumour motion may still be present. 
This residual tumour motion still causes blurring of the FDG-PET image, diminishing the 
potential reduction in target volume. Another physical aspect is the wider photon beam 
penumbra in lung tissue. Due to extended electron ranges in lung tissue, the distance from 
beam edge to target volume increases in order to obtain full dose coverage of the target 
volume. Regarding our results, the target volume reduction is apparently not large enough 
to compensate for this. Moreover, delineation method used in the radiotherapy planning 
system, which is performed by means of interpolation of pixels at the border of the contour, 
may further diminish the observed reduction between target volumes based on non-gated 
and ORG PET images.
 Although a limited number of tumours has been assessed, increasing the number of 
patients studied will most probably not significantly increase the differences in radiation 
dose to the OAR. This is due to the fact that the tumours have been selected beforehand 
as they displayed the largest reduction of gated tumour volumes compared to the 
corresponding non-gated volumes.
 After sorting the tumours according to localization within the lungs, the reduction 
of CTV and PTV lost significance. This is counterintuitive as one may expect a larger effect 
on lower lobe tumours compared to upper lobe tumours as tumour movement has 
shown to be larger for these tumours [20]. The loss of significance is probably due to the 
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avoidance of healthy tissue when the CTV is created by circumferential expansion of the 
GTV. Furthermore, as the GTV shape is often irregular, circumferential expansion of such 
an irregular GTV (resembling for example a horseshoe Figure) creates a sphere like CTV 
resulting in a (partial) loss of the target volume reduction achieved with respiratory gating.
The target volumes created with gated FDG-PET were matter of investigation in two other 
studies. Guerra et al. [21] analyzed 13 lung cancer patients undergoing a free breathing CT 
together with a gated FDG-PET–CT. The latter was reconstructed into 6 breathing phases 
used for the delineation of one internal target volume (ITV). Despite the fact the ITVs were 
significantly increased using gated FDG-PET–CT, the accompanying PTVs were significantly 
reduced. This unexpected result is explained by the different expansion margins used: 
10 mm circumferential margin for free breathing target volumes versus anisotropic margins 
of 7–8 mm and 5 mm for gated target volumes. Indeed, a target volume margin reduction 
may be appropriate as tumour motion is already (in part) incorporated in the CTV. However, 
it remains unclear whether or not the smaller PTVs are due to this margin reduction, the 
use of gated imaging or a combination of both. For this reason we decided to apply equal 
margins for non-gated and gated treatment plans as only the added value of gated FDG-
PET was under investigation, not the delivery of gated radiotherapy. Aristophanous et al. 
[22] evaluated 22 lung tumours in 10 patients undergoing gated FDG-PET–CT imaging prior 
to radiotherapy. The mean gated target volume was 35% larger compared to the non-gated 
target volume with the lower lobe target volumes showing a more pronounced increase 
compared to the upper lobe target volumes. In both the abovementioned studies the 
ITV concept was applied. This concept considers the extreme ends of tumour motion to 
be the boundary of the GTV which often results in overestimation of the target volume 
as the tumour is located relatively short in that extreme position during the breathing 
cycle.[23] Without being at the expense of good dose coverage, this overestimation can be 
decreased by avoiding the incorporation of the extreme ends of tumour motion using an 
average position method as described by Wolthaus et al. [23]. Although not yet evaluated, 
our method of GTV delineation using ORG FDG-PET may be considered such an average 
position approach. This explains the fact that, compared to the ITV concept, our target 
volumes are on average reduced instead of increased as the incorporation of the extreme 
ends of tumour motion is avoided. 
 In our study we did not only analyse the target volumes created with gated FDG-PET 
imaging, but we also evaluated the actual impact on the dose distributions with regard to 
the radiation doses for the OAR. The latter being of special interest in, for example, radiation 
dose escalation strategies to the entire tumour volume where the avoidance of high dose 
to healthy tissues is of utmost importance. Although the incorporation of gated PET in 
radiation therapy planning failed to show clinically relevant dose reductions for the OAR in 
our study, it may still be of benefit in defining biologically unfavourable subvolumes within 
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the GTV that are suitable for dose painting as the true tumour volume and tracer uptake can 
be more accurately assessed with gated PET [24]. 
 Instead of the commonly used 40% SUVmax fixed threshold segmentation method, 
one may consider different thresholds or other segmentation techniques. However, there 
is no consensus on the optimal segmentation technique. Although one may suggest 
using for example probabilistic or gradient-based approaches to reduce the influence 
of partial volume effects, the partial volume effect is small in our scans since we applied 
high resolution PET with a matrix size of 400×400 (pixel spacing of 2.04 mm). Furthermore, 
the segmentation results were visually checked for plausibility, hence major delineation 
inconsistencies are unlikely. Because our primary goal was to evaluate the impact of gated 
PET on treatment planning and its theoretical sparing of healthy tissues we studied only 
one segmentation method, not the differences between segmentation methods per se. In 
this study, the use of a standard low-dose CT acquired during patient free-breathing for the 
purpose of attenuation correction may have resulted in a small bias in quantification of the 
PET images. Unfortunately, a respiratory-matched low-dose CT was not available for these 
patients. This is subject of further research at our institution. 
Conclusions
In conclusion, this study evaluated the impact of ORG FDG-PET on definition of radiotherapy 
target volumes including the effect on radiotherapy planning regarding radiation doses for 
healthy tissues. Although the respiratory gated target volumes were reduced, the benefit 
in this selected group of NSCLC patients was too small to show clinically significant dose 
reduction for healthy tissues. 
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Abstract
Objectives 
This study evaluated the use of total lesion glycolysis (TLG) determined by different 
automatic segmentation algorithms, for early response monitoring in non-small cell lung 
cancer (NSCLC) patients during concomitant chemoradiotherapy. 
Materials and Methods 
Twenty-seven patients with locally advanced NSCLC treated with concomitant 
chemoradiotherapy underwent 18F-fluorodeoxyglucose (FDG) PET–CT imaging before 
and in the second week of treatment. Segmentation of the primary tumours and lymph 
nodes was performed using fixed threshold segmentation at (i) 40% SUVmax (T40), (ii) 50% 
SUVmax (T50), (iii) relative-threshold-level (RTL), (iv) signal-to-background ratio (SBR), and 
(v) fuzzy locally adaptive Bayesian (FLAB) segmentation. Association of primary tumour TLG 
(TLGT), lymph node TLG (TLGLN), summed TLG (TLGS=TLGT+TLGLN), and relative TLG decrease 
(ΔTLG) with overall-survival (OS) and progression-free survival (PFS) was determined using 
univariate Cox regression models. 
Results 
Pretreatment TLGT was predictive for PFS and OS, irrespective of the segmentation method 
used. Inclusion of TLGLN improved disease and early response assessment, with pretreatment 
TLGSmore strongly associated with PFS and OS than TLGT for all segmentation algorithms. 
This was also the case for ΔTLGS, which was significantly associated with the PFS and OS, 
with exception of RTL and T40. 
Conclusions
ΔTLGS was significantly associated with PFS and OS, except for RTL and T40. Inclusion of TLGLN 
improves early treatment response monitoring during concomitant chemoradiotherapy 
with FDG-PET.
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Introduction
Non-small cell lung (NSCLC) cancer remains a disease with a generally poor prognosis [1]. At 
the time of diagnosis, one third of patients with NSCLC presents with locally advanced non-
metastatic disease [1]. For these patients, radiotherapy in combination with chemotherapy 
is the accepted standard of care. With the aim of improving patient outcome, combined 
and intensified treatment approaches are increasingly being investigated. However, not all 
patients equally benefit from these treatment approaches and rational selection of available 
treatment options in a personalized medicine framework is required [2].
 Positron emission tomography (PET) in combination with X-ray computed 
tomography (CT) with the glucose analogue 18F-fluorodeoxyglucose (FDG) has proven to 
be a valuable tool to personalize treatment for this patient group [2]. Firstly, incorporation 
of FDG-PET images into the radiotherapy planning algorithm improves definition of gross 
tumour volume (GTV) [3-5] and might facilitate the concept of selective nodal irradiation 
[6]. Secondly, it has been shown that FDG-PET can identify areas that are at risk of local 
relapse [7,8], permitting to use the concept of molecular imaging-based dose painting.9 
Thirdly, several studies emphasize the ability of FDG-PET to monitor therapy response at 
an early treatment stage using quantitative PET indices [10-14]. Early response monitoring 
during treatment can facilitate clinical decision-making and improve patient management 
through early treatment adaptation and thereby avoidance of unnecessary side effects and 
costs of ineffective treatment. 
 However, employing the concept of FDG-PET-guided treatment decisions requires 
robust and standardized methods to derive these quantitative indices from PET images. 
Particularly, the strong dependence of most image-derived response indices on 
quantification of lesion volume emphasizes the need for standardized and consistent 
determination of these volumes in PET images. In this regard, there has been a widespread 
interest in the development for automated segmentation algorithms for PET. Over the years, 
there has been a rapid growth of segmentation algorithms for PET reported in the literature 
[15], an event which is also referred to as ‘yapetism’ (“yet another PET segmentation method”) 
[16]. Difficulties encountered by these algorithms for automatic lesion segmentation in PET 
images are local contrast variations due to heterogeneous FDG uptake in the lesion, adjacent 
FDG-avid anatomy and lymph nodes, and relatively high noise content of PET images, 
often rendering the task of automatic lesion delineation challenging [15]. This becomes 
even more difficult when automatic segmentation has to be performed on low contrast 
interim and end-of-treatment PET images, where radiotracer uptake can be considerably 
reduced due to therapy effects. However, up until this day there is no standardized method 
for automatically determining lesion volume on PET images and many studies consider 
different segmentation algorithms for this purpose [17,18]. 
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The purpose of this study was to evaluate this clinical applicability and performance of several 
established segmentation algorithms for generating plausible segmentation volumes that 
can be applied specifically to predict therapy response during treatment for patients with 
locally advanced stage IIIA or IIIB NSCLC treated with concomitant chemoradiotherapy. The 
predictive value of total lesion glycolysis (TLG), as determined by these different algorithms, 
for progression free survival (PFS) and overall survival (OS) was evaluated.
Materials and Methods
Patients
A total of 27 patients with newly diagnosed stage IIIA or stage IIIB NSCLC were prospectively 
included in this study, as described before [10]. Patients were treated with concomitant 
radiotherapy and chemotherapy. This study was approved by the institutional review board 
(IRB) of the Radboud university medical center. Written informed consent was obtained 
from every patient. Patient characteristics are summarized in Table 1. 
Treatment and follow-up
Intensity modulated radiotherapy (IMRT) was performed (10 MV photons), consisting of 33 
fractions of 2 Gy (5 fractions a week for 6 week and 3 days) resulting in a total dose of 66 Gy 
on the primary tumour and affected lymph nodes (i.e. pathologically proven or FDG-avid 
lymph nodes). Chemotherapy consisted of two cycles of cisplatin 50 mg/m2 intravenously 
(day 1, 8, 22, and 29) and etoposide 100 mg/m2 intravenously (day 1–3, and day 22–24). 
Median overall treatment time was 45 days (range 43–48 days). Patients with progressive 
disease during follow-up received palliative treatment. Follow-up during and after treatment 
consisted of clinical examination at regular intervals. When residual or recurrent disease was 
suspected, chest X-ray and chest CT-scans were performed. For each patient, sequential 
FDG-PET–CT imaging was performed before and during treatment. The pretreatment scan 
was obtained before treatment (median 11 days, range 1–28 days) whilst interim FDG-
PET imaging was performed in the second week during concomitant treatment (median 
14 days, range 13–16 days), always before the second cycle of chemotherapy after 20 Gy 
radiotherapy. According to the treatment protocol all patients started with radiotherapy at 
the first day of the first cycle of chemotherapy, i.e. no neo-adjuvant treatment was applied.
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Table 1 | Patients Characteristics
Characteristics of patient population
Male(Female) 18(9)
Median age (range) [y] 58 (42–77)
Histological type
Non-small cell lung cancer (NSCLC)
Squamous cell carcinoma 10
Adenocarcinoma 14
NSCLC not otherwise specified 3
Disease stagec
IIIA 20
IIIB 7
Performance-score (ECOG)
0 20
1 7
Smoking status
Current smoker 11
Former smoker 16
Lesion location
Right upper lobe 10
Right middle lobe 4
Right lower lobe 2
Left upper lobe 7
Left lower lobe 2
Pretreatment PET acquisition
Number of bed positions 7–8
Administered FDG activity [MBq] 267±48
Incubation time [min] 75±7.5
Acquisition time per bed position [min] 4
Interim PET acquisition
Number of bed positions 3–4
Administered FDG activity [MBq] 269±49
Incubation time [min] 78±8.0
Acquisition time per bed position [min] 4
Data are reported as mean±standard deviation. PET, positron emission tomography; FDG, 18F-fluorodeoxyglycose.
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Patient preparation and FDG PET imaging
Imaging was performed using a hybrid Biograph Duo PET–CT scanner (Siemens Medical 
Solution, Knoxville, TN, USA). The PET scanner was accredited by the Research 4 Life (EARL) 
initiative for quantitative FDG-PET–CT studies [19]. Before image acquisition, patients fasted 
for at least six hours and blood glucose levels were lower than 8.2 mmol·L-1 in all patients. The 
amount of activity administered to the patient was adjusted to the patient’s weight and was 
3.45 MBq·kg-1. Details regarding the PET acquisition protocol are summarized in Table 1. No 
respiratory gating was performed. For the purpose of attenuation correction and anatomical 
reference, a low dose (LD) CT scan was acquired with a reference tube current time product 
of 40 mA·s. LDCT scans were acquired during timed unforced expiration breath-hold. 
Modulation of X-ray tube current was performed using CARE Dose 4D. Reconstruction of 
PET images was performed with a 2D ordered subset expectation maximization (2DOSEM) 
algorithm using a matrix size of 128×128, 4 iterations and 16 subsets. Post reconstruction 
filtering was performed using a three-dimensional Gaussian filter kernel with a full width at 
half maximum of 5 mm. 
Image Segmentation
The primary tumour and FDG positive lymph nodes were delineated on the pretreatment 
and interim PET images. Firstly, delineation was performed using a fixed threshold 
region growing segmentation at 40% (T40) and 50% (T50) of the maximum standardized 
uptake value (SUVmax) value. Furthermore, adaptive threshold algorithms were used for 
image segmentation. These included the iterative relative-threshold-level (RTL)[20] and 
signal-to-background ratio (SBR) [21] approach. For the SBR method, the background for 
segmentation of the primary tumour was defined by placing a volume of interest (VOI) in 
parenchyma of the contra-lateral lung. For lymph node segmentation, the background was 
defined by placing a VOI near the aortic root in the mediastinum. The seed-point for the T40, 
T50, RTL, and SBR segmentation was the SUVmax voxel of either the primary tumour (SUVT,max) 
or the corresponding lymph nodes (SUVLN,max). The threshold-based segmentations were 
performed using the Inveon Research Workplace (IRW) 4.1 Software (Preclinical Solutions, 
Siemens Medical Solutions USA, Knoxville Tennessee, USA). In addition to threshold-based 
segmentation, image segmentation was performed using the fuzzy locally adaptive 
Bayesian (FLAB) algorithm [22]. Segmentation with this algorithm is performed using 
custom in-house developed software (ImageD, LaTIM Université de Bretagne Occidentale, 
Brest, France). The number of classes for segmentation was limited to two and parameters 
were automatically determined by the software. 
Image Analysis
The TLG of the primary tumour (TLGT), defined as the product of the mean tumour FDG 
uptake (SUVT,mean) and metabolic tumour volume (MTV), was calculated on the pretreatment 
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and interim PET images. Similarly, lymph node TLG (TLGLN) was defined as the product of 
the mean uptake of the lymph nodes (SUVLN,mean) and the corresponding metabolic volumes 
of the lymph nodes. Furthermore, a summed TLG (TLGS=TLGT+TLGLN) was calculated. 
Evaluation of therapy response was performed by calculating the fractional decrease in 
TLG between preteatment and interim PET images (ΔTLG). Segmentation performance of 
the different algorithms was evaluated through visual assessment by a nuclear medicine 
physician experienced in thoracic imaging. Segmentation failures were visually identified 
andwere defined as the propagation of segmentation into other anatomical structures, or 
premature termination of the algorithm resulting in only partial segmentation of the primary 
tumour and lymph nodes. Lesions that could not be properly segmented according to these 
criteria were omitted from the analysis. In addition, similarity between MTVs obtained with 
different segmentation algorithms was quantified by calculating the spatial overlap using a 
generalization of the Jaccard similarity coefficient (JSC), as described in equation 6.1.
JSC(A, B, ..., n)=
|A  B  ...   n|
(6.1)———————
|A  B  ...  n|
Here the numerator |A  B  ...   n| denotes the intersection between segmented volumes 
(in this study, five in total), whilst the denominator |A  B  ...  n| represents the union of the 
segmented volumes. Perfect spatial overlap is indicated by a value for the JSC of 1.0, whilst 
a value of 0 indicates no spatial overlap of the volumes.
Clinical outcome and statistical analysis
Statistical analysis was performed using SPSS Statistics 20 (IBM, Armonk, New York, USA) 
and GraphPad Prism, version 4.0c (GraphPad Software Inc, La Jolla, California, USA). PFS 
was defined as the interval between the start of treatment and the date of documented 
disease progression as confirmed by imaging or biopsy. If a patient was progression free at 
the closeout-date (January, 2015), time to progression was censored to that date. Similarly, 
if patients were still alive at the closeout-date, patients were censored for OS. The predictive 
value of pretreatment TLG and ΔTLG was determined for different segmentation algorithms 
using univariate Cox regression models. Correlation between the MTVs and TLGs of different 
segmentation algorithms was calculated using Spearman rank correlation. Statistical 
significance was defined for p<0.05.
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Results
Patient follow-up
The median follow-up time for this patient population was 23.4 months (range 3.5–61.9). 
During follow-up eighteen patients died, all related to cancer progression. Three patients 
were lost during follow-up. A total of twenty patients developed recurrent disease during 
follow-up; seven patients developed progression of local disease, whilst metastases were 
seen in 13 patients. Median time to disease progression was 21 months. PFS after study-
baseline at 1 year was 63% (17 out of 27). 
Segmentation of the primary tumour
Of the 27 patients, 25 had a visible primary tumour. For the other two patients, there was 
no radiological evidence for a primary tumour (i.e. cT0). The smallest pretreatment MTVs 
were obtained when segmentation was performed with the T50 segmentation algorithm 
(24.7±30.8 mL), compared to T40 (34.8±39.1 mL), SBR (38.7±42.4 mL) RTL (30.7±34.0 mL). 
Segmentation with FLAB resulted in the largest MTVs (42.3±42.1 mL). Interim PET MTVs 
showed similar trends with the smallest MTV for the T50 (20.8±32.6 mL) method, followed 
by T40 (31.6±44.6 mL), RTL (26.8±37.0 mL), SBR (36.2±50.2 mL) and FLAB (37.6±48.2 mL). 
For the pretreatment PET images, excellent correlation was found between delineation 
methods for MTV (range ρ 0.97–1.0, p<0.0005), TLGT (range ρ 0.95–1.0, p<0.0005) and 
SUVT, mean (range ρ 0.98–1.0, p<0.0005). Similarly, for in-treatment interim PET images, an 
excellent correlation was found between delineation methods for MTV (range ρ 0.93–1.0, 
p<0.0005), TLGT (range ρ 0.94–1.0, p<0.0005) and SUVT, mean (range ρ 0.94–1.0, p<0.0005).
 Quantitative and visual analysis of the MTVs obtained with different segmentation 
algorithms revealed that the MTVs were highly similar regarding shape and spatial overlap. 
Furthermore, the algorithms revealed a similar trend in SUVT,mean and MTV change between 
pretreatment and interim   FDG-PET, as depicted by Figure 1. For most primary tumours, 
there was a stronger MTV decrease compared to SUVmean decrease (i.e. the data points 
situated in the first (upper right) quadrant below the identity function y=x). 
 The T50 volumes were always completely enveloped by the other volumes. The 
generalized JSC for all MTVs on the pretreatment and interim PET was 0.58±0.13 (range 
0.31–0.78) and 0.53±0.16 (range 0.20–0.86). When the T50 volumes were omitted from the 
analysis, the mean JSC for pretreatment and interim PET volumes was 0.74±0.12 (range 
0.46–0.89) and 0.71±0.14 (range 0.47–0.96). In tumours with heterogeneous FDG uptake, 
the T50 algorithm yielded contours that were more erratic and sensitive to discontinuities 
within the tumour, whilst FLAB, SBR, RTL, and T40 algorithms would segment patches with 
FDG-uptake continuously throughout the entire lesion, giving an improved representation 
of the total volume with FDG-uptake. Figure 2 demonstrates the segmentation performance 
of the SBR and T50 algorithms in a lesion with heterogeneous FDG uptake.
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Figure 1 | Relative decrease in SUVmean as a function of metabolic tumour volume (MTV) of the primary 
tumour between pretreatment and interim FDG-PET images. a | Fixed threshold at 40% SUVmax (T40). 
b | Fixed threshold at 50% SUVmax. c | Relative level thresholding (RTL). d | Signal-to-background (SBR). 
e | Fuzzy locally adaptive Bayesian (FLAB) segmentation. The solid and dashed line represent the 
identity functions (i.e. y=x and y=-x respectively).
In the pretreatment PET images, FLAB segmentation resulted in one segmentation failure 
of the primary tumour in one patient due to small size and low contrast. In this patient, all 
segmentation methods failed to segment the primary tumour in the interim PET images. 
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Furthermore, the T40, T50, RTL, and SBR methods failed to segment the primary tumour in 
an additional patient that was presenting with a large lesion with extended growth into the 
central mediastinum on interim PET images. The FLAB algorithm could segment the primary 
tumour in this patient and did not show uncontrolled propagation of segmentation into the 
mediastinal background.
Figure 2 | Pretreatment (a and b) and interim (c and d) 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) images in a 52-year-old female patient with a tumour in the left upper lobe: 
Delineation performance of the 50% SUVmax fixed threshold (T50) (green) and signal-to-background 
ratio (SBR) method (red). This lesion showed a centralized FDG non-avid core with an FDG-avid rim. 
The T50 segmentation method yielded a more erratic contour when compared to the SBR, resulting in 
a discontinuous segmentation of the FDG-avid rim. The methods showed a fractional decrease in TLG 
of 20% and 12% for the T50 and SBR method respectively. 
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Lymph node segmentation
Of the 27 patients, 18 patients had FDG positive lymph nodes on the pre-treatment PET 
images. Given the smaller volumes and in general lower contrast of mediastinal and hilar 
lymph nodes, there were considerably more segmentation failures when performing 
automatic segmentation of lymph nodes. The T40 and RTL algorithms failed to segment 14 
and 17 of the 41 lymph nodes on the pretreatment PET images, respectively. The number of 
segmentation failures for the T50 and FLAB algorithms in the pretreatment PET images was 
9 and 8, respectively. The SBR algorithm had the fewest segmentation failures, with only 6 
lymph nodes segmentation failures in the pretreatment PET images.
 Reduction of lymph node contrast owing to therapy effects on the interim PET images 
resulted in more segmentation failures for the T40, T50, RTL and FLAB algorithms. Of the 41 
lymph nodes in the interim PET, there were 24 segmentation failures for the T40 and RTL 
algorithms. For the T50 and FLAB method, 12 and 14 lymph node segmentation failures 
occurred in the interim PET, respectively. Similar to the pretreatment PET, the SBR algorithm 
had the fewest segmentation failures, with 5 segmentation failures. Failure of lymph node 
segmentation was usually due to uncontrolled propagation of the segmentation algorithm 
in the mediastinal background or primary tumour. Figure 3 depicts the TLGS on pretreatment 
and interim PET images in box whisker plots.
S
Figure 3 | Box and whisker plots of summed total lesion glycolysis (TLGs) of the primary tumor and the 
lymph nodes in pretreatment and interim 18F-fluorodeoxyglucose (FDG) positron emission tomography 
(PET) scans obtained with different segmentation algorithms. Bottom and top of each box are lower 
and upper quartiles. The horizontal line near middle of the box is median. Whiskers are drawn down to 
the 5% percentile up to the 95% percentile, whilst the outliers are indicated by a dot. T40, Fixed level 
threshold segmentation at 40% of the maximum standardized uptake value (SUVmax); T50, Fixed level 
threshold segmentation at 50% of SUVmax; RTL, Relative level thresholding; SBR, Signal-to-background 
segmentation; FLAB, Fuzzy locally adaptive Bayesian segmentation.
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Prognostic value of TLG
Primary tumour
Pretreatment SUVT,max, interim SUVT,max, and relative decrease in SUVT,max was not significantly 
predictive for PFS and OS. Similarly, pretreatment SUVT,mean, interim SUVT,mean, and relative 
decrease in SUVT,mean of the primary tumour was not significantly predictive for PFS and OS 
in this cohort. However, pretreatment TLGT was significantly associated with PFS and OS 
for all segmentation methods. ΔTLGT was significantly predictive with PFS for all methods 
except for FLAB. Furthermore, ΔTLGT was significantly associated with OS for the T50 and SBR 
methods. Hazard ratios (HRs) and corresponding 95% confidence interval (CI) of TLGT and 
ΔTLGT in the univariate Cox regression analysis for PFS and OS are summarized in Table 2.
Table 2 | Hazard ratios (HRs) and 95% confidence interval (CI) of pretreatment primary tumour 
total lesion glycolysis (TLGT) and relative TLG decrease (ΔTLGT) between pretreatment and interim 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a univariate Cox regression 
analysis for progression-free survival (PFS) and overall-survival (OS) 
HR (95% CI) per unit change for PFS Significance level
Pretreatment TLGT
  T40
  T50
  RTL
  SBR
  FLAB
1.002 (1.000–1.004)
1.002 (1.000–1.004)
1.002 (1.000–1.004)
1.002 (1.000–1.003)
1.002 (1.000–1.003)
0.02*
0.03*
0.03*
0.02*
0.03*
ΔTLGT
  T40
  T50
  RTL
  SBR
  FLAB
1.02 (1.003–1.03) 
1.02 (1.003–1.03) 
1.02 (1.003–1.04) 
1.02 (1.004–1.04) 
1.02 (1.000–1.04)
0.03*
0.03*
0.03*
0.02*
0.07
HR (95% CI) per unit change for OS Significance level
Pretreatment TLGT
  T40
  T50
  RTL
  SBR
  FLAB
1.002 (1.001–1.004)
1.003 (1.001–1.004)
1.002 (1.001–1.004)
1.002 (1.001–1.003)
1.002 (1.001–1.003)
0.004*
0.005*
0.004*
0.004*
0.006*
ΔTLGT
  T40
  T50
  RTL
  SBR
  FLAB
1.02 (1.00–1.03) 
1.02 (1.00–1.03) 
1.02 (1.00–1.03) 
1.02 (1.00–1.03) 
1.01 (0.99–1.03)
0.05
0.02*
0.08
0.04* 
0.3
T40, fixed level threshold at 40% of the maximum standardized uptake voxel (SUVmax); T50, fixed level threshold at 50% of 
SUVmax; RTL, relative level thresholding; SBR, signal-to-background-ratio; FLAB, fuzzy locally adaptive Bayesian segmentation. 
Statistical significance is indicated by an asterisk ‘*’.
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Primary tumour and lymph nodes 
Only TLGLN obtained with the SBR and T50 methods was significantly predictive for PFS and 
OS. Furthermore, inclusion of TLGLN improved early response assessment using PET, with 
pretreatment TLGS more strongly associated with PFS and OS than TLGT. Figure 4 depicts 
pretreatment and interim FDG-PET images of two patients with a different lymph node 
response, as reflected by ΔTLGS.
 The differences in lymph node segmentation performance was reflected in the 
significance levels of TLGS measurements in the univariate analysis for PFS and OS. The HRs 
and corresponding 95% CI of TLGS and ΔTLGS in the univariate Cox regression analysis for 
PFS and OS are summarized in Table 3.
Table 3 | Hazard ratios (HRs) and 95% confidence interval (CI) of pretreatment summed total 
lesion glycolysis (TLGS) and relative TLG decrease (ΔTLGS) between pretreatment and interim 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in a univariate Cox regression 
analysis for progression-free survival (PFS) and overall-survival (OS). TLGS is the sum of primary tumour 
TLG (TLGT) and lymph node TLG (TLGLN)
HR (95% CI) per unit change for PFS Significance level
Pretreatment TLGS
 T40
 T50
 RTL
 SBR
 FLAB
1.003 (1.001–1.005)
1.003 (1.001–1.005)
1.003 (1.001–1.005)
1.002 (1.001–1.004)
1.002 (1.001–1.004)
0.002*
0.004*
0.003*
0.004*
0.004*
ΔTLG 
 T40
 T50
 RTL
 SBR
 FLAB
1.02 (1.00–1.05)
1.03 (1.02–1.05) 
1.01 (1.00–1.02)
1.04 (1.02–1.06)
1.02 (1.00–1.04)
0.03*
0.001*
0.2
0.001*
0.04*
HR (95% CI) per unit change for OS Significance level
Pretreatment TLGS
 T40
 T50
 RTL
 SBR
 FLAB
1.003 (1.001–1.004)
1.003 (1.001–1.005)
1.003 (1.001–1.005)
1.002 (1.001–1.004)
1.002 (1.001–1.004)
0.001*
0.002*
0.001*
0.001*
0.002*
ΔTLGS
 T40
 T50
 RTL
 SBR
 FLAB
1.01 (1.00–1.03)
1.02 (1.00–1.04) 
1.00 (1.00–1.01)
1.02 (1.00–1.04)
1.01 (1.00–1.03)
0.4
0.02*
0.9
0.03*
0.02*
T40, fixed level threshold at 40% of the maximum standardized uptake voxel (SUVmax); T50,  fixed level threshold at 50% of 
SUVmax; RTL, relative level thresholding; SBR=signal-to-background-ratio; FLAB, fuzzy locally adaptive Bayesian segmentation. 
Statistical significance is indicated by an asterisk ‘*’.
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Figure 4 | Pretreatment (a and c) and interim (b and d) 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) images of two non-small cell lung cancer (NSCLC) patients. The first patient (a and 
b) showed a good response to treatment on both the primary tumour and lymph nodes. Although 
the primary tumour of the second patient (c and d) showed a good response to treatment, there was 
a limited response considering the lymph nodes, with more FDG positive lymph nodes in the interim 
PET. The mean summed fractional decrease of total lesion glycolysis (ΔTLGS) of the first patient for the 
different segmentation methods was 76±6%, with a progression free survival (PFS) of 11 months and 
overall survival (OS) of 24 months. For the second patient, mean ΔTLGS was 38±6% with a PFS and OS 
of 7 and 21 months, respectively.
Discussion
In this study we showed that TLG is a robust metric to monitor early therapy response 
in patients undergoing concomitant chemoradiotherapy for locally advanced NSCLC. 
Furthermore, inclusion of TLGLN improves early assessment of treatment response in this 
patient population. Results of this study are in line with available data in the literature and 
emphasize the role of FDG-PET imaging for early response monitoring NSCLC [10-14]. In 
particular, TLG outperformed the more traditional indices, such as SUVT,max and SUVT,mean, for 
predicting PFS and OS. This is probably due to the fact that TLG contains information about 
disease load as well as metabolic activity of involved lesions. 
503606-L-bw-Grootjans
155PET for early response monitoring in NSCLC |
6
In general, all segmentation algorithms had a similar performance for segmenting the 
primary tumour in different anatomical locations. The presence of adjacent anatomical 
structures (e.g. lymph nodes, mediastinum, liver), did not result in large differences in 
segmentation performance. Furthermore, lower contrast of the interim PET images resulted 
in a very limited increase in the number of segmentation failures. Absolute differences in 
TLG obtained by the different segmentation methods did not influence its predictive value. 
Due to the limited size and lower contrast, there were considerably more lymph node 
segmentation failures. The number of lymph node segmentation failures increased in the 
interim PET images owing to further reduction in image contrast. Nevertheless, adequate 
lymph node segmentation is of importance, with TLGS having a stronger association with 
PFS and OS. Out of all the segmentation algorithms, the SBR method demonstrated the 
lowest number of segmentation failures. The number of FLAB lymph node segmentation 
failures could be reduced by using a supervised input, with an equal performance to that 
of the SBR method, which is in line with results from another study [23]. However, in view of 
standardizing response measurements, such a user dependency should be avoided and we 
chose only to include the results of automatic FLAB segmentation.
 Although the results emphasize that PET could be used for prediction of early 
treatment response in patients with locally advanced NSCLC treated with concomitant 
chemoradiotherapy, employment of PET-guided decisions for personalizing treatment was 
not explored. Particularly, the strong association of pretreatment TLG with PFS and OS might 
merit the choice for treatment intensification in patients with a high pretreatment TLG such 
as proposed in the PET-boost dose-escalation trial [24]. Furthermore, one might also consider 
treatment intensification when interim PET images demonstrate a limited decrease in TLG, for 
instance by dose escalation to metabolically active sub volumes the primary tumour [25,26], 
in order to improve loco-regional tumour control. However, standardizing PET-based dose 
painting approaches is of utmost importance. This is emphasized in a study by Knudtsen 
et al. where the used PET reconstruction algorithm and choice of segmentation thresholds 
significantly influenced treatment plans incorporating these dose painting concepts [27]. 
Although threshold-based segmentation is frequently used for defining sub volumes for 
dose painting, stability of different algorithms under varying imaging conditions for this 
purpose has yet to be investigated. Interestingly, studies emphasize that there is a high 
stability of FDG uptake in tumour areas during the course of the treatment that can be 
identified on pretreatment FDG-PET images [28]. Although useful, interim PET imaging in 
a molecularly image-guided ART (IGART) setting would still be of great interest to monitor 
changes during radiotherapy [2]. Indeed, employment of IGART using FDG-PET has been 
shown to be of potential value, where the GTV is adapted according to interim FDG-PET 
imaging [2]. Furthermore, results from a study conducted by Nygård et al. emphasize that 
FDG-PET might identify lesion-specific response after a single series of chemotherapy in 
NSCLC and could be a useful addition to guide and individualize radiotherapy strategy [29]. 
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Although dose redistribution might be useful for improving loco-regional tumour control, 
systemic disease control is also an important aspect in this patient group [30]. In this setting, 
interim PET imaging might identify failure of systemic disease control at an early stage (i.e. 
detection of additional lymph node or distant metastasis), making it possible to adapt 
treatment accordingly.
 A limitation of the current study is that only a small patient cohort was considered. 
However, the advantage is that TLG measurements using different automatic segmentation 
algorithms showed consistent results, with most algorithms yielding TLG values that had a 
similar predictive value in this patient cohort.
Conclusions
This study emphasizes that adequate lymph node segmentation in PET images improves 
assessment of early treatment response in NSCLC patients treated with concomitant 
chemoradiotherapy. In this regard, given the relatively ease of implementation and the 
high number of successful lymph node segmentations, SBR is the method of choice for 
calculation of TLG in FDG-PET images of patients with locally advanced NSCLC for the 
purpose of assessment of early treatment response.
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Abstract
Objectives 
Assessment of measurement accuracy of intratumour heterogeneity using texture features 
in positron emission tomography (PET) images is essential to characterize cancer lesions 
with high precision. In this study, we investigated the influence of respiratory motion and 
varying noise levels on quantification of texture features in patients with lung cancer. 
Materials and Methods 
Respiratory gating was performed on list-mode data of 60 lung cancer patients, who 
underwent 18F-fluorodeoxyglucose (FDG) PET, using an optimal respiratory gating 
algorithm (ORG). The ORG images were reconstructed using a duty cycle (percentage of the 
total acquired PET data) of 35%. In addition to ORG images, non-gated images with varying 
statistical quality (using 35% and 100% of PET data) were reconstructed to investigate 
the effects of image noise. Several global image-derived indices and texture parameters 
(entropy, high intensity emphasis (HIE), zone percentage (ZP), and dissimilarity) that have 
been associated with patient outcome, were calculated. Clinical impact of ORG and image 
noise on assessment of intratumour heterogeneity was evaluated using Cox regression 
models with overall survival (OS) as outcome measure for non-small cell lung cancer 
patients. Threshold for statistical significance was adjusted for multiple comparisons using 
Bonferroni. 
Results 
Respiratory motion significantly affected intratumour heterogeneity quantification for 
lesions in the lower lung lobes (p<0.007), with the exception of entropy (p>0.007). The mean 
increase of entropy, dissimilarity, ZP, and HIE, for lower lobe lesions was 1.3±1.5% (p=0.02), 
11.6±11.8% (p=0.006) 2.3±2.2% (p=0.002), and 16.8%±17.2% (p=0.006), respectively. No 
significant differences were observed for lesions located in the upper lung lobes (p>0.007). 
Differences in the statistical quality of the PET images affected the texture parameters to a 
lesser extent than respiratory motion, with no statistically significant differences between 
the images. The median follow-up time of this patient cohort was 35 months (range 7–39 
months). In multivariate analysis for OS, total lesion glycolysis (TLG) and HIE were the two 
most relevant image-derived indices considered to be independent significant co-variates 
for the model, regardless of the image type considered.
Conclusions
The results of this study suggest that the tested textural features are robust in the presence 
of respiratory motion artefacts and varying levels of image noise. 
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Introduction
Positron emission tomography (PET) in combination with X-ray computed tomography (CT) 
imaging has gradually evolved from a diagnostic tool towards a multirole imaging platform 
for the clinical management of patients diagnosed with lung cancer [1]. The advantage of 
PET over other tomographic imaging modalities is the ability to characterize and quantify 
the biological landscape of cancerous lesions with high sensitivity, making it possible to 
identify areas that are linked to therapy resistance or are more aggressive [1].
 In this regard, the development of image-derived indices with the objective to extract 
as much information from PET images as possible, is becoming increasingly important 
[2]. Traditional image-derived indices used in PET typically rely on the quantification of 
lesion standardized uptake values (SUVs) and overall tumour volume, which have been 
shown to be independent prognostic factors for patient outcome and treatment response 
[3]. Although useful, these parameters omit available information related to the spatial 
distribution and specific features regarding intratumour radiotracer accumulation, which 
may limit the possibility to further characterize the biological behaviour of the tumour.
 Interest in the quantification of intrinsic spatial and temporal heterogeneity in 
solid malignancies has been growing over the last few years. Particularly, the role of 
quantifying intratumour heterogeneity using medical imaging for identifying specific 
tumour phenotypes [4], prediction of treatment resistance [5-7], and overall survival (OS) 
[8] is increasingly being recognized. This view fits our current knowledge of cancer, in which 
malignant lesions consist of heterogeneous cell populations with distinct molecular and 
micro-environmental differences [9]. Hence the current interest in using medical imaging to 
repetitively assess intratumour spatial and temporal heterogeneity [4]. 
 However, in order to characterize cancer lesions with high precision, assessment of 
measurement accuracy of such indices under different imaging conditions is essential [10,11]. 
The accuracy and robustness of these measurements is related to the PET acquisition and 
reconstruction protocols, as well as variability in patient physiology. In particular, motion-
blurring due to respiration can significantly influence quantification of lung lesion features 
in PET images [12,13]. Furthermore, it has been reported that PET texture features can be 
sensitive to variations in statistical quality and normal stochastic variations in images [14]. 
In this study, we investigated the clinical impact of respiratory gating and varying image 
noise levels on quantification of several textural features in high resolution time-of-flight 
PET imaging with the glucose analogue 18F-fluorodeoxyglucose (FDG).
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Materials and Methods
Patients
The institutional review board of the Radboud university medical center approved this 
retrospective study and the requirement to obtain informed consent was waived. A 
total of 60 patients of our fast-track outpatient diagnostic program with histologically 
proven lung cancer were included in this study. Only lesions with a minimum volume 
of 3 cm3 were included since this has been previously indicated as the minimum lesion 
size for the calculation of meaningful and of complementary information on intratumour 
heterogeneity in FDG-PET images using textural feature analysis [15]. Patient characteristics 
are summarized in Table 1.
Table 1 | Patient characteristics
Male (Female) 43(17)
Median age (range) [y] 68(49-85)
Body mass* [kg] 77±15
Administered FDG activity* [MBq] 249±48
Incubation time FDG* [min] 79±15
Histological type
Small cell lung cancer 7
Non-small cell lung cancer
Squamous cell carcinoma 28
Adenocarcinoma 25
Disease stage†
IA 5
IB 4
IIA 6
IIB 2
IIIA 17
IIIB 10
IV 16
*Data are reported as mean±standard deviation; †Disease stage according to the 7th revision of the International Association 
for the Study of Lung Cancer.
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Image acquisition and reconstruction
Whole body FDG-PET imaging was performed using a Biograph 40 mCT (Siemens Medical 
Solutions, Knoxville TN, USA) PET/CT scanner. The amount of administered FDG was 
adjusted to the patients’ weight (3.2±0.3 MBq/kg). Full details regarding image acquisition 
and reconstruction have been described previously [12,16]. In short, bed positions covering 
the thorax and upper abdomen were acquired in list-mode with a duration of 6 minutes 
per bed position and the respiratory signal was obtained using an AZ-733V respiratory 
gating system (Anzai Medical Co Ltd, Tokyo, Japan). Reconstruction was performed using 
3 iterations, 21 subsets (Ultra-HD PET), and a transaxial matrix size of 400×400 voxels. Post 
reconstruction filtering was performed using a three-dimensional Gaussian filter kernel 
with a full width half maximum of 3.0 mm.
Respiratory gating
Respiratory gating was performed on the list-mode data using an amplitude-based optimal 
respiratory (ORG) algorithm, integrated in the Syngo 2011A MI.PET/CT software (HD∙Chest, 
Siemens Medical Solutions, Knoxville TN, USA). The main user input for the ORG algorithm is 
the percentage duty cycle, which corresponds to the percentage of the total acquired data 
used for image reconstruction [12]. The ORG images were reconstructed with a duty cycle 
of 35% (ORG35%), which was previously found to provide the best balance between image 
quality and motion rejection [12]. Non-gated images with an equivalent statistical quality 
as the ORG35% images were reconstructed using the first 126 seconds (35%) of the acquired 
PET data (non-gated35%). Furthermore, non-gated images using the full 360 seconds (100%) 
of the acquired PET data (non-gated100%) were reconstructed. The different reconstructed 
images used for image analysis are depicted in Figure 1.
 For each patient, additional gated images during the maximum inspiration and 
expiration phases (by restricting the amplitude range to the maximum and minimum 
amplitude of the respiratory signal respectively) were reconstructed for calculation of lesion 
displacement during the respiratory cycle. These images were reconstructed with a duty 
cycle of 20% (ORG20%) in order to reduce the impact of residual motion in the reconstructed 
PET images to a minimum. The displacement vector was determined by delineating the 
lesions on both PET images and subsequently calculating the distance between the lesion 
centroids, as depicted in Figure 2.
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Figure 1 | Reconstructed PET images used for image analysis. Optimal respiratory gating (ORG) is 
performed through rebinning of list-mode data according to a respiratory signal that is simultaneously 
acquired. a | Non-gated positron emission tomography (PET) image using 100% of the acquired list-
mode data (non-gated100%). b | Non-gated PET image using 35% of the acquired list-mode data (non-
gated35%). c | ORG PET reconstructed using 35% of the acquired list-mode data (ORG35%).
Image analysis
Textural features of the lesions were calculated on the ORG images and compared to the 
respective non-gated35% images. The effect of image noise was investigated by comparing 
the non-gated35% to the non-gated100% images. Delineation of the lesions was performed 
using the fuzzy locally adaptive Bayesian segmentation algorithm, using 2 segmentation 
classes [17]. Local heterogeneity parameters, describing intensity variations between each 
voxel and its immediate neighbours averaged over the entire volume, used for this study 
include entropy and dissimilarity. Regional heterogeneity parameters, considering the 
analysis at the level of groups of voxels and areas of various sizes and intensities, used for 
this study were high intensity emphasis (HIE) and zone percentage (ZP). The voxel intensities 
were quantized using 64-gray-levels, and local features were computed over 13 directions 
[18]. All of the parameters considered in this work have shown to be useful for predicting 
prognosis in patients with non-small cell lung cancer (NSCLC) [8]. Furthermore, metabolic 
tumour volume (MTV), mean standardized uptake value (SUVmean), and total lesion glycolysis 
(TLG) were extracted from the PET images.
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Figure 2 |Analysis of tumour displacement due to the respiratory cycle. a | Maximum inspiration 
optimally respiratory gated (ORG) positron emission tomography (PET) reconstructed using 20% of 
the acquired list-mode data (ORG20,max). b | Maximum expiration ORG-PET reconstructed using 20% of 
the acquired list-mode data (ORG20%,min). c | ORG20%,max fused with ORG20%,min. The displacement vector 
(white arrow) is calculated by segmenting the lesion on the ORG20%,min (dashed contour) and ORG20%,max 
(solid contour) and determining the difference between the lesion’s centroid on both images. 
Lesions were classified into three main anatomical categories; the upper lung lobes, middle 
and lower lung lobes, and the lung hilum/mediastinum (“central group”) [12]. Given that 
different histological subtypes can have a different presentation considering the absolute 
and particular spatial distribution of FDG uptake on PET images, quantification of tumour 
texture was compared for different histological subtypes of lung cancer [19]. In this regard, 
lesions were sorted into three histological subtypes; adenocarcinomas (AC), squamous cell 
carcinomas (SCC), small cell lung carcinomas (SCLCL). 
Statistics
Statistical analysis was performed using SPSS Statistics 21 (IBM, Armonk, New York, USA). 
Adjustment for multiple testing was performed using the Bonferroni correction (i.e. 
pcritical=pα/k, where pcritical is the threshold for statistical significance, pα is the alpha-probability 
(0.05) and k the number of performed tests). Statistical significance is then defined for 
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p<pcritical. Statistical analysis for paired measurements was performed using the Wilcoxon 
signed rank test for paired variables, pcritical=0.007 (7 comparisons). The Kruskal Wallis H test 
was used for comparing different groups regarding tumor displacement (3 comparisons, 
pcritical=0.02) and histological groups (8 comparisons, pcritical=0.006). For the OS analysis, we 
used univariate and multivariate Cox regression analyses. In these analyses, only patients 
with NSCLC histology were included and OS was used as outcome measure, which was 
defined as the interval between the PET acquisition date and time of death. The closeout-
date was August, 2015. Patients who were alive at the closeout-date were censored for OS 
at that date. The multivariate Cox regression models were obtained using semi-automated 
iterative forward and backward selection of image-derived features based on the likelihood 
ratio criterion. The hazard ratio’s (HRs) with their corresponding 95% confidence intervals 
(CIs) were reported. The maximum number of covariates was chosen to be four in order to 
maintain a sufficient number of events per covariate for reliable statistical assessment [20]. 
In addition, Kaplan-Meier analysis was performed to determine the association of different 
PET-derived image indices with OS. All variables were split at their median, to prevent data-
driven dichotomization, yielding a ‘low’ and ‘high’ group of similar size. The Kaplan Meier 
curves were compared using the Mantel-Cox (log rank) statistics.
Results
Lesion displacement
Quantification of lesion displacement for different anatomical locations showed that 
lesions located in the lower lobes typically exhibited the largest displacement during 
patient respiration which was statistically significantly different from the other anatomical 
groups (p<0.02). The central group comprises of lesions with a more heterogeneous 
character, where hilar lesions typically exhibit considerable amounts of displacement 
while mediastinal lesions remained almost stationary. Lesions located in the upper lobe, 
particularly in the apical segments, showed almost no displacement. Lesion displacement 
as a function of anatomical location is summarized in the box and whisker plot in Figure 3. 
Global image-derived indices
There was a significant increase in SUVmean of 2.9±13.0% (p<0.0001) and decrease in MTV 
of 3.6±15.1% (p<0.0001) in the ORG35% images when compared to the non-gated35% PET 
images. However, there were no statistically significant differences in TLG as determined on 
the non-gated35% and ORG35% images (p>0.007).
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Figure 3 | Quantification of lesion displacement as a function of anatomical group. Whiskers indicate 
the 10 and 90 percentile, outliers are indicated by a dot. Statistical significant differences between the 
groups are indicated by an asterisk ‘*’.
Texture features
Considering the entire cohort, respiratory gating did not result in statistically significant 
differences in the heterogeneity parameters (p>0.007). The mean increase for entropy, 
dissimilarity, ZP and HIE between the non-gated35% and ORG35% images was 0.3±2.7% 
(p=0.5), 3.6±14.3% (p=0.2), 0.5±3.3% (p=0.3), 4.2±21.4% (p=0.3) respectively. Respiratory 
gating resulted in statistically significant differences of the texture parameters for lesions in 
the middle and lower, with exception of entropy (p>0.007). The mean increase for entropy, 
dissimilarity, ZP and HIE, considering lesions in the lower lobes was 1.3±1.5% (p=0.02), 
11.6±11.8% (p=0.006) 2.3±2.2% (p=0.002), and 16.8%±17.2% (p=0.006) respectively. Figure 
4 depicts the different PET images of a patient with a lesion in the lower lung lobe. 
For the centrally located lesions, the mean increase for entropy, dissimilarity, ZP and HIE 
was 0.58±3.7% (p=0.6), 5.0±19.0% (p=0.4) 0.59±4.0% (p=0.9), and 4.4±27.8% (p=0.4), 
respectively. Lesions in the upper lobes showed a mean decrease of 0.35±1.8 (p=0.3), 
1.0±7.7% (p=0.3), 0.4±2.7% (p=0.5), 1.7±13.2% (p=0.4), for entropy dissimilarity, ZP and HIE, 
respectively. There was no significant correlation between lesion volume and the change in 
heterogeneity parameters between non-gated and ORG35% images.
 Entropy and HIE were the features that were most affected by the change in statistical 
quality of the images. Comparison of the non-gated100% to the non-gated35% PET images 
showed a statistically significant difference for entropy -0.6±1.8% (p=0.002) and HIE 
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9.1±22.0% (p<0.0001). Dissimilarity and ZP were not significantly affected (p>0.007), with a 
difference of 0.7±8.0% (p=0.4), and -0.4±3.4% (p=0.2) for dissimilarity and ZP respectively. 
Measurement variability due to respiratory motion typically exceeded that of the variability 
due to differences in noise levels in the images.
Figure 4 | Optimally respiratory gated (ORG) positron emission tomography (PET) using 35% of the 
acquired list-mode data (ORG35%) and non-gated PET images of a patient with a NSCLC lesion in the 
right lower lung lobe. a | Non-gated PET image reconstructed using 100% of the acquired list-mode 
data (non-gated100%). b | Non-gated PET images reconstructed using 35% of the acquired list-mode 
data (non-gated35%). c | ORG35% PET.
Table 2 summarizes the calculated texture parameters sorted by histology group. 
 There were no statistically significant differences between any of the texture 
parameters for the different histological groups (p>0.006). Furthermore, ORG did not 
influence characterization of intratumour heterogeneity for lesions with different histology 
with a similar data distribution on non-gated35% and ORG35% images. 
Univariate analysis
Of the 60 patients, 53 were diagnosed with NSCLC and could be included in the OS analysis. 
The median follow-up time was 35 months (range 7–39). During this period, 38 of the 53 
patients (72%) died, all due to cancer progression. 
 The Kaplan-Meier curves obtained for TLG were similar for all three image types, with 
no differences in the patients assigned to the low or high TLG groups. Figure 5 depicts the 
Kaplan-Meier curves for the summed TLG of all intra-pulmonary lesions larger than 3 cm3 
(TLGall). 
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Figure 5 | Kaplan-Meier survival curves of summed total lesion glycolysis for lesions larger than 3cm3 
(TLGall).
The OS curves of TLGall dichotomized at their median were statistically significantly different 
with a strong association of lower TLG values with longer OS (p=0.008). Furthermore, there 
were only minor differences regarding the Kaplan-Meier curves obtained for entropy, 
dissimilarity, ZP, and HIE between the ORG35% and non-gated images. Table 3 summarizes 
the log rank comparison of the OS curves for several image-derived indices.
Table 3 | Log rank comparison of Kaplan-Meier curves for different image-derived indices
Non-gated35% ORG Non-gated100%
MTVprimary p=0.2 p=0.06 p=0.2
TLGprimary p=0.03* p=0.03* p=0.03*
TLGall p=0.008* p=0.008* p=0.008*
Entropy p=0.6 p=0.3 p=0.9
Dissimilarity p=0.4 p=0.3 p=0.2
ZP p=0.6 p=0.2 p=0.4
HIE p=0.6 p=0.1 p=0.1
* = statistically significant.
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Of the clinical covariates, treatment (p<0.0001) and disease stage (p=0.02) were the only 
significant predictors for patient OS. Of the image-derived indices, primary tumour MTV 
(MTVprimary) and TLG (TLGprimary) as well as TLGall were significant predictors for patient OS. 
The SUVmean of the primary tumour (SUVprimary) was not significantly associated with patient 
OS in any of the three image types. Furthermore, none of the four texture parameters 
extracted from the PET images were significantly predictive for OS in this patient group. The 
covariates used in the univariate Cox regression analysis with their respective hazard ratios 
and significance levels are summarized in Table 4 and 5.
Table 4 | Univariate Cox regression analysis of clinical covariates for overall survival (OS) 
Covariate HR 95% CI Significance level
Treatment p<0.0001*
Surgery 1
Chemoradiotherapy 0.5 (0.3–0.9)
Chemotherapy 1.7 (1.0–2.9)
Expectative (no treatment) 3.3 (1.7–6.3)
Stage p=0.02*
I 1
II 0.4 (0.07–1.9)
III 1.6 (0.6–4.4)
IV 4.3 (1.4–13)
Histology
Adenocarcinoma 1 p=0.3
Squamous cell carcinoma 0.7 (0.4–1.4)
Age 1.01 (1.0–1.1) p=0.4
HR, Hazard ratio; CI, confidence interval; * = statistically significant.
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Table 5 | Univariate analysis of patient overall survival (OS) of image-derived covariates. Hazard ratios 
(HRs) are indicated per 100 units change for total lesion glycolysis (TLG) and per 1 unit change for other 
the parameters
Parameter Non-gated35% ORG Non-gated100%
HR  
(95% CI)
Significance 
level
HR 
(95% CI)
Significance 
level
HR 
(95% CI)
Significance 
level
MTVprimary 1.009 
(1.003–1.016)
p=0.004* 1.010 
(1.003–1.016)
p=0.003* 1.009 
(1.003–1.015)
p=0.004*
SUVprimary 1.00 
(0.95–1.06)
p=0.9 1.00 
(0.94–1.05)
p=0.8 1.00 
(0.94–1.06)
p=0.9
TLGprimay 1.08
(1.02–1.14)
p=0.004* 1.08
(1.03–1.13)
p=0.003* 1.08
(1.03–1.14)
p=0.003*
TLGall 1.09
(1.03–1.14)
p=0.002* 1.08
(1.03–1.14)
p=0.002* 1.08
(1.03–1.14)
p=0.002*
Entropy 0.3 (0.2–1.8) p=0.3 0.4 (0.1–1.2) p=0.1 0.7 (0.3–2.0) p=0.5
Dissimilarity 0.9 (0.70–1.1) p=0.2 0.9 (0.7–1.0) p=0.09 0.9 (0.8–1.1) p=0.2
ZP 0.01 (0–16) p=0.2 0.002 (0–1.5) p=0.07 0.3 (0–79) p=0.7
HIE 0.998
(0.996–1.00)
p=0.1 0.998
(0.996–1.00)
p=0.06 0.998
(0.996–1.00)
p=0.07
HR, Hazard ratio; CI, confidence interval; MTVprimary, metabolic tumour volume of the primary tumour; SUVprimary, mean 
standardized uptake value of the primary tumour; TLGprimary, total lesion glycolysis of the primary tumour; TLGall, summed TLG 
for lesions larger than 3 cm3; ZP, zone percentage; HIE, high intensity emphasis; * = statistically significant.
Multivariate analysis
Given that patient treatment and clinical stage had a statistically significant association with 
OS in this patient cohort and are generally known to have a strong association with OS, we 
forced these two covariates in the multivariate model. The multivariate models obtained 
through iterative likelihood backward selection of relevant covariates are summarized in 
Table 6. 
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Table 6 | Multivariate Cox regression models for overall survival (OS). Hazard ratios (HRs) are indicated 
per 100 units change for total lesion glycolysis (TLG) and per 1 unit change for other the parameters
Model Non-gated35% ORG Non-gated100%
HR
(95% CI)
Significance 
level
HR
(95% CI)
Significance 
level
HR
95% CI)
Significance 
level
Fixed input
Disease stage 0.1 0.1 0.1
I 1 1 1
II 0.2
(0.03–1.1)
0.2 
(0.03–1.1)
0.2 (0.04–1.2)
III 1.7
(0.4–8.6)
1.4 
(0.3–7.2)
1.8 
(0.4–8.9)
IV 1.8
(0.3–12)
1.7 
(0.2–12)
1.9 
(0.3–13)
Treatment <0.0001* <0.0001* <0.0001*
Surgery 1 1 1
Chemo-
radiotherapy
0.3
(0.1–0.6)
0.3 
(0.2–0.7)
0.4 
(0.1–1.8)
Chemotherapy 1.1 
(0.5–2.4)
1.1 
(0.5–2.5)
1.6 
(0.3–8.3)
Expectative
(no treatment)
5.2 
(2.2–12)
4.5 
(2.0–10)
7.7 
(1.5–40)
Iterative backward selection
TLGall 1.07 
(1.01–1.13)
0.02* 1.08 
(1.02–1.14)
0.009* 1.07 
(1.01–1.13)
0.04*
HIE 0.997 
(0.995–0.999)
0.02* 0.997 
(0.995–0.999)
0.02* 0.997
(0.995–0.999)
0.02*
HR, Hazard ratio; CI, confidence interval; TLGall, summed TLG for lesions larger than 3 cm
3; HIE, high intensity emphasis; 
* = statistically significant.
There were no differences in the multivariate models obtained by forward and backward 
selection of covariates for all three images types. In these models HIE and TLGall were 
included as independent prognostic image-derived parameters.
Discussion
In this study, we have shown that patient respiration during PET imaging affects 
quantification of intratumour heterogeneity of glucose metabolism, specifically for lesions 
located in the lower lung lobes. Furthermore, results showed that differences in the statistical 
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quality of the PET images affected the texture parameters to a lesser extent than respiratory 
motion, with no statistically significant differences between the images. The blurring effect 
of respiratory motion on quantification of intratumour heterogeneity was shown in studies 
by Yip et al. [13], and Oliver et al. [21]. Although our results are in line with these studies, the 
observed differences were usually small. Furthermore, the clinical impact of the observed 
differences was limited, with no differences in the models for OS.
 With the ORG algorithm, we were able to solely evaluate the effect of respiratory 
motion on quantification of intratumour heterogeneity and to reduce the confounding 
effects of varying noise levels, which is more challenging with other respiratory gating 
methods [12]. In the current study, we have shown that the blurring effect due to respiratory 
motion had the largest impact on lesions located in the middle and lower lung lobes, while 
respiratory motion had only a limited effect on lesions in the upper lung lobes. The effect 
of respiratory motion on blurring of centrally located lesions was more variable, where hilar 
lesions could demonstrate considerable blurring while central mediastinal lesions were 
frequently affected to a lesser extent. These results were supported by analysis of tumour 
motion, where lesions in the lower lung lobes demonstrated the largest displacements.
 Although respiratory motion has shown to have considerable impact on quantification 
of lesion SUVmean and MTV [12], the effect was limited in this patient population. Particularly, 
ORG did not significantly influence quantification of TLG. This might be due to the pre-
selection of lesions for the purpose of feature extraction in which only lesions with a volume 
larger than 3 cm3 were analysed. Therefore, only few lower lung lobe lesions could be 
analysed in this study. Given that the largest blurring effect due to patient respiration is on 
lesions located in the lower lung lobes, this asymmetrical distribution could have resulted 
in underestimation of the blurring effects of respiratory motion. In addition, the increase in 
SUVmean in the ORG images might be cancelled out by the reduction in MTV, making TLG a 
parameter that is more robust in the presence of respiratory motion artefacts.
 One of the limitations of the current study is that a relatively small patient cohort 
could be analysed. This limitation, in combination with the retrospective character of this 
study, limits the possibility to identify which of the parameters are truly associated with OS. 
Identification and validation of image features that are associated with patient outcome 
and OS requires a multicentre prospective study setup. Although these texture parameters 
have been previously associated with patient OS [8], this was not the case in the current 
patient cohort. This could be due to the relatively large number of patients included with 
metastatic disease, which was an exclusion criterion in the previous study.[8] In patients 
with metastatic disease, characteristics of the primary tumour might have limited predictive 
value regarding OS, while indices containing more information about disease load (such as 
TLGall), might more accurately predict patient OS. 
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The obtained multivariate models for OS were consistent over all three image types, 
suggesting that measurement accuracy of the calculated features are robust in the presence 
of respiratory motion artefacts and varying noise levels. In these multivariate models, TLG 
and HIE were the only independent image-derived covariates that were relevant for the 
clinical model, even after correction for treatment and disease stage.
 Although we have studied the influence of important sources of measurement 
variability on quantification of intratumour heterogeneity, several other important sources 
that can contribute to measurement variability are remaining. Indeed, measurement 
variability in PET can stem from a myriad of different factors, ranging from acquisition and 
reconstruction settings to patient physiology [22]. There have been reports on the variability 
of radiomics features in FDG-PET due to test-retest variability [18,23]. In a study conducted 
by Leijenaar and colleagues, the investigated radiomics features showed a high stability in 
an inter-observer and test-retest setup [23]. Furthermore, Tixier et al. reported that several 
texture features derived from PET images showed a high degree of reproducibility as 
determined on double baseline PET acquisitions [18]. It is essential to assess the clinical 
impact of such measurement variations for the development and validation of new image-
derived indices to characterize cancer lesions using PET.
Conclusion
The results of this study suggest that the tested textural features are robust in the presence 
of respiratory motion artefacts and varying levels of image noise. 
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Lung cancer treatment: A call for personalized medicine
Despite considerable developments in the therapeutic options for patients with lung 
cancer, disease-specific survival remains poor. One of the foremost factors contributing to 
the poor survivorship is that many patients already have advanced or metastatic disease at 
the time of diagnosis, drastically reducing the prognosis for the patient [1,2]. Furthermore, 
the heterogeneity of lung cancer with respect to molecular and (epi)genetic features 
complicates selection of an optimal treatment strategy for the individual patient. With the 
aim of improving patient outcome in this patient group, the treatment paradigm has shifted 
from single modality towards intensified treatment approaches combining chemotherapy, 
radiotherapy, and in selected cases surgery [3,4].
 Advances in radiotherapy techniques for precise dose delivery and the development 
of molecularly targeted therapies have expanded the treatment options available for lung 
cancer [4,5]. Nevertheless, these new therapeutic options have failed to substantially improve 
the overall long-term outcome of these patients, with only 10–15% surviving beyond 5 
years after diagnosis [6]. However, specific patient groups can benefit from personalized 
treatment approaches. This concept is well-illustrated in patients with cancers harbouring 
specific molecular alterations, such as mutations in the EGFR; in these patients, treatment 
with agents targeting EGFR, such as gefitinib, have yielded improved response rates when 
compared with conventional chemotherapy agents [7], whereas the use of these targeted 
agents as standard therapy in the general NSCLC patient population was not associated 
with survival benefits [8,9]. Thus, rational selection of the available treatment options based 
on tumour biology might markedly improve patient outcome. Early adaptation of therapy 
according to initial treatment responses is in line with this concept as it allows an early 
discontinuation of treatment that will not be effective.
 However, personalizing treatment to the individual patient remains difficult and 
requires monitoring of biological parameters responsible for treatment resistance to 
facilitate treatment selection, guidance, and adaptation. PET is a well-established molecular 
imaging platform that enables non-invasive quantification of many biological parameters 
that are relevant to both local and systemic therapy. With increasing clinical evidence, PET 
has gradually evolved from a purely diagnostic tool to a multifunctional imaging modality 
that can be utilized for treatment selection, adaptation, early response monitoring, and 
follow up in patients with lung cancer [4]. In this thesis, several aspects of PET in the 
oncological management, including diagnosis and staging, radiotherapy planning, and 
response monitoring, of patients with lung cancer have been discussed.
The role of PET for diagnosis and clinical staging in lung cancer
The first important step in personalization of lung cancer management is accurate diagnosis 
and clinical staging. The combined use of FDG-PET with CT imaging has a major impact on 
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diagnosis and staging of patients with lung cancer. The advantage of FDG-PET–CT imaging 
over diagnostic CT imaging alone is a high sensitivity for detection of pulmonary lesions 
(90%), metastases in normal-sized hilar and/or mediastinal lymph nodes (74–85%), and 
distant metastases (93%) [10]. This added sensitivity of detection considerably improves 
patient management by increasing the accuracy of disease staging, reducing the number 
of futile thoracotomies and mediastinoscopies in patients with inoperable advanced-stage 
tumours [11], and permits selection of patients eligible for either definitive radiotherapy 
with curative intent or palliative treatment [12].
 However, due to the relatively long image acquisition time, typically 3–4 minutes 
per bed position, patients are instructed to breathe freely during PET imaging. If left 
unattended, respiratory motion artefacts will inevitably reside in the PET images, degrading 
image quality and introducing diagnostic inaccuracies, which can in turn lead to suboptimal 
clinical staging and patient management. In Chapter 3, this issue was addressed, using 
respiratory gating to correct PET images for respiratory motion artefacts. The objective was 
to investigate whether respiratory gating significantly influenced clinical staging and patient 
management of a clinically representative group of patients with lung cancer. The results of 
this study showed that neither clinical staging nor subsequent patient management was 
significantly affected when optimally respiratory gating (ORG) was performed. However, 
subgroup analysis revealed that patients with early stage lung cancer might benefit from 
respiratory gating. In particular, nuclear medicine physicians reviewing the ORG PET images 
detected more lesions and lymph nodes. Based on these findings, patient management 
plans would have been changed, particularly for the selected diagnostic procedures to 
confirm the diagnosis in this patient group. Furthermore, using ORG PET slightly improved 
clinical staging for this patient category. This was confirmed by histopathological analysis 
and radiological follow-up. Therefore, the expected impact of respiratory gating will 
be solely on diagnosis and staging of patients with early disease stages, which merits 
further investigation of the impact of ORG in this patient group. However, given that 
histopathological data or radiological follow-up of specific lymph nodes and lesions was 
not always available, it remains unclear whether the detection of additional nodes will 
truly affect false positive or negative rates with respect to lymph node detection. Further 
prospective trials are required to address these important questions.
The role of PET for locally advanced and metastatic lung cancer
An important advantage of PET with respect to other medical imaging modalities is its 
versatility to characterize and quantify the biological landscape of the tumour. In this regard, 
accurate quantification is of pivotal importance when using PET for characterizing disease 
with high precision. Errors in PET image quantification can be the result of a myriad of 
factors related to patient physiology and preparation, scanner hardware, image acquisition 
and reconstruction settings [13,14].
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As stated previously, respiratory motion is an important physiological factor that can 
introduce quantitative inaccuracies during PET imaging of the thorax. Therefore correction 
of PET images for respiratory motion is paramount for improving the use of PET for treatment 
personalization, including therapy response monitoring and radiotherapy planning. In 
this regard, the effect of respiratory gating on quantification of traditional image-derived 
indices, based on quantification of standardized uptake values (SUVs) and lesion volume 
was investigated in Chapter 4. These indices form the cornerstone in many response 
monitoring studies in nuclear oncology.
 In order to correct PET images for respiratory motion artefacts, different respiratory 
gating approaches have been developed. These methods typically rely on the selection 
of data in specific time intervals within the respiratory cycle, thereby creating an image in 
which the main respiratory motion components are removed. This is usually accomplished 
by simultaneously recording a surrogate signal correlated with the patient’s respiratory 
cycle with the PET data [15-17]. Using the surrogate signal, PET data can be selected by 
means of dividing each respiratory cycle into a fixed number of gates (phase-based gating) 
or by defining a certain amplitude range (amplitude-based gating) [15]. However, difficulties 
encountered by many respiratory gating approaches are related to the maintenance of 
acceptable image quality in the presence of irregular breathing frequencies. Particularly 
in phase-based respiratory gating approaches, discarded PET data due to rejection 
of inappropriate triggers results in reduction of image quality whilst acceptation of 
inappropriate triggers results in the definition of gates in different phases of the respiratory 
cycle [15,16]. 
 In contrast to many other respiratory gating algorithms, ORG safeguards image quality 
through calculation of an optimal amplitude range for a specified percentage of acquired 
PET data (duty cycle). In Chapter 4, the performance of ORG in a clinical whole body 
imaging protocol was evaluated in a large representative group of patients with primary 
lung cancer. In particular, the effect of lesion anatomical location and different inputs for the 
algorithm were investigated. Results of this study showed that the magnitude of the effect 
of respiratory motion on image quantification was dependent on anatomical location, with 
the largest differences in lesion uptake and volume for lesions located in the lower lung 
lobes. Furthermore, image reconstruction at smaller duty cycle percentages resulted in 
more effective rejection of respiratory motion from the PET images, as demonstrated by 
larger increases in lesion uptake and reduction in metabolic volumes. However, lowering 
the percentage duty cycle comes at the cost of reduced image quality. Although respiratory 
gating with the ORG algorithm provides convenient integration in a clinical whole body 
protocol with a constant image quality, the algorithm is strongly dependent on the quality 
of the surrogate signal acquired. Furthermore, respiratory gating with the ORG algorithm 
will result in discarding PET data, which either requires lengthening of image acquisition 
time or increasing the amount of administered radiotracer to the patient. 
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Alternatively, data-driven approaches (also known as list-mode gating), which do not 
incorporate measurement of respiratory surrogate signals for the purpose of list-mode 
data rebinning, have been developed. These methods rely on the concept that PET data 
inherently contain information on patient motion that can be used to correct for motion 
artefacts [18-20]. In addition, methods have been described which use all collected PET 
data whilst correcting for motion artefacts, eliminating the difficulties associated with 
statistical quality of PET images [21,22]. Ultimately, development of robust list-mode gating 
approaches permit the use of PET data without using external hardware and lengthening of 
image acquisition times. Furthermore, these methods can be used to reject other important 
sources of motion artefacts from the images, such as those due to the cardiac cycle. However, 
development, validation, and refinement of these methods is still ongoing.
 Another effect that compromises quantitative accuracy of PET images, particularly 
after correction for respiratory motion artefacts, is the existence of a spatial mismatch 
between PET and CT images. In modern hybrid PET–CT imaging, the CT images are 
acquired to improve anatomical localization of radiotracer uptake and attenuation 
correction. Attenuation correction is an important step to obtain quantitative images of 
radiotracer uptake in PET. During PET–CT imaging, the CT images are usually acquired 
using a free-breathing protocol. Given that both the CT images and motion corrected PET 
images can represent patient anatomy at different phases in the respiratory cycle, there is 
a probability that there will exist a spatial mismatch between the CT and PET images. This 
spatial mismatch between the PET and CT images can result in inappropriate attenuation 
correction and subsequent quantitative inaccuracies. In Chapter 4, different strategies 
were discussed to improve spatial matching between PET and CT images. The first method 
relies on providing breathing instructions to patients when the CT images were acquired. 
Given the typical characteristics of the respiratory surrogate signal, the ORG algorithm will 
typically define the amplitude range at the plateau phase during the end-expiratory phase. 
Therefore, patients in this study were either asked to continue free-breathing or perform 
a forced end-expiratory breath-hold manoeuvre when the CT images were acquired. 
Quantification of the spatial match between PET and CT images between the two groups 
revealed that spatial matching was not significantly affected. This could be due to the 
general difficulties associated with breathing instructions, which shows a dependency on 
the operator and patient compliance. Furthermore, in a number of patients, particularly 
those with chronic obstructive pulmonary disease (COPD), the respiratory surrogate signal 
has different characteristics, resulting in an optimal amplitude range defined at a different 
respiratory phase, usually the end-inspiratory phase. This emphasizes the requirement to 
more objectively determine the time point at which to perform CT imaging. In a subsequent 
study, the use of a respiratory triggered CT was used in an attempt to improve spatial 
alignment of PET and CT images. Within this research, patients underwent both low dose 
(LD) CT imaging according to a standard free-breathing protocol and a respiratory triggered 
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protocol. It was observed that spatial alignment was improved when using a respiratory 
triggered CT protocol [23]. However, spatial alignment of anatomy between PET and CT was 
not perfect for some patients, which was revealed to be related to the respiratory tracking 
method and lack of automated integration of the respiratory triggered CT protocol in the 
system. The prototype that was used required external devices and manual definition of 
system parameters (amplitude ranges, curve setup), which introduced a user dependency. 
Furthermore, short CT gantry time-outs in which triggers needed to be provided to the 
system regularly within short time intervals, complicated system setup. Additionally, the 
used respiratory tracking method with a pressure sensor might be suboptimal, especially 
when patients change from breathing pattern during image acquisition. In a number of 
cases, the complex movement of the thorax cannot be accurately measured with the use 
of one abdominal belt sensor [22]. Other tracking methods might be more appropriate for 
lesions in different regions in the lungs, such as methods that track the respiration of the 
patient by measuring the breathed airflow (spirometer). Another method is to gate the PET 
data by using reconstructed images with a high time resolution and performing an elastic 
transformation to match each PET image to the CT. However, these methods are still under 
development and need to be validated in clinical practice. 
 Alternatively, it is possible to acquire CT images during all phases of breathing using 
slow or time-averaged CT, followed by retrospective matching of the CT to the PET data. 
Although this method permits good control over spatial matching between PET and CT 
images, it typically requires a high X-ray dose and is not suitable for routine diagnostic 
PET. However, with developments in CT hardware and reconstruction algorithms, current 
developments aim at considerably reducing radiation dose whilst maintaining image 
quality. This includes modulation of X-ray tube current and voltage [24,25], and the 
development of iterative reconstruction algorithms for CT imaging, such as sinogram-
affirmed iterative reconstruction (SAFIRE; Siemens Healthcare, Forchheim, Germany), and 
image-based de-noising approaches, in which X-ray dose can be considerably reduced 
whilst maintaining image quality [26,27]. When sufficient reduction in radiation dose can 
be achieved at acceptable image quality, these strategies might become suitable for use in 
routine clinical imaging.
Radiotherapy planning
In addition to the added value of PET–CT imaging for the diagnosis, clinical staging and 
determination of treatment strategy, PET has a recognized role in modifying and tailoring of 
the radiotherapy planning procedure. As discussed in Chapter 2, incorporation of PET in the 
algorithm for radiotherapy planning facilitates improved definition of gross tumour volume 
(GTV) when compared to radiotherapy planning using solely CT images [28]. Indeed, using 
FDG-PET images in radiation-treatment planning has shown to reduce intraobserver and 
interobserver variability, and to improve the definition of GTVs by comparing to resected 
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tumour specimen [29]. Moreover, selective nodal irradiation based on FDG-PET data is 
associated with very low isolated nodal failure rates, suggesting that FDG-PET facilitates 
the concept of selective irradiation of mediastinal lymph nodes [30]. However, with the 
respiratory motion artefacts still residing in the PET images, inaccuracies in quantification 
of target volumes on PET images might result in sub-optimal radiotherapy planning. In this 
regard, it was investigated whether radiotherapy planning based on ORG FDG-PET images 
significantly affected the dose delivered to organs at risk (OAR) in volumetric modulated arc 
therapy (VMAT) planning when compared to the non-gated equivalent FDG-PET images 
[31]. Although a significant reduction in GTV was observed when target delineation was 
performed on ORG PET images, the overall absolute reduction in GTV was too small to yield 
clinically significant sparing of radiation dose to the OARs [31]. Although the results of this 
study failed to demonstrate that ORG influences radiotherapy planning with regard to target 
delineation, improved image quantification could be beneficial for novel radiotherapy 
strategies in lung cancer such as molecularly imaging dose painting. These concepts rely on 
the ability of PET to identify areas susceptible to treatment resistance. Although there are 
a number of smaller studies in which sites with disease recurrence could be retrospectively 
linked to areas with high FDG uptake on pre-treatment images [32,33], a definite FDG 
uptake based dose-response relation has yet to be established. If such a relation would exist, 
improved quantification of intratumour uptake and subsequent adaptation in prescribed 
dose might facilitate improved loco-regional control of the tumour.
Response monitoring
The view that ‘one size does not fit all’ regarding lung cancer treatment has been emphasized 
in numerous studies, where prescription of different chemotherapy regimen or molecularly 
targeted therapies as a standard therapy yielded no benefits regarding patient outcome or 
survivorship [8,9,34]. However, a very accurate a priori prediction about which treatment 
would be beneficial for an individual patient is difficult since characterization of cancer 
lesions in clinical routine can be performed only to a certain extent.
 Determining an optimal treatment strategy for the individual out of a vast number of 
available therapeutic options is a genuine difficulty in current clinical practice. A practical 
approach to engage this clinical problem is to gather as much information about the disease 
as possible, and determine the optimal treatment strategy, based on current knowledge 
and disease models. Then, treatment with the highest response probability will be selected. 
However, given that current knowledge about disease mechanisms is still incomplete, the 
prescribed treatment will in a number of cases fail to either induce disease regression or at 
least slow down progression. Therefore, there is a requirement to assess treatment response 
at an early stage of the treatment, preferably after only a few treatment cycles. Indeed, 
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accurate early response assessment would facilitate clinical decision-making by enabling 
fast switching or adaptation of therapy, improving patient management through avoidance 
of unnecessary side effects, and reduce costs of ineffective treatment. Although PET has 
a great potential for this role in lung cancer patients, clinical trials which implement the 
concept of image-guided treatment decisions are still awaited, as discussed in Chapter 2 
[4]. An important issue that is pivotal for the use of PET for early response measurements 
is performing standardized response measurement. Most image-derived response indices 
rely on quantification of lesion standardized uptake values (SUV), metabolic tumour volume 
(MTV), or a combination of both, known as the total lesion glycolysis (TLG). Studies have 
revealed that volumetric parameters derived from PET images are significantly associated 
with patient outcome and survival [35]. However, an important methodological consideration 
for standardizing response measurements using PET is automatic segmentation of target 
lesions from PET images, which was discussed in Chapter 6. In this chapter, the influence 
of a number of well-established automatic segmentation algorithms on calculation of TLG 
for the purpose of early monitoring of therapy response in a cohort of NSCLC patients 
during concomitant chemoradiotherapy was studied. The results of this study emphasize 
that inclusion of lymph node TLG in addition to primary tumour TLG considerably improves 
early response assessment, with a stronger association of progression free survival (PFS) 
and overall survival (OS) with summed TLG when compared to primary tumour TLG alone. 
Although the segmentation performance of the primary tumour was not considerably 
different between the different algorithms, segmentation of lymph nodes, particularly on 
interim PET images proved to be more challenging. Regarding lymph node segmentation, 
the signal-to-background ratio (SBR) segmentation algorithm outperformed the other 
methods.
Development of image-derived response metrics: the era of radiomics
Although traditional volumetric parameters derived from PET images, such as MTV 
and TLG, have great potential for the purpose of disease characterization and response 
monitoring, there remains considerable additional information content in PET images that 
is not utilized. In particular, information regarding spatial and temporal heterogeneity of 
lesions is often discarded. In this regard, interest in the quantification of intrinsic spatial and 
temporal heterogeneity in solid malignancies has been growing. In particular, the role of 
intratumour heterogeneity in identifying tumour type [36,37], aggressiveness, metastatic 
potential, treatment resistance [38-40], prognosis and overall survival [41], in lung cancer is 
increasingly being recognized. This view fits with our current knowledge of cancer, in which 
a cancerous lesions consist of heterogeneous cell populations with distinct molecular and 
micro-environmental differences [42]. 
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The wider field of radiomics focuses on the extraction and validation of such image-derived 
features from medical images and their correlation with underlying tumour biology. 
However, one of the limitations is measurement accuracy, which may limit the use of these 
approaches to characterize cancer lesions with high precision. In Chapter 7, the clinical 
impact of respiratory gating on quantification of several textural features in the era of 
modern high resolution time-of-flight (TOF) FDG-PET imaging was investigated. The results 
of this study showed that there was an anatomical dependency regarding the blurring 
effect of respiratory motion on quantification of intratumour heterogeneity, with only 
lesions located in the lower lung lobes demonstrating significant differences between non-
gated and ORG PET images. Furthermore, the effect of respiratory motion on quantification 
of intratumour heterogeneity was typically larger than variability due to differences in the 
level of noise in the images. However, the clinical impact of the observed differences was 
limited, as the univariate and multivariate survival models based on non-gated and ORG 
PET images were similar. This suggests that the extracted texture features are robust in the 
presence of respiratory motion artefacts and varying noise levels in PET images. However, 
there was no correlation of the texture parameters with patient survival, probably due 
to the heterogeneous character of the current patient cohort. In particular, there was a 
considerable number of patients with advanced and metastatic disease stages. In patients 
with metastatic disease, characteristics of the primary tumor might have limited predictive 
value regarding OS, while indices containing more information about disease load, such as 
summed TLG, might more accurately predict OS in these patients. Although the influence of 
important sources of measurement variability on quantification of intratumor heterogeneity 
was investigated in this study, several other important sources that can contribute to 
measurement variability are remaining. Indeed, measurement variability in PET can stem 
from a myriad of different factors, ranging from acquisition and reconstruction settings 
to patient physiology. It is important to assess the specific expected contribution of such 
variability to the tested heterogeneity parameters.
Future prospects
With the ongoing developments of novel therapeutic strategies for lung cancer patients, 
it is likely that the number of therapeutic options for lung cancer patients will continue to 
increase [5]. This makes selection of optimal treatment for the individual patient increasingly 
complex. An important step towards improving oncological management of these patients 
is development of a better understanding of disease mechanics and more accurate 
disease models [43]. Mathematical modelling contributes to cancer research by helping 
to elucidate mechanisms and by providing quantitative predictions that can be validated. 
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Various authors have provided mathematical models for the purpose of predicting cancer 
evolution, and modes of intrinsic and acquired treatment resistance [44,45]. Mathematical 
models can complement experimental and clinical studies, but also challenge current 
paradigms, redefine our understanding of mechanisms driving tumorigenesis and shape 
future research in cancer biology [44]. Although currently not used in clinical routine, 
implementation of these models in clinical practice can facilitate clinical decision-making 
by providing predictions about cancer behaviour based on data collected from the patient. 
Data that can serve as input for these models include results from molecular analyses, gene 
arrays and information derived from medical imaging. 
 Furthermore, acquired patient data should ideally not be confined to a single patient 
or institution. Instead, pooling of relevant patient data into very large sets of data, known 
as big data, can be used to generate new hypotheses, and to construct and validate new 
disease models. Parsing these large sets of complex data for patterns or perturbations, 
can yield important new insight in a complex diseases such as cancer [46,47]. Ultimately, 
these approaches can be used to construct clinical decision support systems, which can 
support the physician in selecting the optimal treatment strategy for the individual patient. 
Although interest in such clinical decision support systems is growing, substantial work 
remains to be done to realize the potential benefits [48]. 
 The opportunity to integrate data from medical imaging emphasizes the important 
task of extracting as much relevant information as possible from medical images. Currently, 
only a limited amount of information is extracted from medical images to describe cancer 
lesions. Although, classic integer dimension (1D, 2D, 3D, and so on) Euclidean geometry, 
which is routinely used in medical image analysis, can distinguish gross differences in 
geometry (volume, density, and so on), information that is hidden in the complexity of 
the structure under examination (such as texture and statistical properties of shape) can 
often be missed [49]. Also in clinical analysis of lung cancer, the geometrical complexity, 
and the irregularity of shapes and patterns observed in lung tumour growth (over space 
or time), is often omitted. However, quantification of these features may provide additional 
insights in treatment response, biological behaviour, and disease progression. For this 
purpose, fractal analysis is an interesting concept to describe lung cancer lesions in greater 
detail in a standardized manner. In mathematics, a fractal is a set of repeating geometrical 
patterns that is displayed at every scale [49]. This self-similarity has been used to describe 
the architecture of many biological structures, including that of the lung, which can be 
described using fractal mathematics over a finite scale window and non-integer fractal 
dimensions [49]. There are several authors reporting the use of fractal mathematics in CT 
and PET images to detect clinically relevant changes during lung cancer development, 
diagnosis, and treatment [50-52]. Despite the advantages of fractal mathematics for 
characterization of lung cancer lesions, and various studies demonstrating its applicability 
in lung cancer research, many researchers and clinicians remain unaware of its potential 
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[49]. Accurate quantitative mathematical descriptions of lesions in clinical routine might 
provide the physicians with valuable insight in disease mechanics and improve patient 
stratification and diagnosis. In addition to evaluation of the primary tumour, quantification 
of several important biological features of metastatic lesions may be even more important, 
since control of metastatic disease site is the foremost factor determining outcome in 
patients with metastatic lung cancer. These mathematical constructs can eventually be 
used to develop new image-derived metrics that may be correlated with certain biological 
properties of the tumour. 
 The ability to repetitively non-invasively quantify tumour biology makes PET an 
essential molecular imaging platform in the oncological management of lung cancer. 
However, this also stresses the importance of assessing and validating measurement 
accuracy and stability under a wide variety of imaging conditions. This includes the 
accuracy and stability of image-derived metrics in low count imaging [53,54], use of modern 
point-spread function (PSF) based image reconstruction incorporating time-of-flight (TOF) 
measurements [55], and various physiological factors. Although the effects of respiratory 
motion have been extensively evaluated in this thesis, there remain many other important 
physiological and instrumental factors that influence image quantification [14]. In particular 
analysis of uptake patterns and the stability of these image-derived features in the presence 
of noise, either due to instrument fluctuations or image reconstruction, needs to be 
assessed. There is a strong requirement to develop strategies to separate the contribution 
of different noise sources to observed fluctuations in PET images. This would benefit the 
development of new image-derived indices to monitor therapy response or characterize 
cancer lesions. Strategies such as bootstrap resampling of list-mode data, generating 
several different list-mode realizations from recorded PET data to investigate properties of 
noise propagation [56-58], and test re-test studies [59,60], can provide important insight in 
the stability of features extracted from PET images. 
 Although the chapters in this thesis emphasize the potential of PET for the purpose 
of personalizing oncological management in lung cancer patients, there is a strong 
requirement for validation, standardization and development of new image-derived indices 
to characterize lung cancer lesions in greater detail with greater accuracy. Furthermore, 
clinical trials regarding PET-guided treatment decisions are eagerly awaited to validate 
various concepts regarding patient stratification, and treatment response monitoring that 
are currently proposed in literature. Nevertheless, current clinical data unanimously support 
the use of PET for the purpose of personalizing oncological management of lung cancer 
patients. With exiting new therapeutic agents currently being developed and evaluated in 
clinical trials, the role of PET in personalizing the management of lung cancer patients is 
likely to expand, and might ultimately improve outcome and reduction in the frequency 
of acute and late treatment-related adverse events, substantially contributing to improved 
patient care for lung cancer patients.
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Lung cancer is one of the most common forms of cancer, accounting for 13% of all diagnosed 
cancers (around 1.6 million new cases per year worldwide), and for 18% of all cancer-related 
deaths. Despite considerable improvements in the treatment options for advanced-
stage and metastatic lung cancer, disease-specific survival remains poor. With the aim of 
improving patient outcome, the treatment paradigm of locally advanced lung cancer has 
shifted from solely radiotherapy towards combined and intensified treatment approaches. 
However, personalizing treatment to the individual patient remains difficult and requires 
monitoring of biological parameters responsible for treatment resistance to facilitate 
treatment selection, guidance, and adaptation. Positron emission tomography (PET) is a 
well-established molecular imaging platform that enables non-invasive quantification of 
many biological parameters that are relevant to both local and systemic therapy. In this 
thesis, the possibilities and methodological considerations of PET in combination with X-ray 
computed tomography (CT) imaging with the glucose analogue 18F-fluorodeoxyglucose 
(FDG) in oncological management of patients with lung cancer were further explored.
 In Chapter 2, a comprehensive overview of available clinical data on the use of PET–CT 
in the oncological management of patients with locally advanced and metastatic non-small 
cell lung cancer (NSCLC) was provided. In addition to the current role of PET–CT in clinical 
management of this patient group, the future perspectives of PET imaging were discussed. 
The conclusion of this study was that recent developments in radiopharmaceuticals and 
technological advancements in PET hardware and software have resulted in exciting 
possibilities to repetitively visualize and reproducibly quantify important molecular and 
microenvironmental features related to treatment response and resistance mechanisms. 
Clinical studies have demonstrated the potential value of PET imaging before, during, and 
after treatment to individually tailor treatment schedules and facilitate clinical decision-
making. Currently, FDG is the most widely used and best characterized PET radiotracer. 
Diagnosis and clinical staging
The first important step in personalizing oncological management of lung cancer patients is 
to perform accurate diagnosis followed by clinical staging. The introduction of FDGPET–CT 
imaging in the standard clinical work-flow has had a major impact on diagnosis and staging 
of patients with lung cancer. However, due to the relatively long image acquisition time, 
typically 3–4 minutes per bed position, patients are instructed to breathe freely during PET 
imaging. If left uncorrected, respiratory motion artefacts will inevitably reside in the PET 
images, degrading image quality and introducing diagnostic inaccuracies, which in turn can 
lead to suboptimal clinical staging and patient management. In Chapter 3, this issue was 
addressed, using respiratory gating to correct PET images for respiratory motion artefacts. 
The results of this study showed that neither clinical staging nor subsequent patient 
management was significantly affected when optimally respiratory gating (ORG) was 
performed. However, subgroup analysis revealed that patients with early stage lung cancer 
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might benefit from respiratory gating, with a more accurate diagnosis of affected lymph 
nodes. In addition, clinical staging improved when the ORG PET findings were compared 
with histopathological data and radiological follow-up.
Management of respiratory motion artefacts in PET–CT imaging
Accurate quantification is of pivotal importance when using PET for characterizing disease 
with high precision. In Chapter 4, the effect of respiratory gating on quantification of 
traditional image-derived indices based on standardized uptake values (SUVs), which form 
the cornerstone in many response monitoring studies in nuclear oncology, was investigated. 
The first study in this chapter evaluated the performance of ORG in a clinical whole body 
imaging protocol in a large representative group of patients with primary lung cancer. 
Results of this study showed that the effect of respiratory motion on image quantification 
was dependent on anatomical location, with the largest differences in quantification of 
lesion uptake and volume for lesions located in the lower lung lobes. Furthermore, image 
reconstruction using smaller duty cycle percentages resulted in more effective rejection 
of respiratory motion from the PET images, as demonstrated by larger increases in lesion 
uptake and reduction in lesion volume. 
 Another effect that compromises quantitative accuracy of PET images, particularly 
after correction for respiratory motion artefacts, is the occurrence of a spatial mismatch 
between PET and CT images. Given that both the acquired CT images and motion corrected 
PET images can represent patient anatomy at different phases in the respiratory cycle, there 
is a probability that there will exist a spatial mismatch between the CT and PET images. This 
spatial mismatch between the PET and CT images can result in inappropriate attenuation 
correction and subsequent quantitative inaccuracies. In the last two studies of Chapter 
4, different strategies were discussed to improve spatial matching between PET and CT 
images. The first method relies on providing breathing instructions to patients when the CT 
images are acquired. Patients in this study were instructed to either perform a forced end-
expiratory breath-hold manoeuvre or continue with free-breathing when the CT images 
were acquired. Quantification of spatial matching between PET and CT images for these 
two groups revealed that spatial matching was not significantly affected when breathing 
instructions were provided to the patient. In a subsequent study, patients underwent both 
low dose (LD) CT imaging according to a standard free-breathing protocol and a respiratory 
triggered LDCT protocol. It was observed that spatial alignment was improved when using 
a respiratory triggered CT protocol. 
Respiratory gated PET for radiotherapy planning
In addition to the added value of PET–CT imaging for the diagnosis, clinical staging and 
determination of treatment strategy, PET has a recognized role in modifying and tailoring of 
radiotherapy planning procedures. However, with respiratory motion artefacts still residing 
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in the PET images, inaccuracies in quantification of target volumes on PET images might 
result in sub-optimal radiotherapy planning, which was discussed in Chapter 5. In this 
regard, it was investigated whether radiotherapy planning based on ORG FDG-PET images 
significantly affected the dose delivered to organs at risk (OAR) in volumetric modulated 
arc therapy (VMAT) planning when compared to the non-gated equivalent FDG-PET 
images. Although a significant reduction in GTV was observed when target delineation was 
performed on ORG PET images, the overall absolute reduction in GTV was too small to yield 
clinically significant sparing of radiation dose to the OARs. 
Monitoring therapy response with PET
The role of FDG-PET for the purpose of early response monitoring is increasingly being 
recognized. Early assessment of therapy response is of great importance and would 
facilitate clinical decision-making by enabling fast switching or adaptation of therapy, 
improving patient management through avoidance of unnecessary side effects and costs 
of ineffective treatment. An important methodological consideration for standardizing 
response measurements using PET is automatic segmentation of target lesions from PET 
images, which was discussed in Chapter 6. In this chapter, the influence of a number 
of well-established automatic segmentation algorithms on calculation of total lesion 
glycolysis (TLG) for the purpose of early monitoring of therapy response was studied in 
a cohort of NSCLC patients during concomitant chemoradiotherapy. The results of this 
study emphasized that inclusion of lymph node TLG in addition to primary tumour TLG 
considerably improves response assessment, with a stronger association of progression 
free survival (PFS) and overall survival (OS) with summed TLG when compared to primary 
tumour TLG alone. Although the performance of segmentation of the primary tumour 
was not considerably different between the different automatic segmentation algorithms, 
segmentation of lymph nodes, particularly during early response measurements proved 
to be more challenging. These difficulties were reflected by a considerable increase in the 
number of lymph node segmentation failures for most algorithms.
Radiomics
Although traditional quantitative indices derived from PET images have great potential 
for the purpose of disease characterization and response monitoring, there remains 
considerable additional information content in PET images that is not utilized. In particular, 
information regarding spatial heterogeneity and temporal variations of lesions is often 
discarded. In this regard, interest in the quantification of intrinsic spatial and temporal 
heterogeneity in solid malignancies has been growing. However, one of the limitations 
is measurement accuracy, which may limit the use of these approaches to characterize 
cancer lesions with high precision. In Chapter 7, the clinical impact of respiratory gating on 
quantification of several textural features in modern high resolution FDG-PET imaging was 
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investigated. The results of this study showed that there was an anatomical dependency 
regarding the blurring effect of respiratory motion on quantification of intratumour 
heterogeneity, with only lesions located in the lower lung lobes demonstrating significant 
differences between non-gated and ORG PET images. In addition, the texture features were 
shown to be robust to different levels of image noise, where comparison of PET images 
with different statistical quality yielded no significant differences. The clinical impact of the 
observed differences was limited, as the univariate and multivariate Cox regression models 
for OS, based on non-gated and ORG PET images, were similar. These results suggest that 
the extracted texture features are robust in the presence of respiratory motion artefacts and 
varying noise levels in PET images. 
 The conclusion of this thesis is that, in a time of unprecedented scientific breakthroughs 
and technological advancements in the field of medical imaging and oncology, there is 
an important opportunity for PET imaging to facilitate personalized treatment decisions 
for patients diagnosed with lung cancer. Tailoring treatment to the individual patient will 
ultimately contribute to improved patient care and quality of life.
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Longkanker is een veelvoorkomende vorm van kanker, die jaarlijks wereldwijd bij ongeveer 
1.8 miljoen nieuwe patiënten wordt gediagnosticeerd. Er overlijden ongeveer 1.6 miljoen 
patiënten per jaar aan deze ziekte. Afhankelijk van het ziektestadium bij presentatie, bestaat 
de behandeling van longkanker uit lokale (chirurgie of radiotherapie) dan wel systemische 
therapie, of een combinatie van zowel lokale als systemische therapie. In de afgelopen jaren 
is het aantal behandelingsmogelijkheden voor deze patiëntengroep sterk toegenomen. 
Vooral de ontwikkeling van nieuwe bestralingstechnieken en medicijnen gericht tegen 
specifieke moleculaire epitopen op kankercellen, heeft de behandeling van specifieke 
vormen van longkanker sterk verbeterd. Hoewel deze nieuwe behandelingen vaak goed 
werken bij bepaalde patiëntengroepen, heeft het grootste deel van de patiënten geen 
baat bij het gebruik van deze nieuwe middelen. Het is echter erg moeilijk te voorspellen 
welke patiënten baat hebben bij bepaalde types of combinaties van behandelingen. Toch 
is selectie van een optimale behandelstrategie van belang voor de individuele patiënt, 
zeker omdat longkanker geen uniform ziektebeeld betreft, maar gezien kan worden als een 
verzameling van totaal verschillende ziektebeelden. Het is dan ook waarschijnlijk dat het 
toespitsen van de behandeling op het individu een belangrijke stap voorwaarts is om de 
prognose van deze patiëntengroep te verbeteren.
 In de huidige klinische praktijk levert medische beeldvorming een belangrijke 
bijdrage aan het vaststellen van het behandelplan voor de patiënt. Een beeldvormende 
modaliteit die uitermate relevante informatie geeft binnen de oncologie is positron emissie 
tomografie (PET). Het gebruik van PET berust op het toedienen van een radioactief gemerkte 
stof, het radiofarmacon, aan de patiënt. Afhankelijk van het gebruikte radiofarmacon 
kunnen verschillende biologische processen in het lichaam worden afgebeeld. In de 
studies beschreven in dit proefschrift werd gebruik gemaakt van PET beeldvorming met 
het radioactieve glucose-analogon 18F-fluorodeoxyglucose (FDG) voor diagnostiek en vast-
stellen van het klinische beleid voor patiënten met longkanker.
 In Hoofdstuk 2 werd een overzicht gepresenteerd van het gebruik van PET in 
combinatie met computer tomografie (CT) voor het bepalen van het klinische beleid van 
patiënten gediagnosticeerd met een niet-kleincellig longcarcinoom. Het niet-kleincellig 
longcarcinoom vormt een belangrijke groep binnen de longkankers. Naar schatting 
heeft 80-85% van de patiënten deze vorm van longkanker. Dit overzicht laat de potentie 
van PET beeldvorming zien voor het bepalen en aanpassen van de behandeling binnen 
deze patiëntengroep. Met PET kunnen vele biologische processen in kaart gebracht 
worden, die gerelateerd zijn aan resistentie tegen bepaalde behandelingen. Daarnaast 
kan er in een vroeg stadium worden gemeten of een bepaalde behandeling voldoende 
effectief is. De resultaten van deze literatuuranalyse lieten zien dat FDG-PET een uitermate 
geschikte modaliteit is voor de diagnostiek, planning van behandeling en het meten van 
behandeleffectiviteit bij patiënten met longkanker.
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Diagnose en klinische stadiëring
Het bepalen van de optimale behandelstrategie voor een patiënt begint met een 
accurate diagnose en het vaststellen van het ziektestadium met behulp van medische 
beeldvorming, ook wel klinische stadiëring genoemd. Hiervoor heeft het gebruik van FDG-
PET–CT een belangrijke meerwaarde ten opzichte van andere beeldvormende modaliteiten 
door de hoge sensitiviteit voor het detecteren van verdachte laesies in de longen, lokale 
uitzaaiingen in lymfeklieren en uitzaaiingen in andere organen, zoals botten, de lever en 
bijnieren. Studies hebben laten zien dat het toevoegen van FDG-PET–CT beeldvorming 
aan het standaard klinische protocol de patiëntenzorg aanzienlijk verbetert door het 
aantal zinloze chirurgische ingrepen, zoals thoracotomieën en mediastinoscopieën, bij 
inoperabele patiënten sterk te verminderen.
 Er zijn echter vele factoren die de visuele kwaliteit en de kwantitatieve nauwkeurigheid 
van PET beelden kunnen verstoren. Een belangrijke factor die deze verstoringen veroorzaakt 
is gerelateerd aan de relatief lange tijd die nodig is om de PET beelden te verkrijgen. Deze 
lange opnametijd, van tenminste enkele minuten, is noodzakelijk om een diagnostisch 
acceptabel PET beeld te kunnen reconstrueren. Deze lange opnametijd maakt het 
noodzakelijk om de patiënt tijdens de PET opnamen door te laten ademen. Indien hier niet 
voor gecorrigeerd wordt, resulteert dit in verstoringen in de PET beelden (ook wel artefacten 
genoemd). Het resultaat is een verstoorde weergave van de anatomie in de borstkas en het 
ontstaan van onzekerheden in de beoordeling en interpretatie van de PET beelden. 
 In Hoofdstuk 3 werd het effect van deze ademhalingsartefacten op de diagnostiek, 
klinische stadiëring en vorming van het behandelplan bij longkankerpatiënten onderzocht. 
Hiertoe hebben twee nucleair geneeskundigen en longartsen op basis van standaard 
ongecorrigeerde FDG-PET–CT beelden en ademhaling-gecorrigeerde FDG-PET–CT, de 
zogenaamde ‘optimally respiratory gated’ (ORG) PET, een klinisch stadium toegewezen en 
een behandelstrategie vastgesteld. De ORG PET beelden worden verkregen door gelijktijdig 
met de PET data een ademhalingssignaal op te nemen. Dit ademhalingssignaal wordt 
verkregen door een elastische band met een druksensor om de borstkas van de patiënt te 
bevestigen. Door alleen datapunten te selecteren die overeenkomen met een specifieke 
ademhalingsfase, kan een nagenoeg bewegingsvrij beeld worden gereconstrueerd. Het 
klinisch stadium en de behandelplannen gebaseerd op conventionele en ORG PET beelden 
werden met elkaar vergeleken. Daarnaast werden positieve bevindingen op de PET 
beelden gevalideerd met beschikbare histopathologische data en radiologische follow-up 
op basis van CT beeldvorming. Deze studie liet zien dat het gebruik van ORG FDG-PET leidt 
tot slechts beperkte veranderingen in het vastgestelde ziektestadium en behandelstrategie 
van de patiënt. Dit heeft te maken met het feit dat vele patiënten zich initieel presenteren 
met een uitgebreid ziektestadium, waarbij detectie van additionele laesies of pathologische 
lymfeklieren vaak geen verandering van het klinische stadium tot gevolg heeft. Toch kan 
ORG PET van meerwaarde zijn in patiënten met een vroeg ziektestadium, waarbij deze 
nieuwe techniek een betere diagnostiek van lymfeklieren mogelijk maakt. Daarnaast 
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heeft het gebruik van ORG PET geleid tot een verbetering van de klinische stadiëring. Het 
klinisch stadium toegewezen op de ORG PET beelden kwam hierbij beter overeen met 
pathologische stadiëring en radiologische follow-up dan het klinisch stadium gebaseerd 
op de conventionele PET beelden.
Ademhalingsartefacten in PET–CT beeldvorming
Een ander belangrijk aspect van PET beeldvorming is de mogelijkheid tot het kwantificeren 
van vele biologische processen binnen in tumoren. Het kwantificeren van radiofarmacon 
opname door de tumor en bepaling van het tumorvolume van de tumor in PET beelden 
vormt in vele studies een belangrijke basis voor het meten behandeleffectiviteit van 
chemo- en radiotherapie. Hiervoor is kwantitatieve accuratesse een belangrijk aspect dat 
gewaarborgd dient te worden. Naast onnauwkeurigheden in interpretatie en beoordeling 
van PET beelden, kunnen bewegingsartefacten ten gevolge van de ademhaling 
onzekerheden met betrekking tot beeldkwantificatie introduceren. Hoofdstuk 4 bevat 
een drietal studies die gericht zijn op het corrigeren van PET en CT beelden voor adem-
halingsartefacten, met als doel het verbeteren van de kwantitatieve accuratesse van PET 
beelden. In de eerste studie werd de correctie van ademhalingsartefacten met de ORG 
techniek in een grote representatieve groep longkankerpatiënten besproken. De mate 
van de onnauwkeurigheid in de beeldkwantificatie ten gevolge van de ademhaling bleek 
afhankelijk te zijn van de anatomische locatie van de tumor in de longen. Hierbij lieten de 
longtumoren in de lagere longkwabben vlakbij het middenrif de grootste verschillen in 
FDG opname en tumorvolume zien tussen conventionele en ORG PET beelden. Daarnaast 
werd het effect van verschillende invoerparameters aan de ORG software onderzocht. Er 
werd vastgesteld dat het ORG algoritme een goede balans geeft tussen het corrigeren van 
ademhalingsartefacten en de beeldkwaliteit.
 Naast correctie van bewegingsartefacten veroorzaakt door de ademhalingscyclus 
is een accurate registratie tussen PET en CT beelden belangrijk voor het waarborgen van 
de kwantitatieve accuratesse van de PET beelden. Tijdens PET–CT beeldvorming zijn de 
CT beelden van essentieel belang voor het uitvoeren van verzwakkingscorrecties van 
de PET beelden. Tijdens de CT beeldvorming zal de patiënt geïnstrueerd worden om 
te blijven doorademen. Het gevolg hiervan is dat de CT beelden gedurende een andere 
ademhalingsfase gemaakt kunnen zijn dan dat de ORG PET beelden weergeven. Dit 
kan tot gevolg hebben dat anatomische structuren op de PET en CT beelden niet met 
elkaar overeenkomen, wat kan resulteren in onnauwkeurigheden met betrekking tot 
kwantificatie van de radiofarmaconopname. De vervolgstudies in Hoofdstuk 4 beschrijven 
twee verschillende methoden die trachten de CT acquisitie met de PET beeldvorming te 
synchroniseren met als doel de registratie tussen de PET en CT beelden te verbeteren.
In de eerste studie werd een methode beschreven, die berust op het geven van 
ademhalingsinstructies aan de patiënt tijdens de CT beeldvorming. Hiertoe werden 
patiënten verdeeld over twee groepen. De eerste groep kreeg ademhalingsinstructies 
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tijdens de CT beeldvorming; de tweede groep kregen geen instructies en ademden door 
tijdens het maken van de scan. Kwantificatie van de overlap tussen PET en CT beelden 
liet zien dat de overlap tussen de beelden nauwelijks werd beïnvloed door het geven van 
ademhalingsinstructies. Het succesvol uitvoeren van de beschreven methode is mede 
afhankelijk van de interpretatie van de ademhalingsinstructies door de patiënt en of deze 
in staat is om de instructies uit te voeren. Deze resultaten benadrukken het belang van 
het objectief meten en aansturen van de CT beeldvorming om deze te synchroniseren 
met de PET beelden. In de laatste studie van dit hoofdstuk werd een methode beschreven 
waarbij door middel van het PET ademhalingssignaal de CT acquisitie werd aangestuurd. 
Deze methode berust op het verkrijgen van de CT beelden na de PET acquisitie, zodat de 
aansturing van de CT kan worden ingesteld op het amplitudebereik waarin de PET wordt 
gereconstrueerd. Bij deze patiënten werd de CT beeldvorming volgens het standaard 
doorgeademde protocol en met de nieuwe opnametechniek uitgevoerd. De resultaten 
lieten zien dat de registratie tussen de PET en CT beelden verbeterde wanneer deze nieuwe 
techniek voor CT beeldvorming werd gebruikt. 
Radiotherapieplanning
Naast de meerwaarde van FDG-PET–CT voor diagnose, klinische stadiering en het 
vaststellen van de behandelstrategie, heeft deze beeldvormende modaliteit een belang-
rijke taak voor het verbeteren van de radiotherapieplanning. Het integreren van FDG-
PET–CT beeldvorming in het radiotherapieplanning algoritme leidt tot een verbeterde 
definiëring van bestralingsvolumes ten opzichte van alleen CT beeldvorming. Het effect 
van ademhalingsartefacten en de correctie hiervoor op de bepaling van radiotherapie 
doelvolumes werd onderzocht in Hoofdstuk 5. In deze studie werden bestralingsplannen 
voor volumetrische arc therapie (VMAT) gecreëerd op basis van conventionele FDG-
PET en ORG FDG-PET beelden. Hoewel er een significante reductie in doelvolume werd 
waargenomen in de ORG FDG-PET beelden, waren er geen significante veranderingen in 
de stralingsdosis toegebracht aan omliggende anatomische structuren (hart, slokdarm, 
ruggenmerg en omliggend longweefsel). 
Respons monitoring
Naast diagnostiek en therapieplanning heeft FDG-PET een belangrijke meerwaarde voor het 
in een vroeg stadium meten van de effectiviteit van een behandeling. Het accuraat meten 
van therapie respons vroeg in de behandeling maakt het mogelijk om tijdig de therapie 
aan te passen indien deze onvoldoende effect heeft. Dit is van groot belang om ernstige 
bijwerkingen en kosten van een ineffectieve therapie te vermijden. Meerdere studies hebben 
de meerwaarde van FDG-PET–CT voor het meten van therapierespons in een vroeg stadium 
van de behandeling aangetoond. Echter zijn er veel methodologische overwegingen welke 
gemaakt moeten worden om dergelijke metingen op een gestandaardiseerde wijze uit te 
voeren. 
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In Hoofdstuk 6 werd de invloed van automatische volumebepalingen van longtumoren 
in FDG-PET beelden onderzocht. Hiertoe werd de voorspellende waarde van totale laesie 
glycolyse (TLG) voor overleving van patiënten met een niet-kleincellig longcarcinoom 
onderzocht. De patiënten zijn behandeld met gelijktijdige chemoradiotherapie en hebben 
voor en tijdens de behandeling een FDG-PET–CT scan gehad. De resultaten lieten zien dat 
er geringe verschillen waren tussen de volumebepalingen met de verschillende methoden 
voor de primaire tumor. Echter waren accurate volumebepalingen van de lymfeklieren 
slechts voor enkele methoden mogelijk. Dit is van belang omdat een gezamenlijke lymfeklier 
en primaire tumor TLG een betere voorspellende waarde geeft voor patiëntoverleving 
dan alleen primaire tumor TLG. Daarnaast onderstreept deze studie dat TLG-afname een 
belangrijke voorspeller is van therapie respons. 
Radiomics
Naast volumebepalingen en kwantificatie van radiofarmaconopname van tumoren in PET 
beelden wordt er in toenemende mate onderzoek gedaan naar opnamepatronen van 
het radiofarmacon in de tumor. Enkele studies laten zien dat dergelijke textuuranalyses 
belangrijke informatie kunnen verstrekken omtrent het biologische gedrag van de tumor. 
Radiomics is een vakgebied dat zich richt op het ontwikkelen en valideren van dergelijke 
textuurparameters. Voor deze textuurparameters is meetnauwkeurigheid wederom van 
belang zodat tumoren met grote precisie kunnen worden gekarakteriseerd. In Hoofdstuk 
7 werd de stabiliteit van enkele welbekende textuurparameters onderzocht in de 
aanwezigheid van ademhalingsartefacten en verschillende ruisniveaus in PET beelden. De 
textuurparameters bleken nauwelijks te variëren tussen conventionele en ORG PET beelden. 
Voor tumoren gelokaliseerd inde lagere longkwabben was er echter wel een statistisch 
significant verschil tussen beide PET beelden. Het effect van verschillende hoeveelheden 
ruis in het beeld had nauwelijks invloed op de textuurparameters, wat suggereert dat deze 
parameters stabiel zijn met betrekking tot verschillen in ruisniveau. De resultaten van deze 
studie lieten zien dat de klinische relevantie van de variaties beperkt zijn, waarbij dezelfde 
overlevingsmodellen gebaseerd op de verschillende PET beelden werden verkregen. 
 Met de huidige en toekomstige ontwikkelingen binnen de medische oncologie, 
radiotherapie, thoracale chirurgie en medische beeldvorming, zullen de therapeutische 
mogelijkheden voor longkankerpatiënten blijven toenemen. Het gebruik van PET voor de 
verschillende aspecten in het klinische beleid voor longkankerpatiënten, zoals besproken 
in dit proefschrift, zal hiermee blijven groeien. Het is dan ook waarschijnlijk dat PET 
beeldvorming in een steeds belangrijkere mate zal gaan bijdragen aan de verbetering en 
personalisatie van de behandeling van deze patiëntengroep, met als uiteindelijke doel een 
verbetering van de overleving van de patiënten en van hun kwaliteit van leven.
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Hoewel een proefschrift veelal vol staat met nieuwe wetenschappelijke bevindingen en 
interessante toekomstperspectieven, blijft het dankwoord is één van de meest gelezen 
stukken tekst. Ook bij het schrijven van een dankwoord is het erg belangrijk om de juiste 
woorden te vinden en vooral geen details of personen te vergeten. Ik hoop dan ook dat ik 
niemand te kort doe en ook zeker niemand ben vergeten. Wanneer dit zo is valt dit te wijten 
aan de tekortkomingen van mijn geheugen en bied ik op voorhand mijn oprechte excuses 
aan.
 Graag zou ik willen beginnen met het bedanken van mijn promotoren en co-
promotoren voor hun begeleiding tijdens het promotietraject. 
 Prof. dr. Lioe-Fee de Geus-Oei, beste Fee, ik heb zoveel aan je te danken, ik weet niet 
eens waar ik moet beginnen. Hoewel we elkaar al vaker in de kliniek waren tegengekomen 
tijdens mijn stages op de nucleaire geneeskunde, vond ons eerste wetenschappelijke 
contact plaats tijdens het promotietraject. De inspirerende wijze waarop je de begeleiding 
van je promovendi uitvoerde heeft mij veel geleerd. Je maakte een prachtig metafoor 
waarbij je het promoveren vergeleek met het opvoeden van een kind, met de nodige 
puberale en rebellerende fases. Bedankt voor het vertrouwen die je in mij had en dat je 
mij de gelegenheid hebt gegeven om mijn eigen krachten en zwakheden te ontdekken. Ik 
ben blij dat we onze samenwerking kunnen voortzetten in een ander instituut met nieuwe 
kansen en mogelijkheden. Wetende dat we samen een geweldig wetenschappelijk team 
hebben, ben ik met volle vertrouwen in dit nieuwe Leidse avontuur gestapt. 
 Prof. dr. Wim Oyen, beste Wim, er zijn weinig mensen die zo’n compleet overzicht 
hebben van het vak nucleaire geneeskunde zoals jij die hebt. Je wijsheid en intelligentie 
hebben mij enorm geholpen om belangrijke keuzes tijdens mijn promotietraject zo goed 
mogelijk te maken. Je ideeën en inzichten zorgden ervoor dat we onze manuscripten en 
onderzoeksmethodieken altijd wel weer konden verbeteren. Daarnaast kon ik ook altijd bij 
je terecht voor advies over mijn toekomstige loopbaan. Bedankt voor je begeleiding tijdens 
de promotie en ik hoop dat we in de toekomst kunnen blijven samenwerken.
 Dr. Eric Visser, beste Eric, bedankt voor je begeleiding al deze jaren. Ik heb veel geleerd 
van je wetenschappelijke inzichten en kritische blik op de geschreven manuscripten, 
waarbij elk woord en formulering werd gewogen op een ‘gouden weegschaaltje’. Ik 
vond het altijd fijn dat je deur voor mij open stond wanneer ik hulp nodig had. Onze 
gedeelde passie voor natuurkunde vormde vaak een goede basis voor lange discussies 
over fundamentele eigenschappen van het universum (waarbij we gelukkig toch nog af 
en toe een terugkoppeling naar de nucleaire geneeskunde konden maken). Bedankt 
voor al je wijsheid en zorg deze jaren en heel veel succes met het opzetten van nieuwe 
wetenschappelijke lijnen op de afdeling.
 Dr. Johan Bussink, beste Jan, door je passie voor moleculaire beeldvorming in 
radiotherapietoepassingen was je een essentiële toevoeging aan het promotieteam. Je 
hebt mij veel geleerd over jullie prachtige vak. Je motiveerde mij altijd om het maximale 
503606-L-bw-Grootjans
211Dankwoord | 
eruit te halen, wat vaak tot mooie resultaten heeft geleid! Onze overlappende interesses 
in radiomics en PET beeldvorming hebben geresulteerd in mooie gezamenlijke projecten 
tussen de afdeling nucleaire geneeskunde en radiotherapie. Ik hoop dat we onze 
samenwerking kunnen voortzetten in de toekomst.
 Lieve Charlotte, bedankt voor de fijne samenwerking in de afgelopen jaren. Je was 
mijn ‘partner in crime’ tijdens al onze mooie HD∙Chest projecten (ik veelal de PET, jij de CT). 
Ik heb altijd veel steun gehad aan je intelligentie en optimisme. Je bracht structuur aan 
mijn vaak wat chaotische ideeën (want je weet, zoals mijn bureau eruit ziet, zo werkt ook 
mijn geest!) en zorgde ervoor dat deze in goede banen bleven lopen. Zonder jou was dit 
proefschrift lang niet zo mooi geworden zoals deze dat nu is, dankjewel!
 Beste Antoi, door je praktijkervaring en probleemoplossende inslag was je voor mij 
het aanspreekpunt wanneer we op zoek waren naar praktische oplossingen. Of het nu ging 
om het uitdenken van experimenten of het bouwen van testopstellingen, je vond altijd 
wel belangrijke punten waar we achteraf niet zo goed over nagedacht hadden. Ik heb onze 
samenwerking altijd als zeer prettig ervaren en ik ga onze discussies in de koffiekamer over 
de actualiteiten zeker missen! Bedankt dat je altijd klaar stond om mij te helpen. 
 Siemens staff: Antje Schulte, James Hamill, Marcel Grootens, Martin Hagebeek, Bob 
Hogeboom, Bianca Baudewijns. Without support from Siemens, I would not have been able 
to conduct the research in this thesis. I would like to thank you all for your support during 
the years. I very much appreciated the passion and dedication from your side to make this 
project successful and enjoyed our collaborations during the PhD.
   Prof. dr. Otto Boerman, Beste Otto, ik heb grote waardering voor de wijze waarop je 
de researchgroep aanstuurt. Je optimisme en oprechte interesse zorgen voor een goede 
sfeer binnen de groep. Hier kunnen veel mensen nog wat van leren! Bedankt voor je 
behulpzaamheid, wijze woorden en adviezen om mij verder te helpen. 
 Prof. dr. Martin Gotthardt, beste Martin, hoewel onze wetenschappelijke paden slechts 
incidenteel kruisten, heb ik veel geleerd van je inspiratie en denkwijze. Over één ding zijn 
we het zeker met elkaar eens, Russische straaljagers zijn de beste in de wereld! 
 Wim van den Broek, beste Wim, bedankt voor de goede samenwerking in de afgelopen 
jaren. Ik waardeer de wijze waarop je altijd op zoekt bent de klinische praktijk te verbeteren 
(dit is iets waar ik als Technisch Geneeskundige blij van word). Je wijsheid en relativerende 
vermogen hebben mij niet alleen geholpen om sterk te blijven staan tijdens het ‘half-time 
imaging’ project, maar ook zeker daarbuiten.
 Dear Sara and Monique, I am humbled that I had the opportunity to work with 
such smart ladies. During our scientific project together with Wim, I not only learned 
that Portuguese students are very intelligent, but the language they speak is also very 
beautiful (although still rather difficult for me). Thank you for endless attempts to polish my 
Portuguese! At least now I know that frango means chicken in Portuguese! Thank you for all 
your efforts on the project, you did well and I am very proud of you. Cumprimentos!
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Harry en Ria Philipsen, mijn avontuur in Nijmegen begon bij jullie. Ik was in het tweede 
jaar van mijn Technische Geneeskunde master opzoek naar woonruimte in Nijmegen voor 
mijn stage in het Radboud. Na lang en intensief gezocht te hebben kwam ik terecht in het 
idyllische Beek Ubbergen, vlakbij Nijmegen. Hier mocht ik bijna een jaar bij jullie verblijven. 
Bedankt voor jullie gezelligheid en enorme gastvrijheid. Ik heb genoten van de verhalen 
over de bakkerij en de vele reizen die jullie gemaakt hebben. Voor mij voelde het als een 
tweede thuis!
 Lieve Annemarie (lieve Eki), het organiseren van evenementen en uitstapjes kan je als 
geen ander! We hebben er dan ook heel wat meegemaakt in de afgelopen jaren (feestjes, 
barbecues, etentjes voor de voetbalclub, waar je hebt laten zien dat je ook nog eens voor 
iedereen heerlijk kan koken). Of we nu tot 6 uur in de ochtend in de Fuik stonden of via 
een omweg in Dollars belandden, het was altijd een geweldige avond! Daarnaast hebben 
we heel wat tijd (vaak net iets te lang op de avond) gespendeerd in onze stamkroeg 
Ammy’s. Hier konden we na het voetballen voor de derde helft terugvallen op zelfgemaakte 
gehaktballen van de café eigenares (toevallig ook Annemarie) en Heineken (of dat nu altijd 
positief was...). Bedankt voor je gezelligheid al deze jaren en hopelijk kunnen we deze trend 
nog voor een lange tijd doorzetten!
 Martin Engels, beste Martin, bedankt voor je gezelligheid tijdens de talloze uitstapjes 
en borrels in de afgelopen jaren, er was altijd wel een goede reden te vinden om het glas 
te heffen! Ook zijn we heel wat sportieve uitdagingen aangegaan, met als hoogtepunt 
natuurlijk de zwemtocht in de ‘Maas’ van ‘Batenburg’ naar ‘Appeltern’. Naast de sportieve 
prestaties werd ook ons culinaire uithoudingsvermogen getest. We hebben heel wat 
records weten te vestigen in de lokale snackbar/cafetaria Tweety. Wanneer het nu ging om 
het wegwerken van één meter frikandel speciaal, een kapsalon, of porties verschillende 
soorten friet (‘Vlaams’, ‘Biologisch’, ‘Ras’), er was altijd wel weer een nieuwe uitdaging te 
vinden. 
 Dear Wael, together we survived the harsh conditions during our PhD. I always 
appreciated the times when we could discuss life with a nice cup of cappuccino and a piece 
of ‘apple pie’ or ‘apple flap’ (still looking for a proper translation) at the restaurant. I am nearly 
crossing the finish line, but you will be there soon my brother.
 NG Research: Wael, Charlotte, Wietske, Rian, Anne, Tom, Inge, Stefanie, Tessa, Selen, 
Marlène, Stijn, Sandra, Rafke, Maarten, Peter, Mark, Jonathan, Desirée, Marti, Annemarie, 
Otto, Mijke, Lieke, Laura, Gerben, Cathelijne, Danny, Daphne, Frans, Dennis, Susanne, Antoi, 
Michel, Janneke, Katja. Bedankt voor jullie gezelligheid tijdens onze talloze uitstapjes naar 
de Aeusculaaf en avonden uit op congressen. De goede sfeer, toewijding en samenwerking 
was terug te zien in al het mooie werk dat door jullie is afgeleverd. Voor al dat harde werken 
is in ieder geval heel wat suiker nodig. Dit was voornamelijk af te leiden aan de inhoud van 
de snoep pot, met een half-waarde tijd korter dan dat van menig kortlevend radionuclide. 
Een kilo suikerbanaantjes kon met gemak binnen een halve dag worden weggewerkt (ik 
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noem geen namen). Daarnaast ging menig gesprek in de koffiekamer over de laagste 
inkoopprijs van Bastognekoekjes (ik geloof dat we in het toen heersende economische 
klimaat op 79 cent per pak uitkwamen, maar dat was wel het huismerk). Gelukkig waren er 
geheime voorraden over de afdeling verspreid zodat de wetenschappelijke productiviteit 
niet in het geding zou komen.
 De kliniek: Erik, Edwin, Christel, Anne, Jeroen, Elske, Rick, Linda, Ben, Marcel, Martin 
E, Merijn, Tom, Marga, Maichel, Michelle, Dennis, Maartje, Eddy, Marie Claire, Marie-Louise, 
Bernadette, Jurrian, Jacqueline, Sylvia, Lisette, Maike, Peter, Sabine, Marjo, Diana, Martin G, 
Natascha. Naast onderzoek heeft de kliniek een belangrijk deel van mijn opleiding gevormd. 
Ik heb het geluk gehad dat ik tijdens mijn stages en promotie zulke goede collega’s aan 
jullie heb gehad. Ondanks jullie drukke schema hebben jullie altijd tijd gevonden om mij 
van alles over dit ‘stralende’ vak te leren zonder daarbij het belang van de patiënt uit het 
oog te verliezen. Daarnaast was er altijd ruimte voor gezelligheid. Bedankt dat ik deel mocht 
uitmaken van jullie team!
 De voetbalclub: Gerwin, Alex, Christian, Annemarie, Taco, Wouter, Tom, Ran, Eric, Frank, 
Ghaith, Maarten, Thomas, Clive, Thomas, Eelco, Martijn, Wael. One of the best times of the 
week was undoubtedly Thursday evening, where we would gather at the ‘Julianapark’ or 
‘Goffertpark’ (during the summer) or at the gym at the ‘Marie Curie straat’ (during winter) to 
play a game of soccer. We had some really nice games. Thank you all for these great times!
 De sportieve helden van de nucleaire geneeskunde: Martin, Merijn, Daphne, Alex en 
Jurrian. Naast voetbal was er ook tijd voor zwemmen. Wat hebben we gelachen tijdens dit 
wekelijkse ritueel. Vooral de interacties met de dobbermutsen uit baan 1 leverden vaak 
interessante discussies op. Gelukkig konden we na deze sportieve activiteiten bijkomen in 
de lokale cafetaria Tweety!
 Afdeling radiotherapie: Bianca, Robin, Jasper, Laura, Tineke, Esther. Jullie zijn het bewijs 
dat radiotherapeuten een grote passie kunnen hebben voor moleculaire beeldvorming. 
Ik heb grote waardering voor jullie vak! We hebben mooie publicaties samen geschreven 
(en natuurlijk samen voor een heel jaar de cover gehaald van Nature Reviews Clinical 
Oncology!). Dank voor de goede samenwerking gedurende de afgelopen jaren! Hopelijk 
kunnen we onze samenwerking in de toekomst voort zetten.
 Afdeling longziekten: Erik, Olga, bedankt voor de goede samenwerking tijdens deze 
promotie. Ik heb veel van jullie geleerd over de klinische aspecten van deze patiëntengroep 
en waar wij als beeldvormers ons bewust van moeten zijn. We hebben samen een aantal 
mooie publicaties geschreven waar we trots op kunnen zijn.
 De vrijdagmiddag borrelclub: Martin, Peter, Marcel, Merijn, Eddy, Jurrian, Bernadette. 
Na afloop van de week was het tijd voor een formele afsluiting met evaluatie van de week, 
de vrijdagmiddag borrel. Hier werd de week doorgenomen onder het genot van een glas 
whisky of speciaal bier (of een gele bak met een gistende vegetarische maaltijd welke per 
abuis wel eens in de prullenbak is verdwenen (sorry Merijn!)). 
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De intellectuelen van de pubquiz: Annemarie, Gerwin, Eelco, Christian. Op de dinsdag 
was het tijd voor een intellectuele uitdaging tijdens de pubquiz in ‘Proeflokaal Beij Ons’. 
Door onze krachten te bundelen in een multidisciplinair team (met ware autoriteiten 
op de vlakken van wetenschap, astronomie, moderne geschiedenis, kunst, muziek en 
roddelbladen), hebben we na talloze pogingen toch één keer een schaal bittergarnituur 
weten te winnen bij de schattingsvraag!
 De pizzaclub: Lisanne en Martijn, over de jaren heen hebben we heel wat expertise 
weten op te bouwen in het bakken van zelfgemaakte pizza’s. Naast pizza was er altijd ruimte 
om herinneringen op te halen van die goede oude tijd. Dank voor jullie gezelligheid!
 De Technische Geneeskunde club: Raimon en Omar, als oud collega’s van technische 
geneeskunde hebben we altijd contact weten te houden. Dank voor jullie gezelligheid 
tijdens de opleiding en in de talloze uitstapjes die we gemaakt hebben, we kunnen deze 
traditie nu aan het westelijke deel van het land voort zetten. 
 De congrescommissie: Paul, Esther, Merijn, Anita, Martine, Ilse, Daan, jullie hebben 
bewezen dat wanneer een groep enthousiaste en gemotiveerde mensen samenkomt, 
werkelijk alles mogelijk is. Na een jaar hard werken hebben we een mooi lustrumcongres 
weten te organiseren. Het belangrijkste is dat we er ook ongelofelijk veel plezier aan hebben 
gehad, dank voor jullie gezelligheid!
 Vriendengroep: Thijs, Lisanne, Daphne, Maarten, Oscar, Anne, Sabine. We zijn het 
voorbeeld dat een groep na vele jaren (voor mij sinds 4VWO) nog steeds bij elkaar kan 
blijven. Zelfs de toenemende geografische afstand tussen ons (van Groningen tot Nijmegen 
tot Oldenzaal tot Utrecht en Leiden) en de steeds vollere agenda’s hebben daar geen invloed 
op. Regelmatig een keer film, bowlen, laser gamen, of een jaarlijkse wintersport vakantie, 
we zijn het allemaal blijven doen. Bedankt voor jullie gezelligheid al deze jaren en hopelijk 
kunnen we deze trend nog lang voortzetten.
 Afdeling Nucleaire Geneeskunde Leiden: Petra, Michael, Patrick, Jacqueline, Willeke, 
Johan, Sylvia, Ina, Daphne, Lenka, Frits, Richard, Lioe-Fee, Erik, Renato, Lisanne, Dennis, 
Angela, Mieke, Anne, Nancy, Anja, Hans, Ko, Carlijn, Koos, Floris, Clemens, Marieke. Ik heb 
altijd gezegd dat ik nooit naar de Randstad zou verhuizen, toch heb ik de overstap gewaagd 
(en gelukkig maar, want ik ben op een ongelofelijke leuke afdeling terecht gekomen met 
ontzettend leuke collega’s). Bedankt voor jullie gezelligheid en ik kijk er naar uit om de 
komende jaren met jullie samen te werken!
 Hoewel ik mij in dit proefschrift voornamelijk heb bezig gehouden met de problematiek 
rondom de fysiologie van ademhaling tijdens medische beeldvorming, heb ik me ook 
bezig gehouden met een hele andere fysiologische uitdaging (het op pijl houden van mijn 
bloedglucose). Men zegt wel eens dat iedereen een beschermengel op zijn schouder heeft, 
ik tel er minsten 28 bij mij (dit is exclusief 12 ambulancebroeders en zusters en 2 eerste 
hulpartsen waarvan ik de namen helaas niet meer weet): Pap, mam, Robert, Roelof, Daphne, 
Thijs, Oscar, Anne, Sabine, Maarten, Stijn, Tessa, Sandra, Floris, Petra, Martin, Stefanie, 
503606-L-bw-Grootjans
215Dankwoord | 
Charlotte, Harrie, Ria, Martijn, Wietske, Eric, Lioe-Fee, Dennis, Lisanne, Anne, Annemarie, 
Christian. Dank voor jullie goede zorg op momenten dat ik het nodig had! 
 Robert en Roelof, we hebben veel in ons leven samen opgetrokken. Onze 
gemeenschappelijke interesse in wetenschap en techniek (en natuurlijk gamen) heeft ons 
altijd met elkaar verbonden. We werden door onze omgeving dan ook vaak als een enkele 
een eenheid beschouwt, waarbij we wel eens de ‘Grootjans mafia’ zijn genoemd. Bedankt 
dat jullie mijn paranimfen willen zijn voor deze dag!
 Pap en Mam, ik heb alles aan jullie te danken, het feit dat ik hier nu sta komt door jullie 
inspiratie en motivatie, maar vooral ook de vrijheid die ik altijd van jullie heb gekregen. 
Jullie hebben altijd in ons gelooft en werkelijk alles voor ons gedaan. Er zijn letterlijk 
bibliotheken met boeken geschreven over hoe je kinderen moet opvoeden en iedereen 
heeft er tegenwoordig wel een mening over, maar het is heel simpel, jullie weten hoe het 
moet. Betere ouders heb ik niet kunnen wensen.
 Lieve Pap, ik heb ongelofelijk veel waardering voor hoe je alles hebt opgepakt. Naast 
de zorg voor mam vind je tijd om te koken, de was te doen, te klussen, het huis op te ruimen, 
boodschappen te doen en te werken (want ‘de strijd tegen de fraude gaat altijd door’ zoals 
je altijd gekscherend zegt). Wanneer ik voor het weekend naar Oldenzaal kwam wist ik dat 
ik weer van je kookkunsten kon genieten.
 Lieve Mam, je kunt niet op alles voorbereid zijn in het leven en sommige gebeurtenissen 
zetten alles op zijn kop. Drie jaar geleden kregen wij het bericht dat je ongeneeslijk ziek bent. 
Je heb je al deze tijd zo ongelofelijk dapper verzet, ondanks terugkerende tumult rondom 
scan- en testuitslagen. Je was altijd optimistisch en liet je niet uit het veld slaan, zelfs nu na 
het zien van zoveel medische specialisten en letterlijk dagen in het ziekenhuis te hebben 
doorgebracht ben je net zo strijdvaardig als altijd. Ook tijdens de moeilijke gesprekken had 
je altijd aandacht voor anderen, waarbij je tegen menig collega en medisch specialist hebt 
verteld hoe trots je wel niet op je jongens bent. We weten niet wat de toekomst brengt, 
maar we hopen met ons allen dat we nog lang met ons vijven met elkaar samen kunnen 
zijn. We denken ook vooral terug aan de goede tijden die we met elkaar hebben gehad.
503606-L-bw-Grootjans
503606-L-bw-Grootjans
curriculuM vitae
503606-L-bw-Grootjans
218 | Curriculum Vitae
Willem Grootjans werd geboren op 24 oktober 
1987 in Oldenzaal. In een gezin van drie kinderen is 
hij de oudste. In 2006 behaalde hij zijn voortgezet 
wetenschappelijk onderwijs (VWO) eindexamen in de 
profielen Natuur & Techniek en Natuur & Gezondheid 
aan het Twents Carmel College de Thij in Oldenzaal. In 
hetzelfde jaar startte hij met de opleiding ‘Technische 
Geneeskunde’ aan de Universiteit Twente in Enschede. 
In 2010 behaalde hij zijn graad ‘Bachelor of Science’ 
in Technische Geneeskunde. In het afsluitende 
Bachelor onderzoek onderzocht hij het synthetiseren 
van kraakbeenconstructen voor de regeneratie van beschadigt kraakbeenweefsel 
met autologe mesenchymale stamcellen. Direct aansluitend startte hij met de Master 
specialisatie ‘Robotica en Beeldvorming’. In 2011 begon hij met zijn klinische stage op het 
Radboud universitair medisch centrum in Nijmegen op de afdeling Neurochirurgie onder 
begeleiding van professor Grotenhuis. Gedurende deze periode onderzocht hij het gebruik 
van intra-operatieve beeldvormende technieken voor het verbeteren van de chirurgische 
verwijdering van cerebrale arterioveneuze malformaties. De hierop volgende stage volgde 
hij aan de afdeling Radiologie van het Radboud Universitair Medisch centrum. Onder 
begeleiding van professor Schultze Kool, doctor Fütterer en doctor de Lange onderzocht 
hij in deze stage de implementatie van percutane cryoablatieprocedures van niertumoren 
op het Philips Allura angiografiesysteem. De derde stage volgde hij aan de afdeling 
Nucleaire Geneeskunde van hetzelfde instituut onder begeleiding van doctor Visser, Anne 
Arens en professor Troost. Tijdens deze stage onderzocht hij het gebruik van verschillende 
automatische segmentatiemethoden voor het meten van behandelrespons op radio- 
chemottherapie in hoofd-hals kanker patiënten met behulp van 18F-fluorothymidine 
positron emissie tomografie (PET) beelden. De vierde klinische stage volgde hij op het 
radiotherapeutisch instituut stedendriehoek en omgevingen (RISO) in Deventer onder 
begeleiding van doctor ingenieur Minken, Hendrik Westendorp en Carel Hoekstra. 
Gedurende deze stage werd de klinische meerwaarde van magnetische resonantie (MR) 
beeldvorming ten opzichte van echobeeldvorming onderzocht voor het definiëren 
van bestralingsvolumes van de prostaat voor prostaatkankerpatiënten geëvalueerd. In 
2011 begon Willem aan zijn afstudeerstage Technische Geneeskunde op de afdeling 
nucleaire geneeskunde van het Radboud universitair medisch centrum in Nijmegen. 
Tijdens deze stage onderzocht hij de beeldvormingskarakteristieken van de toen nieuw 
geïnstalleerde Siemens Biograph mCT PET scanner. Daarnaast onderzocht hij verschillende 
beeldreconstructie technieken voor ‘single photon emission computed tomography 
(SPECT) beelden met lage telstatistiek. In september 2012 behaalde hij zijn graad ‘Master 
of Science’ in Technische Geneeskunde met het predicaat ‘cum laude’. Direct aansluitend 
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startte hij op dezelfde afdeling met zijn promotietraject waarin het gebruik van moderne 
PET beeldvorming met het radioactieve glucose analogon 18F-fluorodeoxyglucose (FDG) 
voor het oncologische beleid van longkanker patiënten werd onderzocht. Naast de PET 
beeldvorming nam hij deel aan en begeleide verschillende wetenschappelijke projecten 
op de afdeling, waaronder het verkorten van beeldacquisitietijden voor botscintigrafie 
en diagnostische kwaliteit van SPECT beeldvorming. Ook nam hij enkele keren zitting als 
extern adviseur in afstudeercommissies van de opleiding ‘Medische Beeldvormende en 
Radiotherapeutische Technieken’ aan de Fontys Hogeschool in Eindhoven. Tijdens het 
promotietraject werd hem een reissubsidie toegekend door de Franse organisatie voor de 
onderzoek naar kanker ‘Cancéropôle Grand-Ouest’ om een radiotherapie workshop op ‘L’île 
de Berder’ bij te wonen. Daarnaast organiseerde hij samen met andere vijf andere Technisch 
Geneeskundigen het lustrumcongres voor de Nederlandse Vereniging van Technische 
Geneeskunde (NVvTG). In december 2015 is Willem gaan werken op de afdeling Radiologie 
van het Leids universitair medisch centrum met als aandachtgebied het gebruik van PET 
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